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Abstract 
A sub population of human Müller glia contained within the neural retina is 
known to exhibit stem cell characteristics. Previous studies in the host 
laboratory have investigated their ability to differentiate into different retinal 
populations in vitro, providing a potential source of cells for development of 
therapies to treat retinal degenerative diseases. This study investigated 
molecular factors involved in differentiation of retina ganglion cells (RGCs) 
derived from human Müller stem cells. It also aimed to explore the feasibility 
of transplanting RGC derived from Müller stem cells into large mammalian 
eyes, using collagen based cellular scaffolds. These objectives ultimately 
aimed to study the potential application of Müller stem cells for treatment of 
late stage glaucoma. 
As determined by microarray analysis of total RNA specimens, in vitro 
culture of Müller stem cells undergoing Notch inhibition in the presence or 
absence of bFGF, led to alteration in microRNA (miRNA) profiles. These are 
short RNA molecules synthesised within cells that play a role in various 
cellular processes. MicroRNAs associated with Notch signalling, cell cycling 
and differentiation, were enriched in Müller cell populations undergoing 
Notch inhibition, conditions previously shown to induce RGC development. 
Elevated expression of these specific miRNAs suggests the emergence of 
novel targets under the regulation of the Notch pathway in Müller stem cells. 
These constitute factors that could be potentially used to develop therapies 
which facilitate endogenous neural differentiation of the latent Müller stem 
cell population in the human neural retina.  
Collagen based cellular scaffolds were developed to deliver RGCs derived 
from Müller stem cells onto the inner retina of the large mammalian eye. 
Collagen is a ubiquitous protein found within numerous tissues types, acting 
as a framework for cellular support and adhesion. Delivery of grafted cells 
onto retinal explants in vitro, and transplantation of scaffolds into the rabbit 
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eye in vivo, was examined by confocal microscopy and showed that plastic 
compressed collagen scaffolds served as a potential suitable substrate for 
transfer of cells to the host retina.  Integration was observed in some cases 
and rarely observed into host tissue, facilitated by degradation of the 
extracellular matrix by chondroitinase ABC and by the use of the anti-
inflammatory agent triamcinolone in vivo.  
In conclusion, the present study showed that standardised protocols used to 
differentiate Müller stem cells into RGC promoted alterations in Müller stem 
cell miRNAs associated with RGC development and maturation. In addition, 
compressed collagen scaffolds were shown to aid delivery of RGCs onto the 
inner retinal surface. These observations pave the way for further 
investigations to promote endogenous retina regeneration and refinement of 
transplantation strategies to apply these cells to the development of human 
therapies.  
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1.1. Retinogenesis 
Cell lineages contained within the vertebrate eye have been extensively 
conserved in many species (Andreazzoli, 2009), where the majority of 
molecular regulation of cell fate is mediated by transcription factors, which 
are able to control RNA transcription. Many of these factors act 
synergistically to yield specification to the retinal progenitor population at 
birth. Researchers in the regenerative medicine field are currently targeting 
molecular and epigenetic regulators to develop ocular degenerative 
therapies. Knowledge of the coordinated processes involved in retinogenesis 
will improve our understanding of age-related or inherited retinal diseases 
and will aid in the design of regenerative therapies for degeneration of 
specific cell niches.  
There are seven types of cells born during ocular organogenesis; six 
neurons and one glial population, namely the Müller glia. Synchronised 
development of the retina involves transcriptional and translational control 
which is governed by intrinsic or environmental mechanisms. The eye 
structure is defined within the ectoderm germ layer, specifically involving the 
anterior neural plate and its cellular content. This region undergoes 
repression of Wingless (Wnt1) and bone morphogenetic protein (BMP), by its 
inhibitor Noggin, and is coupled with increased production of basic fibroblast 
growth factor (bFGF) and insulin-like growth factor (IGF) (Pera et al., 2001, 
Delaune et al., 2005). This single region separates to give origin to distinct 
retinal compartments. The newly born retinal primordial tissues then gives 
rise to the optic vesicles (Chow and Lang, 2001, Rembold et al., 2006) which 
house the neuroblasts that will undergo cell division to form the different 
retinal cell layers. Cellular proliferation causes the tissue to evaginate 
laterally, yielding two optic cups where the pigmented RPE lines the outer 
surface, surrounding the developing neural retina (Andreazzoli, 2009).  
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The formation of the mature retina involves an evolutionary conserved time-
competent generation of neurons and glia by the retinal progenitors. Broadly, 
the retinal ganglion cells (RGCs) are produced initially, followed by cones 
and horizontal cells, and at a later stage amacrine cells, rods and bipolar 
cells. Finally, the Müller glia are produced (Figure 1.1). The different retinal 
neurons are all derived from the same population of progenitors that pass 
through various proliferative states (Livesey and Cepko, 2001, Marquardt 
and Gruss, 2002). These cell states are regulated by organisational signals 
provided within the tissue, whether extrinsic or intrinsic. Early retinal 
progenitors are all primarily plastic and able to produce all retinal cell sub-
types, whilst later progenitors have a limited potency and have the capacity 
to produce post-mitotic neural populations that are generated during the later 
stages of organogenesis. The early progenitors are elongated bipolar-like 
cells, which span the final width of the retina, their nuclei are housed within 
the central domain of the retinal microenvironment and are able to migrate 
basally or apically during development, this is commonly known as 
interkinetic migration (IKNM) (Baye and Link, 2007). Early division is 
asymmetrical, where progenitors give rise to two variant daughter cells, one 
becoming an early post-mitotic neuron being ganglion, cone or horizontal in 
fate, whilst the other replenishes the progenitor pool and retains its mother’s 
potency. This mode of division lasts a short time. However, in larger 
mammals it can be a prolonged process before the later neurons are born 
(LaVail et al., 1991). Once early RGCs are generated, they commence 
differentiation into mature ganglion morphologies by developing radial 
extensions towards the inner basal layer. These initially act to anchor the cell 
body into the inner lamina, where they then send extensive axonal 
outgrowths adjacent to the progenitor end feet, directed towards the future 
optic nerve (Hinds and Hinds, 1974). Late progenitors produce the late-born 
post-mitotic neurons, as well as the glial population. The late progenitors are 
similar in their phenotypes to young Müller glia, which retain an elongated  
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Figure 1.1:  Eye field specification and retinogenesis diagrams. 
A) Eye field determination (blue) from the neural plate B) Following 
neuralation and eye field specification, the two retinal territories 
separate. C) Evagination of retinal territories, creating optic vesicles 
with neural retina (NR), RPE and optic stalk. D) mature organisation 
of the ocular tissues and neural retina containing the ganglion cell 
layer (GCL), inner nuclear layer (INL), inner plexiform layer (IPL), 
outer nuclear layer (ONL), and optic nerve (ON) (Adapted from 
Andreazzoli, 2009).  
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bipolar morphology. They also produce late born bipolar and amacrine cells, 
as well as provide the solid scaffold which neurons use to travel towards their 
final destinations within the growing neuroepithelium (Meller and Tetzlaff, 
1976, Reichenbach et al., 1994a, Reichenbach et al., 1994b). Müller glia also 
facilitate the outgrowth of ganglion cell dendrites into the inner plexiform 
layer (Bauch et al., 1998), in order to create synapses with other proximal 
neurons. This is a very similar process utilised by other neural retinal cells 
when developing interlinking signalling networks, such as those observed 
between bipolar cells and both populations of photoreceptors. Müller glia 
guide the cells during late retinogenesis, but also ensure the formation of 
synapses between neurons born both early and late. Once migration and 
proliferation has concluded, the two plexiform-synaptic layers are formed. 
These separate the three retinal nuclear layers to create the final retinal 
mosaic.  
1.1.1. Transcriptional regulators of retinal progenitors 
The signalling and molecular controls imposed on retinogenesis have in part 
been attributed to two synergistic paths, one which down-regulates the 
expression of factors that promote differentiation, whilst the other acting to 
promote multipotency and proliferation. Together these mechanisms work to 
maintain a pool of self-renewing and undifferentiated cells during 
organogenesis. Transcription factors are proteins that act in a sequential 
manner to control the maintenance of adult tissue or the development of 
embryonic tissues. Pax6 is a paired homeobox transcription factor that has 
been termed a “master controller” of eye development, it has been shown to 
regulate the proliferative rate of early progenitors during eye development, 
ensuring enough cells are created to satisfy the cell numbers required for 
retinogenesis. Knockout Pax6 murine models only produce amacrine cells 
following organogenesis, demonstrating the vital role that Pax6 has 
(Marquardt et al., 2001) in retinal development.   
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Sex determining region Y (SRY)-box 2 (Sox2), is another transcription factor 
that regulates early retinal progenitors (Bhatia et al., 2011b) and appears to 
have a direct positive action on the Notch signalling pathway and its 
downstream target Hairy and enhancer of split-1 (Hes1) (Taranova et al., 
2006). Its constitutive activation causes suppression of genes that induce cell 
commitment down a neural lineage, preventing proliferation and self-renewal.  
Notch signalling demonstrates how the microenvironment can be employed 
to alter the fate of different sub-sets of cells within a population of potent 
cells. Increasing the cellular expression of the Notch antagonist Delta, 
progenitors can self-induce differentiation which represses their internal 
Notch signalling, creating a negative feedback loop for their own production. 
This hinders the triggering of the signalling cascade, and in this way can 
commit a population of potent cells to mature (Andreazzoli, 2009). 
Furthermore, Notch signalling has demonstrated a control over apical-basal 
spatial differentiation in both zebrafish and mice, where cells born from 
progenitors within the basal region will become post-mitotic and undergo 
symmetrical division. In contrast, those born proximal to the apical domain 
will undergo asymmetric division, where one daughter cell will maintain its 
Notch signalling and retain a potent ability (Del Bene et al., 2008).  
It has been shown recently that some molecules can intrinsically monitor and 
alter the phenotypes of retinal progenitors. These are known as micro RNAs, 
which can control the extent of translation and/or the degree of proteomic 
expression within a plastic retinal population (Slack et al., 2000, Moss et al., 
1997). These agents have been shown to be involved in layer formation, 
apoptosis and the timing of cellular maturation. 
Müller cells give rise to rod progenitors during normal development in the 
zebrafish. However in dystrophic retina, Müller glia are able to de-
differentiate, regenerate and repopulate injured retina (Bernardos et al., 
2007). This was first observed in lower vertebrates and amphibians, but 
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more recent studies have identified this regenerative potential in mammalian 
species (Fischer and Reh, 2001, Fischer and Reh, 2003). Rat retinal 
progenitors have been isolated and incubated under in vitro conditions and it 
has been suggested that their over expression of Notch1 and Hes1 appears 
to induce generation of Müller glia (Blackshaw et al., 2004). Murine models 
transplanted with activated Müller glia due to injury, have demonstrated the 
capacity to produce neurons of all retinal laminations which is attributed to 
the alteration of their Notch1 profile (Das et al., 2006). These findings 
suggest that Müller glia within mammals, do retain some stem cell 
characteristics, and appear to react under the guidance of the Notch 
signalling pathway. Understanding the mechanisms and factors implicated in 
retinogenesis may aid in the design of novel strategies to target retinal 
degenerations.  
1.2. Retinal Degenerative Diseases 
Retinal degeneration is a feature of diseases that affect the posterior 
segment of the eye specifically the retina and choroid. Degeneration of the 
retina leads to neuronal loss and is the predominant cause underlying visual 
loss (Figure 1.2). The eye, in addition to the highly organised system of 
neurons, also houses a complex network of vasculature. Problems within the 
vasculature may lead to leakage or ischaemia, whilst neuropathies lead to 
progressive neuronal atrophy. Loss of vision generally involves an 
abnormality in either or both of these networks.  
Based on the estimated figures released by the World health organisation in 
2010 (Pascolini and Mariotti, 2012), 284 million people are considered 
visually impaired, with over 39.3 million being completely blind. Retinal 
degeneration accounts for 14% of the world’s blind population with 51% due 
to cataract. In developed countries such as the United Kingdom, where 
blindness caused by cataract is no longer a main problem, retinal 
degenerative diseases, such as glaucoma, diabetic retinopathy and age-  
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Figure 1.2: Retinal structures affected by the common causes of retina- 
associated visual loss and their clinical presentation. Glaucoma occurs 
as a consequence of retinal ganglion cell degeneration, Retinitis Pigmentosa 
(RP) is a combination of genetic mutations leading to malfunctions within the 
photoreceptors and retinal pigment epithelium (RPE), Age-related Macular 
Degeneration (AMD) is caused by the abnormalities of the RPE and choroid 
leading to secondary photoreceptor degeneration and Diabetic Retinopathy is 
caused by vascular leakage and retinal ischaemia.   
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related macular degeneration (AMD) are significantly more prominent. At 
present pharmacological interventions used to treat these disorders are 
aimed at controlling their progression, but in many cases, progression cannot 
be halted and patients may go on to develop total and permanent visual loss.    
Diabetic retinopathy (DR) is a condition caused by complications of either 
poorly controlled or a lengthy duration of diabetes mellitus. Hyperglycaemia 
is associated with pericyte loss in the retinal vasculature (Chistiakov, 2011). 
This leads to thickening of the connective tissue, causing retinal vessels to 
become increasingly permeable resulting in localised vascular leakage 
(Hudson, 1996, Wilkinson et al., 2003). As the blood supply becomes more 
restricted retinal ischaemia develops and may be associated with secondary 
neural degeneration as well leading to later sequelae such as 
neovascularisation, haemorrhage and tractional retinal detachment.  
AMD is a leading cause of irreversible blindness that first affects the retinal 
pigmented epithelium (RPE). The ageing process within RPE layer appears 
to trigger a cascade of events that results in neural degeneration. Atrophy of 
RPE manifests in the eventual depletion of photoreceptors and finally loss of 
visual acuity (de Jong, 2006). Lipid containing lesions, known as drusen, are 
deposited between the choroid and RPE at the posterior pole, and are one of 
the earliest manifestations of the disease. Damage is focused on the macula 
region and therefore diminishes the central field of vision. In dry AMD the 
onset is of slow progression, but in wet AMD, the exudative form of the 
disease, the progression may be rapid with sudden and devastating visual 
impairment.  
Primary retinal degenerative diseases include congenital defects that affect 
the development and maturation of the neural retina itself. Retinitis 
Pigmentosa (RP) is usully an inherited condition leading to photoreceptor 
degeneration affecting the rods more than cones and is of a progressive 
nature. It has diverse modes of inheritance where the photoreceptors 
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deteriorate, coupled with secondary degeneration of the RPE (Berson, 
2007). Other congenital defects that lead to macular degeneration and 
neuronal loss are Stargardt’s disease (Kapadia, 2000) and Leber’s 
Congenital Amaurosis (Maguire et al., 2008). All these conditions are 
associated with progressive visual loss with no proven treatments currently 
available. 
1.3. Glaucoma 
Glaucoma is characterised by a progressive optic neuropathy associated 
with loss of RGCs within the inner retina. It is the leading cause of blindness 
in the world after cataract, accounting for 8% of the total blind population. 
This neuropathy is commonly associated with increased intraocular pressure 
(IOP) which results in atrophy of RGCs and their axons, together with the 
clinical observation of optic nerve head cupping (Levin, 2005, Singh, 2005). 
RGCs have long axonal processes which converge collectively to form the 
optic nerve. The optic nerve serves as the nerve channel that relays sensory 
information gathered by the eye to the brain. It acts by transducing the 
pattern of electrical impulses collected within the retina to the visual cortex. 
Generally there is a ratio of 100 cones and rods transmitting visual data to 
one RGC depending on the retinal region. Hence, RGC death or damage 
can lead to loss of vision, if prolonged, to complete blindness.  
The mechanisms which lead to the onset of glaucoma include cell death 
within the ganglion cell population, which ultimately impacts on the complex 
network of the neural retina as well as the efficiency of phototransduction to 
the visual cortex. Peripheral vision is lost initially and complete blindness can 
ensue if not treated. Treatments used to reduce IOP and arrest progression 
of the disease are both medical and surgical. Medical treatments currently 
target the trabecular meshwork (TM) or the ciliary body. These act by 
increasing outflow mechanisms of the TM and reducing aqueous humour 
production in order to reduce IOP, such as Lumigan. Surgical intervention is 
37 
 
used when medical treatments are no longer effective and involve laser 
treatment of the TM to increase aqueous outflow or filtration procedures to 
divert the aqueous humour into the subconjunctival space. Evidence 
suggests that patients that have advanced glaucoma with extensive nerve 
fibre degeneration of greater than 90% are still able to perform tasks to look 
after themselves and maintain a reasonable quality of life (Alward, 1999). 
This suggests that 1% of functional ganglion axons are able to retain 
sufficient central vision and can be the difference between being blind and 
being able to perform day to day tasks.  
1.4. Potential of cell-based therapies for Glaucoma 
In order to develop cell based therapies for retinal degenerations, anatomical 
constrictions need to be considered. Studies have mainly concentrated on 
RPE and photoreceptor delivery, due to the accessibility of this region for 
transplantation. Sub-retinal delivery of cells for RPE or photoreceptor disease 
are not dependent upon migration into the neural retina and y do not need to 
form neurite outgrowths for synaptic connections. Hence direct injection 
adjacent to the host RPE layer delivers the cells to their site of activity and 
need. However, cellular transplantation for inner retinal disease faces 
different obstacles compared to photoreceptor or RPE delivery.  
Tissue engineering is required in order to ensure maximum cellular 
integration of transplanted cells within the inner retina when considering cell 
replacement therapies for. Intravitreal injection of cells into the rat eye does 
appear to ensure adequate therapeutic delivery of cells into the inner retina 
(Bull et al., 2011, Johnson et al., 2009, Singhal et al., 2012). However, this 
approach of cellular transplantation onto the inner retinal surface using 
intravitreal injection into larger mammalian eyes is likely to be less 
successful. Rodents have a comparatively large lens; occupying 
approximately over half of the intraocular volume, compared to larger 
mammals, including humans (Hughes, 1979). It is therefore possible that the 
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presence of a large lens in rodents may serve as a scaffold to maintain 
cellular orientation of transplanted cells onto the retina. On this basis, cellular 
scaffolds have been proposed for use to physically support transplanted cells 
onto the retina. The use of scaffolds has also been investigated for non-stem 
cell derived RPE grafting (Falkner-Radler et al., 2011).   
Cellular environments are crucial to the development and growth of cells and 
can direct maturation and differentiation. Hence transplanting cells into 
dystrophic retinal tissue may hinder the regenerative capacity of the cells, 
within its diseased architecture. The extent of integration undergone by 
transplanted stem cells appears to depend on the state of cellular 
maturation. This has been demonstrated by the ability of grafted cells to 
integrate more efficiently when differentiated (Ong and da Cruz, 2012, 
Tibbetts et al., 2012, Stern and Temple, 2011, MacLaren et al., 2006). This 
indicates that pre-differentiation of stem cell populations would be a pre-
requisite for optimal integration and therapeutic efficacy. 
 
Cellular therapies targeted for glaucoma would aim to differentiate cells 
towards an RGC fate. Stem cell therapies for this group of neurons may also 
intend to regenerate the optic nerve itself, which is a far more challenging 
objective. There are five main subdivisions of RGCs; midget, parasol, 
bistratified, photosensitive and finally a group of ganglions cells that are 
involved in fast eye movements.  
When considering cell replacement of RGCs the mode of delivery is pivotal 
as it is important that transplanted cells are able to move into the ganglion 
cell layer and are able to migrate within it. This would ensure optimal 
integration into host tissue, maximising the degree of potential cell 
replacement. Following integration within the inner retina, cells would also 
need to form synaptic connections with the host tissue. Synapse formation 
within the ganglion cell layer itself, as well as within the inner plexiform layer 
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is essential for true RGC function. In addition in order to regenerate the optic 
nerve, cells face the immense challenge of creating long neurite processes 
that must migrate towards the lateral geniculate nucleus of the host brain. 
These steps would be required for fulfilment of adequate cell replacement 
therapies and to date have not all been achieved.  
The enhancement of RGC function observed after stem cell transplantation 
in experimental glaucoma may be due to the secretion of neurotrophic 
factors by the transplanted cells. This therapeutic response is seen across 
the whole central nervous system when stem cells are transplanted, and 
potentially constitute another avenue for cell based therapies (De Feo et al., 
2012).  
Stem cells derived from the bone marrow have been investigated for possible 
use in cell based therapies for glaucoma. Human mesenchymal stem cells 
(MSCs) have been injected into the vitreous of optic nerve axotomised rats 
(Johnson et al., 2010) and have proved to significantly reduced ganglion cell 
death. Ganglion cell survival was further enhanced by inducing the cells to 
express neurotrophic factors (NTFs). Similar observations were seen with 
human MSCs in another rat model of glaucoma (Levkovitch-Verbin et al., 
2010). In this instance IOP was increased using laser to scar the TM in order 
to reduce aqueous outflow. The MSCs rescued the retinal ganglions cells 
from further axonal damage and were also identified as releasing NTFs 
within the degenerative retinal environment. These studies however did not 
show improvement in optic nerve atrophy or cupping. Another bone marrow 
derived MSC population; with extensive stromal phenotype, were 
transplanted into glaucomatous Wistar rats. This model was achieved by 
cautery of the episcleral veins. Transplanted cells did not integrate within the 
host ganglion layer but instead lined along the inner limiting membrane. The 
cells survived for the duration of the experiment and expressed high levels of 
NTFs. Higher levels of ganglion cell survival were observed within the 
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injected glaucomatous eyes compared to their controls of increased IOPs 
(Levkovitch-Verbin et al., 2010). 
Multipotent adult stem cells have also been proposed as a tool for retinal 
ganglion cell regeneration. Recent work has demonstrated that adult human 
Müller stem cells have the ability to restore RGC function in a rodent model 
of glaucoma. This stem cell population was able to refine their gene 
expression pattern to that of a ganglion cell precursor invitro prior to 
transplantation. Functional data within this rat model of glaucoma consisting 
of ganglion cell depletion, has demonstrated the ability of these cells to 
partially restore ganglion cell function (Singhal et al., 2012). An alternative 
adult cell population used in experimental studies to treat glaucoma-like 
disease is the olfactory ensheathing cells (OECs), isolated from rat cadaveric 
nasal tissue. These cells when injected into eyes with optic nerve transection 
had a neuroprotective effect, which appears to be mediated by the secretion 
of Brain-derived neurotrophic factor (BDNF) (Li et al., 2003). 
Debates about the pathological progression and cause of glaucoma have led 
to development of different experimental models. This has built controversy 
on the extent of rescue delivered by these cell therapies. Methods for 
gathering data of ganglion cell survival and optic nerve protection are vast 
and researchers in this field use different outcome measures, including 
ganglion cell numbers, optic nerve head cupping, pattern electroretinograms 
and scotopic negative threshold responses. On this basis, to avoid variations 
in the analysis of stem cell uses, standardised methods need to be 
employed. Specifically when assessing the real functional benefit provided by 
cell therapies for glaucoma. 
Replacing or improving the health of the resident RGCs, even by a small 
proportion can have a large impact on a patient’s quality of life. Replacing 
such a low number of the RGCs is a simpler task than repopulating the whole 
ganglion cell layer and would be a significant advance for those who are 
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afflicted with advanced glaucoma. Glaucoma patients may potentially benefit 
from the repopulation of small areas of the central retina, which could 
potentially improve the range of tasks the patients could perform. This 
assumption may require the combination of stem cells therapy and tissue 
engineering.    
1.5. Stem Cells  
Stem cells are able to maintain an undifferentiated state as well as having 
the ability to continuously divide and self-renew.  These cells can produce 
daughter cells that can commit to lineages of a variety of cell types, and 
therefore have the potential to regenerate any type of tissue.  
Stem cells taken from different mature or immature tissues represent cells 
with different competencies and plasticity, based upon their development, 
source and birth. Cells taken from adult tissue that possess the stem cell 
attribute of self-renewal and ability to maintain their population, are able to 
re-enter the cell cycle, but are not always capable of generating cells from all 
the primary embryonic tissues.  
Mammalian stem cells can be sourced from either embryos or post natal 
tissues. Post natal stem cells include cells isolated from infant or adult bone 
marrow and visceral tissues.  Therefore it is conceivable that cell based 
therapies could provide a viable option for patients facing terminal vision 
loss. 
1.5.1. Embryonic stem cells 
Embryonic stem cells (ESCs) derive from the internal cells of the developing 
embryo at the blastocyst stage. These cells can be taken from the inner cell  
42 
 
  
Figure 1.3: A sub-population of Müller glia from adult human post 
mortem retinal tissue express markers of neural stem cells in vitro. 
Müller stem cells in culture express (A) the intermediate filament nestin, 
a marker of neural stem cells, (B) SOX2 which is a marker of all neural 
stem cells and including those of the retina, and (C) the early retinal 
progenitor marker CHX10. (D) These cells can be grown indefinitely 
and form neurospheres of Nestin positive cells. Following culture under 
differentiating conditions, they express neural morphology and markers 
of various retinal neurons (Figure adapted from Bhatia et al., 2010 and 
Lawrence et al., 2007)  
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mass (ICM) and exhibit the capacity to develop into all mature cells types 
present within an adult (Evans and Kaufman, 1981). This pluripotent nature 
is coupled with the ability to continuously proliferate, for which they can 
theoretically be made to propagate infinitively in vitro. This poses an 
attractive source of cells for cell-based therapies, as ESCs are able to adapt 
their morphology and phenotype in vitro in order to generate all adult cell 
types upon specific conditions in culture. As such, this led to the conclusion 
that these cells would be able to differentiate into specific cell lineages, using 
well defined external factors. Such lineages have included the production of 
hepatocytes (Watt and Forrester, 2006), retinal pigmented epithelium (Hirano 
et al., 2003), cardiomyocytes (Zhang et al., 2002), neurons (Bibel et al., 
2004) and glia (Vadivelu et al., 2005). Human ESCs (hESCs) have also 
shown the ability to differentiate into photoreceptor progenitors, mature 
photoreceptors and RPE (Lamba et al., 2009, Idelson et al., 2009), 
determined by their pattern of gene expression. Transplantation of RPE 
differentiated cells into a rodent model of photoreceptor depletion, was 
shown to induce functional improvement in response to light stimuli in vivo 
(Lamba et al., 2009). Although ESCs can potentially generate a multitude of 
cell types, the ethical restraints and the use of allogeneic material is still 
being deliberated. The main moral argument against this type of therapy lies 
with the use of embryos as a source of cells. Like induced pluripotent cells 
(iPS), ESCs have the ability to over proliferate under standard cultural  
protocols, and to form teratomas (Hentze et al., 2009). Classification and 
validation of this stem cell source still requires many investigations before 
designing cell based therapies for retinal degenerations.     
1.5.2. Induced pluripotent stem cells 
Within the last 5 years, a new group of pluripotent stem cells has been 
generated in vitro; these cells are known as induced pluripotent stem (iPS) 
cells. These originate from terminally differentiated somatic cells that have 
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undergone genetic reprogramming, arbitrated by either vector or non-vector 
means. Keratinocytes or fibroblasts from skin biopsies, are coaxed into 
continuously expressing a combination of different transcription factors; 
Octamer 3/4, Oct4, cellular myelocytomatosis oncogene, c-Myc, Krüppel-like 
factor 4, Klf4 and Sox2. Alternatively, they can be induced by only four 
factors Oct4, Sox2, Nanog and Lin28 (Takahashi and Yamanaka, 2006, 
Okita et al., 2007). Generation of these “artificial stem cells” remove some of 
the controversy surrounding the use of embryonic stem cells as they can be 
engineered from the patient’s own cells.  The use of these cells may also 
limit some of the difficulties found when harvesting tissue-specific adult stem 
cells, or when using allogeneic donor strategies. Hence, iPS cells would 
remove the restraint of the use of immunosuppressive drugs to maintain the 
survival of non-autologous transplanted cells. iPS cell therapy potentially can 
be optimised to expand cells of a required lineage under standardised 
protocols using exogenous factors, such as mitogens and basement 
proteins.  
iPS cells like embryonic stem cells are pluripotent and harbour the capacity 
to produce a variety of cell types spontaneously. However, due to the 
methods used to generate these cells, iPS cells may not be proved safe for 
transplantation. This is due to the risks faced when transforming these cells, 
as inducing the cells to up-regulate oncogenes has been shown to promote 
teratoma formation and the onset of uncontrollable proliferation. Ex vivo 
teratomas produced from iPS cultures have been shown to contain normal 
tissues of all three embryonic germ layers in an unorganised, sporadic 
pattern. Up-regulation of c-Myc has been shown to encourage the 
establishment of proliferation at an abnormal rate. Due to the increased rate 
of cell cycling there is an increased possibility of random genomic integration 
of these genes following transduction which can lead to oncogenesis and 
malignancy (Nakagawa et al., 2008). Improving methods of reprogramming 
have partly reduced the risk of promoting over proliferation. In addition, 
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reduction in the number of reprogramming genes used, as well as the 
regimes undertaken to induce pluripotency, has minimised the incidence of 
teratoma formation. Alternative induction methods have included the use of 
non-vector or -viral mediated transduction; whether by non-integrating gene 
processes or small molecules (Okita et al., 2008). However, to date the 
methods have not yielded complete success when eradicating the risk of 
inducing severe genomic alterations and unwanted cellular division. 
In relation to the application of iPS cells for retinal therapies, a type of cell 
that can be spontaneously produced using iPS cells are RPE cells, 
characterised by pigment production and atypical tight cell-cell interactions 
accompanied by expression of RPE markers (Carr et al., 2009). Alternative, 
differentiating regimes have also produced neural and glial-like cells (Dimos 
et al., 2008, Tokumoto et al., 2010, Jang et al., 2010). 
1.6. Adult tissue-derived stem cells 
Adult stem cells are found within most mature tissues where they are thought 
to repair and maintain tissues of the body. Examples of these cells are those 
found within the crypts of Lieberkuhn in the ileum (Al-Dewachi et al., 1979), 
and the Limbus within the ocular surface of the cornea (Thoft et al., 1989). 
Cell culture of adult stem cells can develop into finite lineages that can 
potentially be used to replenish specific cell niches such as haematopoietic, 
nerve or muscle. Although adult stem cells are multipotent, their function is 
generally limited to their location when induced to differentiate. Retinal stem 
cells or progenitors isolated from the adult or foetal human ocular tissue have 
been explored as a possible source for stem cell therapies directed for retinal 
degenerations (Lawrence et al., 2007, Klassen et al., 2004). They retain the 
ability to produce multiple cell types contained within the retina. It had been 
previously shown that the tissue from which retinal stem-like cells originate is 
the early post natal ciliary margin (Xu et al., 2007) within the xenopus and 
zebrafish. Tropepe et al. later showed that in mice these cells were contained 
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within a similar region to the amphibian ciliary marginal zone, and had the 
innate ability to differentiate into a range of retinal neurons as well as, to 
lesser extent, RPE cells (Tropepe et al., 2000). However, more recent 
studies have identified stem cells within the neural retina itself, which has 
been shown to be a sub-population of Müller glia (Bhatia et al., 2009, Bhatia 
et al., 2010, Bhatia et al., 2011a, Lawrence et al., 2007).  
1.6.1. Müller stem cells 
Müller cells are the main glial cells of the retina and are located throughout 
its whole structure. They provide biochemical support to the neurons and 
blood vessels of the retina, as well as structural support. The cell bodies of 
Müller glia are found within the inner nuclear layer, with cytoplasmic 
projections extending laterally and transversely throughout this layer, 
enabling interactions between themselves and other neural cell bodies.  
These interactions ensure that Müller cells can participate in neural 
homeostasis within the retinal microenvironment. Müller cells are 
characterised by the expression of epidermal growth factor receptor; EGF-R, 
glutamine synthetase, vimentin and cellular retinaldehyde binding protein; 
CRALBP.   
Within the developing mammalian adult brain, radial glia have been found to 
have the ability to repopulate both the neural cell populations as well as the 
glial population itself (Merkle et al., 2004). Other pools of glia within the CNS 
have also shown neural stem cell traits. Bergmann glia housed in the 
cerebellum of adult mice express the neural stem cell markers Sox1 and 
Sox2 (Sottile et al., 2006).  
 
Müller glial stem cells could provide a possible tool for the design of cell 
based therapies to regenerate the human retina (Lawrence et al., 2007). 
Müller stem cells have been shown to regenerate the retina after damage in 
various species, including post natal chick (Fischer and Reh, 2001, Fischer 
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and Reh, 2000), rodents (Das et al., 2006) and zebrafish (Yurco and 
Cameron, 2005, 2012). It had been thought that these innate characteristics 
had not been conserved within adult humans, despite the retina harbouring 
this cell type. Recent evidence in our laboratory has shown that these cells 
upon transplantation can partially restore retinal function in rat models of 
retinal degeneration, including neurotoxic damage to the ganglion cell layer 
(Singhal et al., 2012).  
Like most adult stem cells, human Müller stem cells appear to be multipotent 
and therefore tissue specific and restricted to producing different retinal cell 
subtypes. They express Sox2, Pax6, Chx10 and Notch1 (Lawrence et al., 
2007, Bhatia et al., 2011b). Immortalised cells cultured in vitro are able to 
differentiate into a variety of retinal neurons, which in turn express distinctive 
markers. These include; peripherin, a marker of photoreceptors, Protein 
Kinase, a marker of bipolar cells, calretinin, a marker of both amacrine and 
horizontal cells along with Brn3b; an early marker of committed RGC 
precursors (Lawrence et al., 2007, Singhal et al., 2012, Bhatia et al., 2011b).  
These cells are also able to form neurospheres that express Nestin, a protein 
marker of early stem cell differentiation (Figure 1.3). The formation of 
neurospheres and subsequent ability to differentiate in vitro is achieved using 
bioactive growth factors such as basic fibroblast growth factor (bFGF), 
epithelium growth factor (EGF) or insulin.   
Sourcing human Müller stem cells is a relatively easy procedure as they can 
be obtained from cadaveric donor tissues and can be induced to undergo 
extensive expansion in vitro. Use of these cells for human therapies would 
eradicate the ethical and moral objections to embryonic stem cell based 
therapies and merits investigations. 
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1.6.1.1. Differentiation of Müller stem cells into retinal ganglion 
cells 
Committing the Müller stem cell population to a RGC fate involves inhibiting 
the Notch signalling pathway, one of the early regulatory signalling cascades 
that prevent specification of both early and late retinal progenitors 
(Andreazzoli, 2009). This pathway involves a family of transmembrane 
protein receptors that act to suppress differentiation of stem cells and 
maintain a constant level of proliferation. When a Notch ligand binds the 
receptor, an intracellular domain of the protein activates and triggers a 
cascade reaction (Jadhav et al., 2006). By upregulating its target genes, the 
pathway causes inhibition of differentiation by down regulating factors that 
encourage neural development. Progenitors and stem cells maintain their 
pluripotent state during development by maintaining this signalling pathway 
active. Hence in order to differentiate, signalling via this pathway must be 
prevented.  
Human Müller stem cells treated with a Notch inhibitor undergo a significant 
adaptation to a proneural state. When this state is exploited by the 
subsequent addition of bFGF, it causes the cells to downregulate their  gene 
expression of markers of Müller cells and convert to the expression of 
markers an early RGC precursor, demonstrating their ability to revert back to 
the mitotic phase and differentiate towards a RGC phenotype (Singhal et al., 
2012).  
Over the last ten years investigators have found another group of 
translational modulators, in the form of microRNAs (miRNA), active during 
development and adulthood. microRNAs are short sequences of RNA that 
are simultaneously generated alongside their messenger RNA (mRNA). 
They function by suppressing the translation of proteins by steric hindrance 
or degradation of the mRNA preventing translation. miRNAs are involved in 
the regulation of the downstream targets of Notch, and have also been 
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targeted themselves by Notch, preventing differentiation (Garzia et al., 2009). 
Investigating their capacity within Müller stem cells could potentially be used 
to promote differentiation of latent Müller glia within dystrophic retina, 
removing the need for invasive therapy of cellular scaffolds. 
1.6.2. Bone marrow derived stem cells 
The bone marrow houses a heterogeneous population of stem cells that 
perform specific duties. The two main subsets of stem cells present in the 
bone marrow are haematopoietic and mesenchymal stem cells. Use of 
autologous bone marrow cells eliminates the potential risk of allogenic 
transplantation, which in many cases necessitates lifelong 
immunosuppression. Haematopoietic stem cells (HSCs) are able to induce 
differentiation down various haematopoietic lineages giving rise to all the 
blood cells of the circulatory system, whilst maintaining a pool of blood stem 
cells and progenitors. Mesenchymal stem cells represent a population that 
exhibit large mononuclei and have the ability to adhere to plastic culture 
surfaces. These cells have also been retrieved from non-bone marrow 
sources derived from tissue originating from the mesoderm, such as adipose 
tissue, as well as non-mesoderm tissues including liver, umbilical cord, cord 
blood and placenta. MSCs possess cellular features typical of cells contained 
within both the stroma and mesenchyme. These are the connective tissues 
which surround the organs of the body. Whilst the stroma imparts structural 
support, the mesenchyme forms loosely around the organs and contains 
highly mobile cells. These stem cells have been shown to differentiate into a 
wide range of cells, displaying pluripotent ability (Shakhbazau et al., 2011, 
Chen et al., 2012, Khlusov et al., 2011). It was assumed that MSCs would 
exhibit only a multipotent capability, only differentiating into restricted 
lineages. However these cells are able to produce daughter cells that 
possess cellular attributes characteristic not only of the mesoderm, but also 
the ectoderm and endoderm germ layers. Bone marrow derived stem cells 
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demonstrate a potential pool of cells that can undergo multipotent 
differentiation for possible retinal degeneration applications.    
1.7. Retinal ganglion cell differentiation 
RGCs are the first cells generated during mammalian retinogenesis from the 
primary retinal neuroblasts, following initial formation of the optic cups from 
the neural plate at embryonic day (E) 8.0 (Young, 1985). The neuroblasts 
present then proliferate under the influence of Pax6 (Livesey and Cepko, 
2001, Marquardt et al., 2001). RGCs appear in the mouse at E11.5, when 
the stem cells begin to divide asymmetrically producing a progeny of 
daughter cells which have exited cell cycling (Young, 1985). These primary 
RGC precursors do not all develop into ganglion cells but this early 
specification begins within the temporal, central region of the young retina 
and spreads out to the anterior periphery (Hu and Easter, 1999). This 
primary proliferation is prompted by the secretion of Shh which follows a 
route to the outer regions of the retina and has been evidenced in zebrafish, 
in which it appears to be the main factor responsible for RGC specification. 
The next stage involves a refinement period of cell competence that 
determines their development; this comprises the expression of basic helix-
loop-helix (bHLH) transcription factors Ath5 and NeuroD at E13.5 in the 
mouse, that induce these precursors to commit to RGC fate (Brown et al., 
1998, Pennesi et al., 2003). In addition, inhibitors of the cell cycle; p27
Kip1 
and p57
Kip2
 are also expressed within these precursor cells, and are charged 
with hindering the activity of cyclin kinases (Dyer and Cepko, 2001). The 
exact combination of gene expressions that contribute to RGC precursor 
development does not appear to be completely defined due to the early birth 
of this population. The scenario may involve RGC precursor commitment 
being determined during early progenitor proliferation, where a progenitor 
competent in becoming any retinal cell decides to devote its lineage to a 
ganglion fate. Alternatively postmitotic cells become ganglion cells when all 
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the progenitor divisions have concluded. Despite this we see genes, 
consecutively involved in the tailoring of retinal cell genesis. Specifically for 
RGCs we find Pax6, Six3, Rx, Chx10 and the Notch pathway including the 
Ath5 and the Brn3 family (Mu and Klein, 2004, Marquardt et al., 2001). 
These factors determine the correct spatial patterning of the ganglion cell 
layer and ensure its networking organisation is correctly established.  
The Notch pathway prevents the expression of proneural genes and triggers 
the expression of an alternative set of bHLH factors; Hes1 and Hes5 which 
have been shown to target the Ath family for repression. Ath5 is essential for 
RGC production and alterations in its expression is manifested in changes in 
the amount of ganglion cells made during retinogenesis. Overexpression of 
Ath5 results in an excess of RGCs made at the expense of other neurons 
and glia in chick (Liu et al., 2001) and xenopus (Kanekar et al., 1997) retinae. 
Knock-out experiments in mice (Wang et al., 2001) and zebrafish (Kay et al., 
2001) for Ath5 homologs ended with the almost complete lack of RGCs and 
a surplus of both cones and amacrine cells. Though Ath5 expression is 
essential for RGC initiation and determination and all cells committed to a 
ganglion fate expressed Ath5, not all the Ath5-expressing cells become 
RGCs, suggesting the upstream roll of this bHLH in RGC specification as 
well as the presence of other influential cues involved in ganglion 
differentiation. Hence the over production of RGCs observed in knock-in 
studies indicates the creation of a larger cohort of proliferative progeny 
competent to generate RGCs.  
Downstream targets of Ath5 are the earliest determinant switches of RGC 
differentiation. The class IV POU domain transcription factor; Brn3b is similar 
to other transcription factors. Like Pax6, Brn3b has a bipartite DNA binding 
domain (Liu et al., 2000) and it has been reported that Brn3b expression is 
vital for RGC development and maturation. BRN3B knockout mice fail to 
produce a normal population of ganglion cells, losing 70% viability (Liu et al., 
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2000). Brn3b expression occurs rapidly, once the progenitors of the retina 
have exited the cell cycle and have committed to a RGC specification. Ath5 
proceeds the expression of Brn3b in competent ganglion cell progenitors, 
whilst Brn3b expression is exclusively found in post mitotic RGC precursors 
as well as mature ganglion cells (Gan et al., 1999). It is thought Ath5 
commences Brn3b expression, however its maintenance involves other cues 
once Ath5 production ceases, indicative of the presence of cofactors that lie 
between the two genes and may act to maintain Brn3b independently of 
Ath5, or in association. Apoptosis of ganglion cell progenitors coincides with 
a depression of BRN3B, indicating a close synergy between RGC maturation 
and BRN3B expression. 
Final differentiation entails the spatial localisation of the RGC and the 
development of functional axons, dendrites and synapses. This organisation 
requires genes able to orchestrate ion channel formation, axon guiding 
agents and synaptic neurotransmitters. Cells undergoing differentiation 
commit to migrate to the inner layer of the neuroepithelium and become 
polarised in morphology and send out axonal projections which ultimately 
converge together to from the optic nerve. 87 genes have been reported, 
which are under the regulation of Brn3b are the controllers of the final 
differentiation of RGC and are involved in their maturation and maintenance 
of function (Mu and Klein, 2004). Brn3b also has a negative impact on Shh 
secretion and acts to prevent abnormal amounts of proliferation once 
maturation has commenced (Zhang and Yang, 2001). The transcriptional 
control of ganglion cells gives an insight into how stem cell differentiation 
may be influenced to follow a neural lineage, as well as how control of the 
transcription factors by epigenetic targeting may be induced.    
1.8. Tissue Engineering for Stem Cell Transplantation into the Eye 
The eye is considered to be an extension of the brain, and as such is part of 
the central nervous system (CNS). Damage within the CNS is irreversible 
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due to the lack of regenerative cells and the non-permissive architecture of 
these tissues (Jacobs and Fehlings, 2003). Regeneration of the retina may 
not be possible, but studies are aimed at improving function by either 
replacing damaged cells or promoting survival and regeneration of the 
remaining cells. To this effect, cell delivery to replace neural populations, 
would need to achieve differentiation, integration and survival with the host 
tissue (Mason and Dunnill, 2008). Encouraging residual dystrophic cells to 
survive and maintain their inherent functionality may also be achieved by 
delivery of cells that release trophic factors, as well as injections of 
therapeutic drugs, genes or factors. Tissue engineering aims to enhance, 
restore or maintain tissue function and involves the application of various 
disciplines in the biological, engineering and medical fields. 
Natural polymers are favoured by tissue engineers due to their inherent 
biocompatibility with the body, and have been extensively employed clinically 
to create in vivo substrates, such as lubricants, dermal and wound sealants, 
surgical sponges and dermal fillers (Johl and Burgett, 2006, Lapcik et al., 
1998). Cell delivery by such polymers has been studied using astrocytes, 
Schwann cells and neural progenitors, and these potentially can be used for 
retinal cell transplantation.  
Collagens are an important source of natural polymers and are a family of 
ubiquitous proteins, which constitute a significant proportion of the basement 
membrane and support tissue structures. Type I collagen is used currently in 
the clinic in the form of surgical sponges for swabbing and wound dressings, 
and has also been used for drug delivery in this form (Bai et al., 2010). Both 
collagen hydrogels and electrospun matrices have also been studied for 
clinical application.  Since both collagen gels and scaffolds are inherently 
weak, similar to other natural polymers following extraction processes, they 
require structural reinforcement (Matthews et al., 2002, Pieper et al., 2002). 
Chemical crosslinkers are currently the prime candidate used to improve 
54 
 
durability and give strength to such matrices. Glutaraldehyde (GTA) is an 
aldehyde derivative used in laboratory settings as a fixative which has the 
ability to crosslink cellular proteins, and as such is used to strengthen 
collagen matrices. However the use of such chemicals is cytotoxic when 
implanted in vivo, due to the release of residual reactive moieties from GTA. 
In addition, to chemical crosslinkers, non-toxic crosslinking catalysts are also 
used to enhance collagen robustness as well as other natural polymers 
(Macaya and Spector, 2012). Genipin is sourced from gardenia plants and is 
an aglycone (non-saccharide sugar component) which constitutes a natural 
protein crosslinker that catalyses protein fibre coupling. Following 
crosslinking, collagen matrices have been studied for its factor loading 
capabilities where evidence demonstrated the ability of collagen being able 
to stably release ciliary neurotrophic factor (CNTF) to proximal rat neural 
stem cells, safeguarding their proliferation and survival, under culture 
conditions (Yang et al., 2010).  
An alternative source of natural material is hyaluronan (HA), which like 
collagen is found extensively in connective tissues and within cellular 
supportive matrices. It has an innate feature which enables cells to grow and 
proliferative in vivo as well as aiding wound healing processes (Pakulska et 
al., 2012). HA is intrinsically weak and unlike other natural polymers, it is 
unable to polymerise once it has been extracted from native tissues and is 
prone to digestion unless exhaustively crosslinked or blended with other 
polymers which impart strength to the mixture (Ji et al., 2006, Zheng Shu et 
al., 2004). One such example is the blending of methylcellulose and HA for 
gels containing bFGF and EGF for transplantation for spinal cord (Kang et 
al., 2009) and stroke (Cooke et al., 2011) degenerations. It was initially 
evident that in order to sustain factor loading of HA mixed matrices would 
require further modulation, as factors were seen to leach fully within 24 hours 
following loading. To sequester the factors suitably poly(lactic-co-glycolic 
acid (PLGA) nanoparticles were made to incorporate the factors which were 
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then included into the matrices, which improved the release profile of these 
factors (Baumann et al., 2009). 
Synthetic materials have also been proposed, and have generally been used 
in the past as co-polymers; however researchers are examining the potential 
of their standalone application for drug and cell delivery. The processing of 
such polymers gives researchers the opportunity to synthesise materials 
from the bottom up, where the features can be tailored for a distinct use. 
Both BDNF and NT-3 have been incorporated into synthetic materials 
composing of poly-(N-isopropylacrylamide) (PNIPAAm) with the addition of 
poly-(ethylene glycol) (PEG) functional groups. Constructs were found to 
release the two factors over a period of 30 days in vitro (Vernengo et al., 
2008). Poly-(lactic acid) (PLA) is usually used in biology as a co-polymer. 
Modification of its monomer sequence can be made to include agents such 
as NT-3, which can subsequently prolong its release for up to 14 days in 
murine models of spinal cord injury (SCI) (Piantino et al., 2006). Retinal 
progenitors have been cultured on synthetic PLA, and its derivatives (Tomita 
et al., 2005), polycaprolactone (PCL) (Sodha et al., 2011) and poly-(glycerol-
sebacate) (PGS) (Neeley et al., 2008) have been investigated for their 
potential to support cells for transplantation.  
Construct-tissue dynamics has been shown to be integral to the survival of 
grafted cells, integration into host tissue and prevention of necrosis of local 
cell populations. Preventing cellular aggregation of transplanted cells and 
encouraging cellular distribution on a tissues surface has been shown to 
promote cell survival and host integration (Pakulska et al., 2012). Whilst 
uniform distribution of grafted cells can favour survival of transplants, the 
presence of a cellular support which provides an adherent surface for grafted 
cells limits anoikis (a form of cell death) (Frisch and Francis, 1994, Frisch 
and Screaton, 2001) and suggests an advantage over cell suspension 
delivery.  
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An ideal engineered construct needs to have an in vitro 3D structure able to 
regulate and control cell function. Proteins of the basement membrane have 
been used as a 2D planar culture layers or in a 3D form, and this includes 
extracellular membrane proteins reconstituted from the basement 
membrane. These are aimed to support cell growth, attachment and 
differentiation. The extent to which uniform cellular integration occurs 
throughout the whole inner surface of the retina following transportation has 
so far been limited in our laboratory with an uneven distribution of 
transplanted cells observed upon injection of cell suspensions. Cellular 
scaffolds or nanostructures have been proposed to address this problem, 
whilst supporting the cells structurally and assisting in their delivery onto the 
damaged retina. Employing a cellular scaffold involves engineering a 
structure which has biocompatibility and bio mimicry.  
There is therefore the need to create a vehicle for cell delivery in order to 
regenerate the retinal ganglion cell population after degeneration, the major 
pathology of glaucoma. The creation of a suitable construct would provide a 
platform for uniform cellular distribution which would aim to promote host 
integration and cell survival. This project favoured the use of Collagen Type-I 
as a natural polymer, which has recently been modified by non-toxic 
processing involving physical crosslinking removing the need for using 
chemicals. Collagen scaffolds produced by plastic compression (PC) (Brown 
et al., 2005) can be produced that have a geometrical conformation 
resembling the in vivo dimensions of a basement membrane. Type-I 
Collagen is a readily sourced protein that can be tailored to build these 
matrices to provide biological support to cells. Stem cell transplantation 
studies to repair degenerated retina have not yet achieved adequate cellular 
distribution across the neural retina. This is partly attributed to the anatomical 
features of the retina and surrounding tissues that prevent optimal migration 
and integration of injected cells. There is therefore the need to develop 
57 
 
methods that can efficiently and safely deliver cells into the retina as a tool 
for cell based therapies to treat retinal disease. 
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1.9. Objectives of this thesis 
Based on the current knowledge within the field of stem cell biology and 
transplantation, and the need for the design of cell based therapies to treat 
end stage glaucoma, it is important to define parameters to ensure optimal 
differentiation of retinal ganglion cells (RGCs) from Müller stem cells, as well 
as to design appropriate methods to ensure widespread delivery of these 
cells into the RGC layer. To validate previous protocols used for RGC 
generation in vitro  this study investigated molecular mechanisms known to 
promote RGC differentiation during development. The project also aimed to 
develop collagen-based scaffolds for cellular delivery onto the retina in vitro 
and in vivo, and examined the interaction between Müller  stem cell-derived 
RGCs and the scaffolds. 
The following objectives were therefore formulated. 
1. To investigate downstream targets involved in the Notch signalling 
pathway that lead to differentiation of Müller stem cells into RGCs in 
vitro. This part of the study involved the examination of miRNA 
expression by cells undergoing Notch inhibition, as well as the 
determination of transcription factors controlled by Notch activation, 
and upregulation of known RGC markers. 
 
2. To develop protocols for the design of cellular scaffolds to facilitate 
uniform transplantation of RGCs onto the inner retina. This research 
involved the use of electrospinning protocols as well as compression 
methods to produce collagen scaffolds which could serve as supports 
for cell transplantation. Various crosslinking agents as well as their 
affect on cell viability, proliferation and differentiation were used in the 
study. 
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3. To determine the capacity of cellular scaffolds to support migration 
and integration of RGCS into the retina. This part of the study 
examined the ability of scaffolds to facilitate migration of RGCs onto 
the human retinal explants in vitro and onto rabbit retina in vivo.  
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Chapter 2: Changes in MicroRNA Expression 
during Retinal Ganglion Cell 
Differentiation of Müller Stem Cells 
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2.1. Müller Glia with stem cell characteristics in the adult retina 
Adult retinal stem cells have been identified within the mature human retina. 
Investigations into the features of this population have identified them as a 
population of Müller glia. These cells appear to remain quiescent within adult 
tissue and are unable to regenerate retina, however they constitute a 
population that has the potential for establishing cell-based therapies for 
retinal degenerations. To understand this capacity, a better understanding of 
the properties of retinal stem cells within the Müller population is required. 
RGCs are the first cells to be born in the retina, with Müller glia being 
generated last. In fish and amphibians Müller cells are able to repair retinal 
damage incurred even during adulthood (Bernardos et al., 2007). It is 
thought that the cohort of cells that possess the capacity to regenerate retinal 
tissue in these species are a population of late radial glial progenitors that 
appear to have retained their progenitor potential, and are able to re-enter 
the cell cycle (Walcott and Provis, 2003, Seigel et al., 1996, Das et al., 2006). 
They also retain their predecessors’ morphology of elongated bipolar-like 
structures, which during development aids with the migration of young 
neurons to their various retinal laminae (Meller and Tetzlaff, 1976). 
Retinogenesis involves two distinct histogenic periods, one involves early 
neuronal development and the second involves the generation of late born 
neurons and the glial population. Assuming that the radial glial progenitors 
are conserved within the mature Müller population, it could imply that these 
cells would be restricted in producing progeny born later during 
retinogenesis. However in fish and amphibians this is not the case. 
In response to injury, quiescent Müller stem cells in amphibians have the 
ability to undergo phenotypic adaptations to permit de-differentiation, 
controlled proliferation, migration to damaged lamina and differentiation into 
new neurons (Reh and Fischer, 2001, Ooto et al., 2004). Both fish and 
amphibian retinae can undergo neural growth through the proliferation of 
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Müller stem cells in the ciliary marginal zone (CMZ) (Mack et al., 1998), 
which is the junction at which the neural retina and ciliary body meet. Müller 
stem cells are also housed within the main body of the teleost fish retina and 
largely yield RGCs following damage, although the primary production of new 
cells is co-ordinated from the CMZ (Julian et al., 1998, Kassen et al., 2008). 
Amphibian retina can also undergo regeneration through trans-differentiation 
of their RPE (Raymond, 1991), as well as the stem cells of the CMZ (Umino 
and Saito, 2002). The outer nuclear layer (ONL) of the adult fish contains rod 
precursors able to respond to rod photoreceptor damage, and can stimulate 
proximal Müller stem cells to proliferate into photoreceptors and migrate into 
the ONL along the surface of non-plastic residual Müller glia (Reh and 
Levine, 1998, Morris et al., 2008, Otteson and Hitchcock, 2003). In zebrafish 
Müller cells express the “master controller” transcription factor Pax6, cone 
rod homeobox (CRX) and α1-tubulin (Fausett and Goldman, 2006, Fausett et 
al., 2008), indicative of the innate capacity of these cells to enable production 
of all retinal neurons in the post-natal period (Bernardos et al., 2007). Müller 
glia from zebrafish constitutively upregulate the expression of the basic helix-
helix (b-HLH) transcript achaete-scute homolog-1a (ash-1a), which is thought 
to assist in the transformation of dormant Müller stem cells into potent 
progenitors, encouraging a pro-neuronal, cell cycling state (Fausett et al., 
2008).  
Whilst adult cold blooded vertebrates demonstrate the innate ability to 
regenerate the neural retina, warm blooded animals show a restricted 
capacity, which in most cases ceases rapidly following birth. When damaged, 
the young chick retina has the ability for a cohort of Müller glia to alter their 
expression profile to that of a pro-neuronal state. This behaviour is mediated 
by the ash-1a homolog CASH-1, Pax6 and Chx10. These cells mainly 
generate other Müller cells with or without progenitor features, however a 
number of them are able to exit the cell cycle and differentiate into retinal 
neurons, demonstrating their regenerative capabilities (Fischer and Reh, 
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2001, Fischer and Reh, 2003). However this regenerative ability becomes 
less potent over time and decreases with increasing age. The anatomical 
region housing the majority of the progenitor-like cells diminishes over time, 
and is observed to regress to the more peripheral retinal domains.  
In vivo de-differentiation and proliferation of the latent Müller stem cell 
population can be induced by bFGF and insulin injections (Fischer et al., 
2002). Expression of NeuroD contributes to neuronal differentiation of chick 
Müller stem cells, but it is thought that the relatively low degree of glial to 
neuronal differentiation is due to the presence of pro-glial signalling mediated 
by bone morphogenetic proteins (BMPs) within injured retinal tissue (Fischer 
et al., 2004b, Fischer et al., 2004a). Notch is also a major contributory factor 
to the progenicity of Müller stem cells following injury. Its constitutive 
signalling maintains the proliferative and undifferentiated state of the Müller 
stem cell population, and also limits the extent of neuronal de-differentiation 
by Müller glia within the retina (Hayes et al., 2007). 
Mammalian retinae have also exhibited evidence of a restricted level of 
retinal regeneration, driven by a sub-population of Müller cells in early post-
natal life (Blackshaw et al., 2004). Both rat and murine retina have been 
shown to contain a cohort of Müller cells that express the homeodomain 
transcription factors Pax6 and Chx10 (Rowan and Cepko, 2004), with murine 
Müller cells directing their plasticity via their expression of Notch and  Nestin 
(Roesch et al., 2008). Various markers of neuronal development have been 
also found to be upregulated within rodent Müller stem cells following injury. 
The adult human retina also harbours a population of Müller cells that 
express proteins of early retinal progenitors such as, Sox2, Chx10 and Pax6, 
as well as markers of retinal glia and neurons (Bhatia et al., 2011b).  
The main pathways involved in co-ordinating Müller-derived retinal 
regeneration in mammalian retina have been identified as the Notch and 
Wnt/β-catenin signalling cascades (Das et al., 2006, Osakada et al., 2007). 
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Wnt3a promotes proliferation of Müller stem cells in murine models of 
photoreceptor deficiency, whilst in humans Notch-1 has been shown to play 
a role in maintaining cell cycling and an undifferentiated state in vitro. 
Inhibition of this pathway in human Müller stem cells has been shown to 
induce RGC differentiation (Singhal et al., 2012). 
2.1.1. The Notch pathway 
The Notch pathway has been shown to play a significant role within the 
development of the central nervous system. Since the Notch-1 pathway is an 
integral component of Müller stem cell differentiation, the understanding of 
how Notch controls RGC maturation is crucial in determining the extent of 
RGC development in vitro, as well as the mechanisms involved in such a 
process. 
The Notch pathway involves the constitutive signalling of a heterodimeric 
transmembrane receptor within stem cell populations, and is a highly 
conserved signalling mechanism observed in many species (Yu et al., 2008). 
This pathway mediates the maturation as well as the maintenance of stem 
cell niches, especially those involved in neurogenesis. The Notch receptor 
family of proteins span the plasma membrane in a characteristic single pass 
fashion where the extracellular domain, consisting of multiple EGF-like 
motifs, is involved in the ligand binding process (Faigle and Song, 2013) 
(Figure 2.1). There are four members of the Notch family, identified by the 
number of EGF repeat motifs. In Drosophila the protein receptor is activated 
by the binding of its extracellular domain by its ligand, either Serrate or Delta 
on adjacent cells (Louvi and Artavanis-Tsakonas, 2006). These ligands have 
either an excitatory or inhibitory mode of action, depending on the state and 
or maturation of neighbouring cells. Serrate inhibits the Notch cascade whilst 
Delta and its mammalian homologues, Jagged and Delta-like, activate the 
pathway (Stump et al., 2002). Following binding and activation, both the
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Figure 2.1: Processing and activation of Notch-1 by proteolytic 
cleavage. Upon binding with its ligands (Delta or Jagged) the Notch 
receptor is activated, both the intracellular (ICD) and extracellular domains 
of the receptor are cleaved. The ICD is released by the action of gamma 
secretase and translocates to the nucleus, where it initiates the 
transcription of Hes1 and Hes5, mediated by CSL proteins. Hes1 and 
Hes5 act as transcriptional repressors of pro-neural genes, attenuating 
neural differentiation. (Modified from Hakateyama and Kageyama, 2004, 
using Motifolio) 
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extracellular and intracellular domains undergo enzymatic cleavage. The 
ligand-bound extracellular domain is cleaved by the tumour necrosis factor 
alpha-converting enzyme (TACE) and is in turn endocytosed along with its 
ligand, into the ligand expressing cell. Subsequently the Notch intracellular 
domain (ICD) is also cleaved upon activation, mediated by the enzyme 
presenilin gamma secretase (Miele et al., 2006a, Miele et al., 2006b).  
Upon cleavage from the transmembrane receptor, the Notch ICD 
translocates to the nucleus where it interacts with a member of the 
CBF1/RBP-J kappa, Suppressor of Hairless, Lag-1 (CSL) transcription factor 
family. This association is thought to be mediated by the RBP-J kappa-
association molecule (RAM) of the Notch ICD (Miele et al., 2006a, Miele et 
al., 2006b, Okuyama et al., 2008, Deregowski et al., 2006). A number of 
genetic targets have been identified as housing CSL binding sites that 
propagate the Notch signalling cascade for cellular regulation. These include 
Hairy enhance of split-1 (Hes-1), NF-kB, Cyclin D1 and c-Myc. Some are 
present in all tissue types whilst others are limited to specific tissues 
(Okuyama et al., 2008, Miele and Osborne, 1999). 
Activation of the transcription of Hes1 and subsequently of Hes5 by the 
Notch ICD is followed by their interaction with the transcription repressor 
Groucho (Nagel and Preiss, 2011). This results in the suppression of 
transcription of downstream pro-neuronal genes, hindering differentiation 
during development (Hatakeyama et al., 2006, Das et al., 2005, Ohsawa and 
Kageyama, 2008). The activity of Notch in repressing neural development is 
also synchronised with continuous self-renewal, allowing stem cells to remain 
within the cell cycle. Cyclin D1 and CDK2 transcription factors are directly 
activated by Notch signalling, and when activated via CSL binding, their 
levels of mRNA have been shown to increase in neuroepithelial and cancer 
cells (Ronchini and Capobianco, 2001). Notch signalling plays a regulatory 
role in Müller glial differentiation and maintenance of the glial state (Nelson et 
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al., 2011, Nelson and Hyde, 2012). In addition, downregulation of Notch 
signalling in human Müller glia with stem cell characteristics has been shown 
to induce RGC differentiation (Singhal et al., 2012). 
2.1.2. The Role of the Notch-1 Pathway in Müller Stem Cells 
Ocular development encompasses a range of developmental processes 
including gliogenesis, neurogenesis and vascularisation in a conserved, well-
ordered manner.  
Notch 1 expression has been identified within the developing eye, with  
expression being located on the inner surface of the optic cup. During 
development Notch activity is down regulated once progenitors begin 
differentiation and maturation, which is followed by migration to their 
respective layers within the retina. Ganglion cells being the first to be born 
are the first population where Notch signalling is down regulated. This is an 
essential step for RGC maturation in both Chick and Xenopus retinae 
(Ohsawa and Kageyama, 2008). The loss of Notch activity and its 
downstream effector Hes1 favours an intrinsic establishment of pro-neural 
gene expression inducing differentiation. In terms of the RGC population, this 
involves the upregulation of the human gene ATOH7, as well as its murine 
equivalent Math5 and Mash1. Notch signalling within the initial progenitor 
pool prevents the onset of ganglion cell neurogenesis and aids the 
development of Müller glia during gliogenesis (Gaiano et al., 2000). Prior to 
rod, bipolar and glial differentiation the late progenitors transform into a 
resilient radial glial subtype which retains the bipolar elongated morphology 
and proliferative capacity of their earlier predecessors, ensuring their ability 
to produce glia and neurons. Evidence in Xenopus development has 
demonstrated that cells produced during late retinogenesis that originate 
from late-radial glial progenitors and are able to maintain Notch activity, 
develop into Müller glia (Dorsky et al., 1995). Although these cells require 
Notch signalling to commit initially to gliogenesis, in order to terminally 
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differentiate, Notch signalling must ultimately be repressed (Dorsky et al., 
1995). This mode of progenitor development may be the reason why in lower 
mammals and amphibians Müller glia are able to de-differentiate and re-enter 
the cell cycle in response to neuronal damage. 
2.1.3. MicroRNA function and phenotype regulation  
Neural stem cell renewal and maturation has also been linked to a range of 
external and internal control mechanisms during development. Recent 
research has begun to define the processing cues that act as molecular 
regulators of protein expression profiles by means of restricting or enhancing 
transcript production. These endogenous regulators are known as 
microRNAs (miRNAs). There have been over 1,000 miRNAs identified in the 
human genome. They function to repress translation by targeting gene 
coding transcripts and altering their conformation, ultimately causing steric 
hindrance of their target messenger RNA (mRNA). This changes the gene 
patterning within a cell which can in turn promote different cellular activities, 
for example division, differentiation, potency or apoptosis (Guo et al., 2010, 
Takada and Asahara, 2012).  
miRNAs are short single stranded sequences of RNA which can range 
between 10-22 nucleotides (nt) long, and are encoded within intronic or 
intergenic regions of genomes in a conserved manner between eukaryotic 
species. The transcription of miRNAs provides an extra layer of control on 
post-transcriptional and translational processes, resulting in a system that 
functions to regulate the extent of protein activity. The majority of this control 
is reflected on the production of protein, and manifests at the mRNA level by 
mediating the stability of the mRNA structure. Unlike small interfering RNAs 
(siRNAs), miRNAs are made from single-stranded transcripts rather than 
long double-stranded sequences. Targeted genes undergo transcription by 
Polymerase III which simultaneously triggers the production of miRNA 
transcripts via the action of Polymerase II. This yields a short sequence 
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adjacent to the target gene, producing a hairpin structured primary microRNA 
(pri-miRNA) sequence 72-100 nucleotides (nt) long. Prior to exiting the 
nucleus miRNAs are modified via cleavage of the hairpin ends, which is 
performed by associating with Drosha (RNase III enzyme), DGCR8 (in 
vertebrates) or Pasha (in non-vertebrates), producing smaller hairpin/stem-
loop structures. These are known as precursor microRNA (pre-miRNA) 
duplex comprising of 65-70nt, or less, with 2-5nt 3’ overhangs (Liu et al., 
2008, Okamura et al., 2008a, Okamura et al., 2008b). The molecule then 
exits the nucleus and enters the cytoplasm through the nuclear pores aided 
by Exportin-5 complexes, powered by Ran-GTP. Upon entry into the cytosol, 
pre-miRNAs form complexes with Dicer, which consequently remodels and 
cleaves the RNA molecule to produce mature miRNAs, approximately 22nt 
long (Khvorova et al., 2003, Schwarz et al., 2003). The resulting duplex binds 
RNA-induced silencing complex (RISC) as well as Argonaut proteins, namely 
Ago1, Ago2, Ago3 and Ago4, to aid the stabilisation of the short RNA 
molecule. This causes the complementary strand of the small hairpin to be 
discarded (Parker and Barford, 2006). The binding is mediated by RNA 
binding proteins such as HIV-1 TAR RNA binding protein (TRBP) and 
Cellular protein activator of PKR (PACT), and supports the association 
between the two molecules. Dependent on the complementary nature of the 
mature miRNA sequence to its mRNA target, it is able to cause degradation 
of the mRNA transcript upon its binding to Ago2 (Takada and Asahara, 
2012). When miRNA sequences are not fully complementary there is semi- 
efficient binding of the complex to its targets, resulting in mRNA retention for 
either gene silencing or translational inhibition (Figure 2.2). The mechanisms 
by which miRNA finally degrades mRNA or disrupts translation is by binding 
to the 3’ untranslated regions (UTRs) of target mRNAs. miRNAs are able to 
target and suppress multiple mRNA transcripts, whilst one mRNA can be 
targeted by numerous miRNAs depending on their location, maturation and 
function. 
70 
 
  
Figure 2.2: microRNA biogenesis.  The primary miRNA hairpin structure is 
synthesised via the action of RNA polymerase II, which is then modified by 
DRGC8/Drosha complex, resulting in the production of the precursor miRNA 
molecule. The RNA molecule is exported out of the nucleus and undergoes 
cleavage by Dicer. One of the final, mature strands associates with RNA 
induced silencing complex (RISC), where the miRNA and its transcript target 
interact, which either leads to translation suppression or mRNA degradation.  
(Modified from Liu et al, 2008, using Motifolio). 
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Although mature miRNAs are regulatory agents within translational 
processes, they themselves have been shown to be under regulation by 
other components of the gene expression machinery. The majority of miRNA 
modulation involves their repression in the nucleus by transcription factors, 
cofactors and other miRNAs. Transcription factors determine the expression 
of mature miRNA by preventing pri-miRNA production (Rodriguez et al., 
2004). Cofactors involved in miRNA maturation can prevent or enhance their 
production. Proteins recruited to hinder miRNA maturation alter the cleavage 
of immature miRNAs by Drosha or Dicer and the Argonaut proteins (Zhang 
and Zeng, 2010). Enhancing miRNA generation involves proteins facilitating 
cleavage by either Dicer or Drosha. KH-type splicing regulatory protein 
(KHSRP) contains several multifunctional RNA-binding sites intended to aid 
both Drosha and Dicer recruitment of a number of RNA transcripts, 
especially pre-miRNAs and pri-RNAs (Trabucchi et al., 2009). Other auxiliary 
protein expression, involved in miRNA production can alter their generation, 
including Argonaut proteins (Zhang et al., 2009) and the nuclear pore protein 
Exportin-5 (Yi et al., 2005). These can all effect cellular proliferation, 
differentiation and maturation within different tissues.  
2.1.4. MicroRNA Expression in the Retina 
miRNAs are extensively expressed within mammalian brain tissue, indicative 
of their possible role in neural function and development. Different families of 
miRNAs have demonstrated the ability to refine neural progenitor 
differentiation, directing their fate and function (Wienholds et al., 2005, Du 
and Zamore, 2005, Krichevsky et al., 2003). miR-124 and miR-128 are highly 
expressed in adult brain neurons, whilst miR-23 is primarily expressed in 
astrocytes. Additionally, miR-9 and miR-125 are constitutively found across 
all neuronal sub-types (Smirnova et al., 2005). miRNAs are attractive targets 
for controlling the onset of neurogenesis and lineage-specific gene 
expression within neural stem cells, as well as retinal stem cells. Inducing 
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dysfunctional expression of miRNAs contained within the brain during 
development showed altered population densities within this tissue. Forced 
ectopic expression of miR-9, miR-124 and miR-128 in late neural precursors 
reduced the production of astrocytes whilst reducing miR-9 activity, either in 
combination with miR-124 or alone, hindered neural generation. It is thought 
that both miRNAs exert their control by regulating the signalling pathways of 
STAT3 and Notch, which are involved in the proliferative and neurogenic 
ability of stem cells (Krichevsky et al., 2006). Let-7 is another miRNA 
expressed in stem cells within the murine brain and it is suggested to have a 
role in early neural specification (Wulczyn et al., 2007). Notable miRNA 
differences have been found between post-natal mouse brain and retina. 
These include, miR-9, miR-335, miR-31, miR-106, miR-129, miR-3p, miR-
691and miR-26b (Huang et al., 2008, Loscher et al., 2007).  
Whole eye analysis has indicated the enriched presence of miR-204 and 
miR-96 in both mice (Lagos-Quintana et al., 2003) and zebrafish tissue 
(Wienholds et al., 2005), suggesting an important role for eye function. 
However, extraction of murine embryonic retinal tissue at E.10.5, 
demonstrated different expression profiles. miR-204 was highly expressed in 
the ciliary body, lens and RPE, whilst miR-184 was absent from retinal tissue 
but was expressed in the lens and cornea. The developing optic cup 
demonstrated enriched expression of miR-124a miR-9, miR-29 and miR-
181a at E10.5, with their adult expression profiles confined to the retina 
(Karali et al., 2007). Within postnatal P7 mouse retina, miR-181 was found 
within the ganglion and inner plexiform layer only and miR-204 was located 
in the RPE and ciliary body regions (Ryan et al., 2006). One month old 
murine retinas showed distinct locations of three retinal miRNAs: miR-182 
was detected within the ONL and let-7 and miR-181a were identified in the 
INL, and in the mature RGCs(Loscher et al., 2007). 
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2.1.5. MicroRNA regulation of the Notch-1 Pathway 
To understand and fully utilise miRNAs in mature and developing retina for 
regenerative therapies, it is important to predict and verify their targets. 
miRNAs have been shown to interact with the Notch pathway, by either 
regulating it up- or down- stream of its locus, impacting on its functional role 
in both oncogenic and stem cells. The majority of evidence demonstrating 
Notch and miRNA interaction is from studies involving tumorigenesis or 
development. Like the genetic transcripts involved in tumour progression, 
miRNAs can be either ontogenetic or tumour-suppressive in their action. 
Upstream modulators of Notch include miRNAs that act as tumour-
suppressor agents that inhibit the expression genes involved in the 
translation of Notch or factors involved in its signalling (Figure 2.3).  
In the Drosophila miR-1 targets Notch via Delta repression preventing 
activation and nuclear translocation of its ICD (Kwon et al., 2005). miR-1 also 
suppresses the Notch pathway in murine ESCs during development (Ivey et 
al., 2008). Another tumour-suppressive agent involved in Notch regulation is 
miR-34. This has been shown to arrest Notch-1 and -2 signalling in 
gastrointestinal pancreatic cancer cells and appears to prevent cellular self-
renewal and abnormal growth (Ji et al., 2009, Ji et al., 2008). miR-124a 
activity is preferentially expressed in neurons, and has been implicated in 
neurogenesis and differentiation in the subventricular zone (SVZ), where it 
represses Sox9 during neural development. Following focal cerebral 
ischemia in adult rats miR-124a was shown to markedly decrease in the 
SVZ, coupled with the onset of Notch activation. Forced the expression of 
miR-124a in SVZ cells led to Jagged-1 (JAG-1 the Delta ligand homolog) 
repression, which acts normally to activate Notch (Liu et al., 2011). This 
resulted in decreased proliferation of neural progenitors but enhanced 
differentiation. 
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Figure 2.3: Regulation of the Notch signaling pathway by miRNAs.  A 
schematic illustration of Notch targeting for miRNA silencing by both 
upstream and downstream mature miRNAs, based on up to date 
oncogenetic studies.  
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In contrast, miRNAs are also able to repress downstream targets of the 
Notch pathway, preventing propagation of its signalling. The miR-199 family 
negatively regulates Notch targets, and acts downstream of Notch, inhibiting 
their activity by promoting differentiation rather than maintaining an 
undifferentiated state. Downregulation of the miR-199 family has resulted in 
the progression of different cancers. Specifically miR-199a expression is 
markedly reduced in both hepatocellular carcinoma (HCC) (Murakami et al., 
2006) and ovarian cancers (Iorio et al., 2007) and has been shown to 
prevent cell cycling by acting at the G2/M phase.  miR-199b-5p targets Hes-1 
to inhibit transcription of pro-differentiating genes in medulloblastoma (MB) 
cancer cells. MB patients that presented with metastatic tumours had 
reduced levels of miR-199b-5p compared to non-metastatic patients, 
indicating that this miRNA is an important onco- and Notch- suppressive 
agent (Andolfo et al., 2012, Garzia et al., 2009). 
Lastly, the miR-200 family has been shown to act as a Notch-1 antagonist in 
cancer stem cells undergoing epithelial-mesenchymal transition (EMT) (Burk 
et al., 2008). Notch-1 promotes the activation of the zinc-fingered E-box 
binding homeobox (ZEB) proteins, ZEB1 and ZEB2, as well as CD44, 
EpCam and Hes-1 in different cancer cell lines, including the human 
pancreatic cancer cell line AsPC-1 (Korpal et al., 2008, Park et al., 2008, 
Gregory et al., 2008). When these cells are induced to ectopically express 
Notch-1 miR-200b and miR-200c are reduced significantly. Conversely, when 
the expression of these two miRNAs was upregulated, EMT diminished, 
Notch signally ceased and E-cadherin, a cell attachment protein, increased 
(Bao et al., 2011, Kong et al., 2010, Li et al., 2009). These observations 
indicate that miR-200 family and Notch act antagonistically, inhibiting each 
other’s expression depending on the cellular state.  
Emerging evidence suggests that miRNAs are potential agents that could be 
targeted for novel therapy strategies in cancer or regenerative medicine. 
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Human Müller stem cells, which appear to lie dormant in the human retina in 
vivo, regulate their renewal and progenicity through Notch-1 signalling in vitro 
(Singhal et al., 2012). Therefore Notch constitutes a target for either 
induction of endogenous regeneration in vivo or regulation of cell 
differentiation for in vivo grafting. The extent of miRNA control is yet to be 
examined in these cells and understanding the roles these molecules may 
play in Müller stem cell differentiation in vitro, may aid in the development of 
regenerative therapies using these cells. On this basis, this chapter aimed to 
investigate the expression of miRNAs by Müller stem cells following 
differentiation into RGC phenotypes. 
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2.2. Objectives and experimental design 
The aim of this chapter was to investigate changes in miRNA expression by 
Müller stem cells following a differentiation protocol aimed at inducing Notch 
downregulation to yield an enriched population of RGC precursors. Current 
research suggests that miRNAs involved in neural stem cell differentiation 
are controlled by other miRNAs and various co-factors and transcription 
factors. The epigenetic control of neural cell populations by miRNAs has 
identified some signalling pathways, illustrating a control of transcription and 
downstream expression of neuronal genes. It was therefore important to 
identify changes in miRNA expression profiles during human Müller stem cell 
differentiation into RGCs in vitro. Understanding the role of these molecules 
and the timing of generation may aid in the design of cell therapies to replace 
RGC damaged by degeneration.  
The general objectives of this chapter were: 
1. To identify the downstream Notch pathway targets that lead to 
differentiation of human Müller stem cells into RGC in vitro. 
2. To investigate changes in microRNA expression profiles following 
inhibition of the Notch pathway in human of Müller stem cells. 
3. To investigate changes in microRNA expression following inhibition of 
the Notch pathway in the presence of bFGF in Müller stem cells. 
To fulfil the above objectives, the following experiments were performed: 
1. Investigation of the effect of Notch inhibition with N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
(DAPT) in the presence of bFGF, on Hes1 and retinal ganglion cell 
markers by differentiated Müller stem cells. This was assessed using 
RT-PCR, immunocytochemistry and western blotting techniques. 
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2. Evaluation of differentially expressed miRNAs in undifferentiated 
Müller stem cells and comparison with cells undergoing Notch 
inhibition in the absence of bFGF, using microarray analysis with 
Agilent platform. 
3. Evaluation of differentially expressed miRNAs in undifferentiated 
Müller stem cells in comparison with cells undergoing Notch inhibition 
in the presence of bFGF, a protocol known to induce RGC 
differentiation of Müller stem cells, using microarray analysis, 
performed as indicated above.  
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2.3. Results 
2.3.1. The effect of Notch inhibition in Müller stem cells cultured in 
the absence of bFGF 
Cells were cultured for one week in the presence of 50µM DAPT with or 
without ECM. The ECM gel used was composed primarily of laminin, 
collagen type IV, heparan sulfate proteoglycan and entactin, and was used to 
facilitate the differentiation of RGC-derived Müller stem cells, as previously 
demonstrated by our laboratory (Singhal et al., 2012). This treatment was 
observed to induce morphological cell changes consistent with acquisition of 
neural features. These included formation of long cytoplasmic projections 
and branching occurring on cultured cells, coupled with the appearance of 
phase-bright nuclei (Figure 2.4A) suggestive of neural differentiation. These 
projections were measured and demonstrated the induction of neurite 
development with Notch inhibition, which was significantly increased in the 
presence of ECM (Figure 2.4B).  
Notch inhibition was also examined by gene expression analysis of various 
genes involved in the Notch pathway during normal stem cell maturation. 
This investigation demonstrated that in the DAPT treated cells Notch-1 
expression in Müller stem cells was not modified, either in the presence or 
absence of ECM, as compared with the DMSO control (Figure 2.5). In 
contrast, Hes-1, a downstream factor of the Notch pathway, was significantly 
decreased by culturing Müller stem cells with DAPT in the presence or 
absence of ECM. Analysis of Hey2 (another factor of the Notch pathway) 
expression showed that Notch inhibition with DAPT caused a decrease in 
mRNA levels of this molecule. Culture of these cells on ECM caused 
increased expression of Hey2, but lower levels were observed when DAPT 
was added to cells cultured on ECM, as compared with controls. Marked 
elevations were observed in mature transcripts involved in RGC 
development, namely Brn3b and Islet-1 (Figure 2.6). Brn3-b is a member of  
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A 
B 
Figure 2.4: Effect of Notch inhibition in the absence of bFGF on Müller stem 
cell morphology. Phase-contrast imaging of Müller stem cells cultured under 
control conditions (no treatment), in the presence of DMSO (vehicle), and in the 
presence of DAPT, either with or without ECM coating. In this Müller stem cell 
population DAPT induced morphological changes, with development of phase-bright 
nuclei and outgrowth of long neurites (white arrow). Freehand measurement of the 
cellular projections, using a calibrated image J scale enabled analysis of neurite 
length which was markedly increased in the presence of DAPT in presence and 
absence of ECM. Scale bar=100μm  
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A 
B 
C 
Figure 2.5: Expression of transcription factors of neural development by 
Müller stem cells, following Notch inhibition in the absence of bFGF. RT-PCR 
showing expression of genes involved in Notch signaling, specifically Notch-1, Hes1, 
and Hey2, following culture with DAPT for 7 days with or without ECM. A) Notch-1 
remained unaltered following treatment with DAPT. Beta actin was used as the 
housekeeping gene to normalise gene expression levels. B) Treatment with DAPT 
induced decreased expression of Hes1 in the presence and absence of ECM. C) 
Hey2 expression levels decreased significantly with DAPT treatment in the absence 
of ECM, however a marked increase in its expression was observed in cell cultured 
without DAPT in the presence of ECM Gel images are representations of the 
expression of these factors, whilst histograms represent the mean ± SEM of 4 
experiments.  
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Figure 2.6: Markers of RGC precursors following Notch inhibition in Müller 
stem cells in the absence of bFGF. RT-PCR demonstrating the expression of 
Brn3b and Islet-1.Following Notch repression with DAPT after 7 days culture with or 
without ECM coatings. A) DAPT induced Brn3b to elevate significantly in the 
presence of ECM, although ECM coating also induced marked elevations of Brn3b 
expression. B) Treatment with DAPT induced an increase in mRNA expression of 
Islet-1 either in the presence and absence of ECM. Beta actin was used as the 
housekeeping gene to normalise gene expression levels. The results are the mean ±  
SEM of 4 experiments 
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the POU-domain family and serves as a neuronal transcription factor during 
the early stages of RGC development. Islet-1 is a LIM-homeodomain 
transcription factor and is thought to have a synergistic function with Brn3-b 
during the early stages of retinogenesis and RGC maturation (Mu et al., 
2008). These factors were used to determine the effect of the Notch pathway 
on the development of RGC-derived Müller stem cells. Raised levels of 
Brn3b were only observed when cells were cultured in the presence of DAPT 
and ECM.  
Following initial examination of Hes1 and Notch1 expression at the mRNA 
transcript level, western blotting and immunocytochemical analysis were 
performed on cell populations cultured with the Notch inhibitor DAPT. Protein 
preparations were made by lysis of cells cultured in the presence or absence 
of DAPT. Untreated cells showed elevated baseline expression of Notch 
(Figure 2.7B) and Hes1 (Figure 2.8B) proteins, as compared with treated 
cells. Cells cultured with the Notch inhibitor DAPT demonstrated depletion of 
Notch ICD whilst Hes1 expression was also decreased, although not 
significantly (Figure 2.8B). Immunocytochemistry depicted the localisation of 
both Hes1 and Notch within cell cultures. Untreated cells exhibited Notch and 
Hes1 localisation in the nuclear and cytoplasmic domains suggesting that 
Notch signalling pathway is active within these cell populations (Figure 2.7A 
and 2.8A). Treatment with DAPT resulted in decreased cellular expression of 
Notch (Figure 2.7A) and Hes1 (Figure 2.8A) in the nuclei of these cells. 
However, Notch remained within the cytoplasm and Hes1 continued to be 
located within the perinuclear domains, although its intensity appeared to 
decrease with DAPT treatment.  
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Figure 2.7: The effect of Notch inhibition on Notch-1 protein expression in 
Müller stem cells. (A) Immunostaining of control (untreated cells) for Notch-1 
showed widespread intracellular localization of this factor within the cells. 
Staining was observed in both the nuclei (white arrows) and cytoplasm. Staining 
of cells treated with DAPT showed a decreased intracellular expression of this 
protein. Notch-1 expression within the perinuclear domains and nuclear regions 
diminished with DAPT treatment (red arrows). (B) Western blotting detected the 
presence of ICD within control and treated cells, although a lower quantity was 
found in DAPT treated cells, with or without ECM. The results are the mean ±  
SEM of 4 experiments. Scale bar=50µm. 
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Figure 2.8: The effect of Notch inhibition on Hes1 protein expression in 
Müller stem cells. (A) Immunostaining of untreated cells with Hes1 antibody 
demonstrated the localization of the transcription factor within the perinuclear 
and nuclear domains of the cells (white arrow). However, staining of cells 
treated with DAPT showed a decreased cellular expression of this factor, there 
was a marked decrease in nuclear and perinuclear staining (red arrows). (B) 
Western blotting confirmed the trend of Hes1 depletion following Notch 
inhibition, although not significant. The results are the mean ± SEM of 4 
experiments. Scale bar=50µm 
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2.3.2. The effect of Notch inhibition in Müller stem cells cultured in 
the presence of bFGF  
Following culture of Müller stem cells on ECM with the addition of DAPT 
(50µM) and bFGF (20ng/ml), a RGC differentiation protocol previously 
developed in our laboratory, cells exhibited neurite outgrowth with primary 
and secondary branching of cellular projections as observed under light 
microscopy (Figure 2.9A). Measurement of the cellular projections 
demonstrated marked increase of neurite length in the presence of 
DAPT+bFGF in both the presence and absence of ECM (Figure 2.9B) 
indicative of a neural morphology and characteristic of in vitro differentiation. 
As previously seen with cells treated with DAPT in the absence of bFGF, 
cells cultured with this Notch inhibitor in the presence of bFGF did not exhibit 
significant changes in their mRNA expression of Notch. However, gene 
expression analysis demonstrated a significant decrease of Hes1 (p<0.0001 
without ECM and p<0.0002 with ECM) and Hey2 transcripts in RNA samples 
taken from cells treated with DAPT and bFGF, in the presence or absence of 
ECM, as compared to untreated cells (Figure 2.10). This suggests that 
knock-down of Notch and its downstream effectors were evident, and that its 
signalling pathway was also altered. Markers that indicate the development 
of RGC precursors, increased following Notch inhibition in the presence of 
bFGF. Islet-1 increased with differentiating protocols in both the presence 
and absence of ECM coating (Figure 2.11B). However, the early RGC 
marker Brn3b increased significantly when treated cells were cultured on 
ECM coated flasks (Figure 2.11A).  
Notch ICD protein expression markedly decreased with DAPT and bFGF 
treatment in the presence of ECM (Figure 2.12B). Hes1 protein levels also 
depleted significantly upon culture with DAPT and bFGF, in both the absence 
and presence of ECM (Figure 2.13B).  
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DMSO/Ctrl DAPT+bFGF 
Figure 2.9: Effect of Notch inhibition following culture with bFGF on Müller stem 
cell morphology. Phase-contrast imaging of Müller stem cells cultured with and 
without ECM under control conditions (no treatment), in the presence of DMSO 
(vehicle), and in the presence of DAPT and bFGF. DAPT and bFGF treatment induced 
morphological changes, with the development of phase-bright nuclei and outgrowth of 
neurite-like structures (white arrow), suggestive of neural morphology. The 
combination of these two factors appeared to have a synergistic effect on neurite 
elongation. Freehand measurement of the cellular projections, using a calibrated 
image J scale enabled analysis of  neurite length which was markedly increased in the 
presence of DAPT+bFGF in both the presence and absence of ECM. Scale 
bar=100μm  
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Figure 2.10: Transcription factors of neural development, following Notch 
inhibition in the presence of bFGF, in Müller stem cells. RT-PCR 
demonstrating the expression of genes involved in Notch signaling, specifically 
Notch-1, Hes1, and Hey2. This determined alterations in their expression profiling 
following Notch repression using DAPT and bFGF after 7 days culture, in the 
presence or absence of ECM coating. A) Notch-1 mRNA levels were not observed 
to change following cellular incubation with DAPT and bFGF, in the presence or 
absence of ECM. B) Hes1 was markedly reduced with DAPT and bFGF treatment 
in the presence and absence of ECM. C) Hey2 was also significantly reduced 
following treatment with DAPT and bFGF, with and without ECM. Beta actin was 
used as the housekeeping gene to normalise gene expression levels to. The 
results are the mean ±  SEM of 4 experiments 
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 Figure 2.11: Markers of RGC precursors following Notch inhibition of Müller 
stem cells, cultured in the presence of bFGF. RT-PCR demonstrating the 
expression of genes associated with RGC precursor development, namely, Brn3b 
and Islet-1. Alteration in their expression was determined following Notch inhibition 
in the presence of bFGF after 7 days culture in the presence or absence of ECM. 
A) Treatment with DAPT and bFGF induced significant increase in Brn3b gene 
expression in the absence and presence of ECM. B) DAPT and bFGF also caused 
marked elevation in Islet-1 mRNA expression in both the absence and presence of 
ECM. Both markers showed increased expression with ECM coating alone, 
suggesting the importance of growth matrix for differentiation. Beta actin was used 
as the housekeeping gene to normalise gene expression levels 
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DAPI NOTCH 1 Merge 
Figure 2.12: Expression of Notch-1 by Müller stem cells undergoing Notch 
signaling inhibition with DAPT, in the presence of bFGF. (A) Immunostaining 
of control (untreated cells) with Notch-1 antibody showed widespread intracellular 
localization within the cells. Staining was observed in both the nuclei (white 
arrows) and cytoplasm. However, staining of cells treated with DAPT and bFGF 
showed a decreased intracellular expression of this protein. Notch-1 expression 
within the perinuclear domains and nuclei diminished with treatment (red arrows). 
(B) Western blotting detected the presence of Notch ICD protein within control and 
treated cells, although a marginally lower quantity was found in cells treated with 
DAPT and bFGF, although not significant. However, a significant reduction in ICD 
expression was observed when cells were grown on ECM and DAPT+bFGF. The 
results are the mean ±  SEM of 4 experiments.Scale bar=50um 
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Figure 2.13: The effect of Notch inhibition on Hes1 protein expression by 
Müller stem cells undergoing Notch signaling repression in the presence of 
bFGF. (A) Immunostaining of untreated cells with Hes1 antibody demonstrated the 
localization of the Hes1 transcription factor within the perinuclear and nuclear 
domains of the cells (white arrow). However, staining of cells treated with DAPT 
and bFGF showed a decreased cellular expression of this factor. There was a 
marked decrease in nuclear and perinuclear staining (red arrows). (B) Western 
blotting confirmed depletion of Hes1 protein expression following Notch inhibition. 
A significant reduction in Hes1 expression was observed cells treated with DAPT 
and bFGF with or without ECM. The results are the mean ± SEM of 4 experiments.  
Scale bar=50µm 
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Immunocytochemical staining of DAPT and bFGF treated cells showed that 
the localisation of Notch was prominent in the cytosol (Figure 2.12A). This 
suggests that the cleavage and subsequent translocation of the Notch ICD 
has been arrested by DAPT, promoting differentiation. The localisation of 
Hes1 also proved to be modified. It was predominantly found within the 
perinuclear regions of treated cells, compared to the nuclear presence in 
untreated cells (Figure 2.13A). These observations suggest that DAPT and 
bFGF treatment led to translational repression of the Notch pathway and the 
promotion of differentiation. 
2.3.3. Validation of Notch inhibition and differentiation protocols in 
various human Müller Stem Cell lines 
In order to further validate the ability of Müller stem cells to differentiate into 
RGC following Notch downregulation, different cell lines were examined. The 
Müller stem cell lines 6387, 6391 and 6426 were cultured for 7 days, in the 
presence of ECM and DAPT ± bFGF. Screening of the three cell lines under 
non-differentiated and differentiated conditions confirmed the changes in 
Notch associated targets, as well as the emergence of RGC development 
using the above differentiation protocols. Confocal microscopy of the Müller 
cell line 6387 (Figure 2.14) demonstrated reduced levels of Hes1 staining 
following Notch inhibition either with or without bFGF. I addition, treatment 
with DAPT alone or with the addition of bFGF resulted in depleted levels of 
Hes1 mRNA (Figure 2.15B). Levels of mRNA coding for Notch did not 
change in cells cultured with DAPT in the presence or absence of bFGF 
(Figure 2.15A). However, the RGC marker Brn3b increased with DAPT 
treatment in the absence of bFGF, in the presence of bFGF its expression 
was not modified (Figure 2.15C). Islet-1 increased with Notch inhibition in the 
absence of bFGF, although its expression was not altered in the presence of 
both DAPT and bFGF (Figure 2.15D). presence of bFGF, reduced nuclear 
expression of Hes1 was also observed  
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DAPI HES1 Merge 
Figure 2.14: Effect of Notch inhibition upon Hes1 localisation in the 6387 
Müller cell line. Confocal and phase-contrast imaging of the 6387 Müller cell line 
demonstrated changes in the morphological appearance and protein expression of 
Hes1. Following DAPT treatment in the presence and absence of bFGF phase-
contrast showed morphological changes towards a neural phenotype. The extent of 
Notch activity  is illustrated by a decrease in Hes1 staining of treated cells, although 
its presence remained located around and in the nucleus (confocal red arrows). 
Untreated cells had intense perinuclear and nuclear staining (confocal white arrows). 
Confocal scale bar=50µm, Phase-contrast scale bar=100µm 
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Figure 2.15: Notch inhibition in the 6387 Müller cell line cultured in the 
presence and absence of bFGF. RT-PCR was performed to examine the gene 
expression in the Muller cell line 6387 treated with DAPT in the presence and 
absence of bFGF, as compared with untreated cultures. A) Notch-1 expression was 
unaltered with treatment. B) Hes1 decreased marginally in cells cultured with DAPT 
in both the presence and absence of bFGF. C) Brn3b increased in cells treated with 
DAPT alone. D) Islet-1 expression increased following culture with DAPT alone. n=1 
A 
B 
C 
D 
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Immunocytochemical analysis of the Müller cell line 6391 showed reduced 
amounts of Hes1 in cells treated with DAPT in either the absence or 
presence of ECM (Figure 2.16). Cells cultured with DAPT either in the 
presence of bFGF showed a decrease in Notch mRNA, although DAPT 
alone did not alter the expression of Notch mRNA expression (Figure 2.17A). 
Similar to that seen with other cell lines, mRNA expression of Hes1 
decreased with DAPT in presence or absence of bFGF (Figure 2.17B). The 
RGC maturation marker Brn3b increased in cells cultured on ECM under all 
culture conditions, however the addition of DAPT and bFGF did not change 
its expression, as compared to untreated cells (Figure 2.17C). Islet-1 
expression remained unaltered with DAPT and bFGF treatment, however 
DAPT alone increased its expression (Figure 2.17D).  
Finally, confocal imaging of the Müller cell line 6426 demonstrated reduced 
intensity of Hes1 antibody staining following treatment with DAPT in both the 
presence and absence of bFGF (Figure 2.18). Notch mRNA expression was 
diminished in the presence of DAPT alone (Figure 2.19A) whilst Hes1 
expression remained unaltered with treatment with DAPT with bFGF (Figure 
2.19B). The expression of Brn3b decreased with DAPT in the presence and 
absence of bFGF (Figure2.19C) and islet-1 decreased in cells treated with 
DAPT alone (Figure 2.19D). Validation of mature RGC gene expression was 
not found in this single experiment. Morphological alterations of neurite 
outgrowths were observed with Notch inhibition with DAPT and RGC 
protocols by confocal and phase-contrast imaging for all three cell lines. 
2.3.4. MicroRNA Expression Profiles in Müller Stem Cells 
Following the in vitro validation of RGC differentiation protocols, microarray 
analysis was conducted on total cellular RNA samples obtained from Müller 
stem cells cultured in the presence or absence of RGC differentiation factors. 
Agilent miRNA probe slides (two in total) were used to detect differences in 
miRNA profiles between Müller stem cells cultured under differentiating and  
96 
 
 
 
 
 
 
Figure 2.16: Effect of Notch inhibition upon Hes1 localisation in the 6391 
Müller cell line. Confocal and phase-contrast imaging of the 6391 Müller cell line 
demonstrated changes in the morphological appearance and protein expression of 
Hes1. Following DAPT treatment in the presence and absence of bFGF phase-
contrast showed morphological changes towards a neural phenotype. The extent of 
Notch activity  is illustrated by a decrease in Hes1 staining of treated cells, although 
its presence remained located around and in the nucleus (confocal red arrows). 
Untreated cells had intense perinuclear and nuclear staining (confocal white arrows). 
Confocal scale bar=50µm, Phase-contrast scale bar=100µm 
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Figure 2.17: Notch inhibition in the 6391 Müller cell line cultured in the 
presence and absence of bFGF. RT-PCR was performed to examine the gene 
expression in the Muller cell line 6391 treated with DAPT in the presence and 
absence of bFGF, as compared with untreated cultures. A) Notch-1 expression 
decreased in cells treated with DAPT in the presence and absence of bFGF. B) 
Hes1 decreased with DAPT in both the presence and absence of bFGF, as well as 
with ECM alone. C) Brn3b expression increased with DAPT treatment alone. D) 
Islet-1 expression increased following culture with DAPT in the absence of bFGF. 
n=1 
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Figure 2.18: Effect of Notch inhibition upon Hes1 localisation in the 6426 
Müller cell line. Confocal and phase-contrast imaging of the 6426 Müller cell line 
demonstrated changes in the morphological appearance and protein expression of 
Hes1. Following DAPT treatment in the presence and absence of bFGF phase-
contrast showed morphological changes towards a neural phenotype. The extent of 
Notch activity is illustrated by a decrease in Hes1 staining of treated cells, although 
its presence remained located around and in the nucleus (confocal red arrows). 
Untreated cells had intense perinuclear and nuclear staining (confocal white arrows). 
Confocal scale bar=50µm, Phase-contrast scale bar=100µm 
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Figure 2.19: Notch inhibition in the 6426 Müller cell line cultured in the 
presence and absence of bFGF. RT-PCR was performed to examine the gene 
expression in the Müller  cell line 6426 treated with DAPT in the presence and 
absence of bFGF, as compared with untreated cultures. A) Notch-1 expression 
decreased in cells treated with DAPT and marginally increased with the addition of 
bFGF. B) Hes1 increased with DAPT treatment in both the presence and absence of 
bFGF. C) Brn3b expression increased with DAPT treatment alone. D) Islet-1 
expression increased following culture with DAPT in the presence of bFGF. n=1 
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untreated conditions. The quality of RNA samples collected and the 
robustness of the isolation process were assessed using an Agilent 2100 
bioanalyzer (Agilent Technologies, UK) which gave a quality read out of 
10/10 (Figure 2.20). The bioanalyser determined the degree of RNA 
degradation, summating and qualifying the different lengths of RNA. It 
distinguished the ribosomal, transfer, messenger and micro RNA amounts 
within the samples. This confirmed the quality of the miRNA within the 
samples and permitted yield efficient probing during the array analysis. 
2.3.4.1. Expression of microRNA by Müller stem cells undergoing 
Notch inhibition in the absence of bFGF 
The study involved comparing the expression of miRNA levels within Müller 
stem cell populations cultured on ECM in the presence of DAPT and 
untreated populations of Müller stem cells. The samples were studied for 
array quality to assure the array procedures produced comprehensive 
results, in order to infer from true representative data. A quality control heat 
map was produced to determine the robustness of the array procedure 
(Figure 2.21). The map shows details of the miRNA expression by cells 
cultured in the absence of ECM and in the presence of DMSO or on ECM in 
the presence of DAPT. The scale illustrates the relationship between the two 
separate treatments, red indicates a low level of correlation whilst yellow 
indicates a high level. The map demonstrates positive correlation between 
Müller populations cultured under the same treatment, whilst showing low 
levels of correlation within cultures grown under different conditions. This is 
indicative of the consistency of miRNA prevalence in the different culture 
groups, as well as the robustness of the processing procedures. The 
microarray heat map for the Müller populations gave an overview of the 
miRNAs upregulated following DAPT treatment (Figure 2.22). For each 
miRNA, the yellow colour indicates miRNAs with high expression; the blue  
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Figure 2.20: Quality Control of RNA samples: Examination of the total RNA 
was performed using the Agilent 2100 Bioanalyzer prior to labelling and 
hybridisation. The results of the analysis are displayed for the three 
experimental conditions, in the form of a gel image and electropherograms. 
Total RNA run on a denaturing agarose gel shows two distinct ribosomal 
peaks corresponding to the 18S (labelled pink) and 28S (labelled green) 
eukaryotic RNA. There are also smaller distinct peaks signifying the 
messenger and short sequence (micro) RNA. The Agilent 2100 expert 
software calculates a RNA Integrity Number (RIN). The readouts for (A) 
DMSO control, (B) DAPT and (C) DAPT with bFGF in the presence of ECM 
indicate stable RNA with high integrity, lacking molecular degradation. 
Samples were given RIN values of 10/10.  
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DMSO CTRL DAPT/ECM 
Figure 2.21: Quality control microarray heat map of Müller stem cells 
undergoing Notch inhibition. Each column represents microRNA isolated 
from Müller stem cells grown in the presence and absence of Notch 
inhibition. The map illustrates the association between treated and untreated 
control specimens, as well as the correlation between the two groups Yellow 
indicates strong correlation whilst red signifies a low correlation, n=4  
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 DMSO Ctrl DAPT/+ECM 
n1 n2 n3 n4 n1 n2 n3 n4 
  +0.5 
hsa-miR-28-5p 
hsa-miR-222-5p 
hsa-miR-30a-5p 
hsa-miR-30c-5p 
hsa-miR-125b-2-3p 
hsa-miR-204-5p 
hsa-miR-221-5p 
hsa-miR-10b-5p 
hsa-miR-29b-5p 
hsa-miR-99a-5p 
hsa-miR-221-3p 
hsa-miR-3907-5p 
hsa-miR-363-5p 
hsa-miR-23b-5p 
hsa-miR-30e-3p 
hsa-miR-30e-5p 
hsa-miR-29c-5p 
hsa-miR-26a-5p 
hsa-miR-140-3p 
hsa-miR-497-5p 
hsa-miR-30d-5p 
hsa-miR-4284 
hsa-miR-15a-5p 
hsa-miR-30a-3p 
Hsv2-mi-RH25 
hsa-miR-361-5p 
hsa-miR-23a-5p 
Figure 2.22: miRNA profiles of Müller stem cells undergoing Notch 
inhibition. Hierarchical clustering analysis was performed on miRNAs, 
isolated from Müller stem cells cultured in the presence or absence of ECM 
and DAPT. miRNAs are listed in abundance on the  right hand side of the 
cluster, indicating the quantities of mature miRNA transcripts detected under 
both differentiating and untreated conditions. For each miRNA probe, data 
was median-centred, with the highest intensities in yellow. Scale= log2, n=4. 
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colour denotes miRNAs with low expression. Hierarchical clustering analysis 
identified the altered expression abundances of 27 different miRNAs 
following Notch inhibition. These miRNAs had significantly altered expression 
profiles between differentiating and untreated Müller populations. The data 
demonstrates large percentage increases that ranged from 21% to 107% 
(Table 2.1) following Notch inhibition with ECM treatment. The largest 
amplification induced by DAPT treatment was seen in the hsa-miR-204 and 
hsa-miR-30a levels, out of the all miRNAs detected. Figure 2.23 illustrates 
the relationship between inhibition of the Notch pathway in the presence of 
ECM coating, and the significant upregulation of miRNAs. The graphical 
representation of the top 27 transcripts found highlights the percentage 
increments within the miRNAs screened.  
2.3.4.2. Expression of microRNA by Müller stem cells undergoing 
Notch inhibition in the presence of bFGF 
The miRNA profile following treatment with DAPT to induce Notch inhibition 
in the presence of bFGF and ECM was also determined by microarray 
analysis. Quality of the array was assessed and determined the robustness 
and consistency of the data gathered (Figure 2.24). The quality control heat 
map indicated a strong correlation between Müller stem cells treated under 
the same culture regimes, whilst low correlation was observed between 
different treatment populations, confirming the efficiency of the array 
procedure, as well as the consistency of the results collated. Hierarchal 
clustering was performed and identified the enriched miRNAs generated by 
RGC differentiated cells as compared with untreated populations. This study 
identified 22 altered miRNA expression profiles and provided an overview of 
the miRNAs elevated with differentiation treatment (Figure 2.25). 
Examination of the percentage change of miRNAs enriched following 
treatment showed that DAPT alone caused hsa-miR-204 to increase by  
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Ascension 
number 
miRNA ID Percentage 
Change (%) 
P-value 
MIMAT0000265
 
hsa-miR-204-5p 107.81 0.023843 
MIMAT0000087 hsa-miR-30a-5p 89.35 0.023843 
MI0015893 hsa-miR-4284 83.06 0.043483 
MIMAT0004514
 
hsa-miR-29b-5p 77.51 0.025284 
MIMAT0000097 hsa-miR-99a-5p 72.89 0.025284 
MIMAT0000244 hsa-miR-30c-5p 72.37 0.023843 
MIMAT0004568 hsa-miR-221-5p 67.59 0.024982 
MIMAT0000088 hsa-miR-30a-3p 62.70 0.025284 
MIMAT0004569
 
hsa-miR-222-5p 58.52 0.015346 
MIMAT0004587 hsa-miR-23b-5p 57.62 0.035565 
MIMAT0004673 hsa-miR-29c-5p 55.93 0.043295 
MIMAT0004496 hsa-miR-23a-5p 55.53 0.048249 
MIMAT0000082 hsa-miR-26a-5p 47.52 0.043295 
MIMAT0000068 hsa-miR-15a-5p 43.74 0.043483 
MIMAT0000254 hsa-miR-10b-5p 41.57 0.025284 
MIMAT0000692 hsa-miR-30e-5p 38.81 0.039297 
MIMAT0000703 hsa-miR-361-5p 37.74 0.043483 
MIMAT0003385 hsa-miR-363-5p 37.32 0.035565 
MIMAT0004568 hsa-miR-221-3p 35.10 0.027823 
MIMAT0002820
 
hsa-miR-497-5p 31.05 0.043295 
MIMAT0004603 hsa-miR-125b-2-3p 30.84 0.023843 
MIMAT0000085 hsa-miR-28-5p 29.69 0.043483 
MIMAT0000245 hsa-miR-30d-5p 28.51 0.043483 
MIMAT0000693 hsa-miR-30e-3p 25.50 0.039297 
MIMAT0000431 hsa-miR-140-3p 23.99 0.043295 
MI0013907 hsv2-miR-H25 22.047 0.034151 
MI0016410 hsa-miR-3907-5p 21.03 0.028681 
Table 2.1: List of miRNAs upregulated in Müller stem cells undergoing 
Notch inhibition. Expression is presented as percentage change in cells 
treated with DAPT, compared to control cultures. miRNAs are listed in 
ascending order,  accession numbers taken from www.miRBase.org, n=4. 
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Figure 2.23: The miRNA expression levels in Müller stem cells 
undergoing Notch inhibition in the presence of ECM, as determined by 
microarray analysis. Graphical depiction of the significantly upregulated 
miRNAs compared to untreated Müller stem cell cultures, following Notch 
inhibition with DAPT with comparison to control cell culture. miRNAs are 
organised in ascending order, left to right. n=4 ***p<0.001 **p<0.01; *p<0.05 
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Figure 2.24: Quality control microarray heat map of Müller stem cells 
undergoing Notch inhibition in the presence of bFGF. Each column 
represents microRNA isolated from Müller stem cells grown in the presence or 
absence of Notch inhibitor with bFGF. The map illustrates the association 
between treated and untreated control specimens, as well as the correlation 
within the two groups. Yellow indicates strong correlation whilst red signifies 
low correlation. n=4  
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hsa-miR-381 
hsa-miR-382 
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hsa-miR-409-3p 
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Figure 2.25: miRNA profiles of Müller stem cells following Notch 
inhibition. Hierarchical clustering analysis was performed on miRNAs, 
isolated from Müller stem cells cultured in the presence and absence of DAPT 
and bFGF. microRNAs are listed in abundance on the  right hand side of the 
cluster, indicating the quantities of mature miRNA transcripts detected under 
both treated and untreated conditions. For each miRNA probe, data was 
median-centred, with the highest intensities in yellow. Scale= log2, n=4. 
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Ascension 
number 
miRNA ID Percentage 
Change 
(%) 
P-value 
MIMAT0000265
 
hsa-miR-204-5p 274.13 0.000287 
MIMAT0000098
 
hsa-miR-100-5p 114.99 0.0053273 
MI0000434 hsa-let-7i 106.45 0.0092618 
MIMAT0004697 hsa-miR-151-5p 106.24 0.0037050 
MIMAT0004569
 
hsa-miR-222-5p 70.14 0.0018665 
MIMAT0004568
 
hsa-miR-221-5p 66.37 0.0164166 
MIMAT0022861
 
hsa-miR-376c-5p 55.43 0.0289856 
MIMAT0000646
 
hsa-miR-155-5p 55.32 0.003705 
MIMAT0000263 hsa-miR-199b-5p 54.77 0.0023067 
MIMAT0003386
 
hsa-miR-376a-5p 53.81 0.0142089 
MIMAT0000459 hsa-miR-193a-3p 48.37 0.0108388 
MIMAT0004568 hsa-miR-221-3p 42.72 0.0108083 
MIMAT0000757 hsa-miR-151-3p 41.84 0.0078666 
MIMAT0022862
 
hsa-miR-381-5p 38.13 0.0117819 
MIMAT0004689
 
hsa-miR-377-5p 38.03 0.0249183 
MIMAT0000446 hsa-miR-127-3p 31.52 0.0307239 
MIMAT0001639 hsa-miR-409-3p 30.11 0.0234527 
MIMAT0000245
 
hsa-miR-30d-5p 28.01 0.0473656 
MIMAT0002890 hsa-miR-299-5p 26.41 0.0222157 
MIMAT0000737
 
hsa-miR-382-5p 23.28 0.0142089 
MIMAT0004814 hsa-miR-654-3p 22.63 0.0297285 
MIMAT0004695 hsa-miR-337-5p 20.58 0.0473656 
MI0013907 Hsv2-miR-H25 12.763 0.034151 
Table 2.2: List of miRNAupregulated in Müller stem cells undergoing Notch 
inhibition in the presence of bFGF. Expression is presented as percentage 
changes in cells treated with DAPT and bFGF, compared to untreated DMSO 
cultures. miRNAs are listed in ascending order alongside their respective p 
values. Accession numbers were taken from miRBase.org, n=4. 
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107%, whilst the addition of bFGF increased the levels of hsa-miR-204 by 
257% (Table 2.2). Illustration of the percentage changes, graphically, 
demonstrates the alteration within the miRNA profiles when ganglion 
maturation is favoured (Figure 2.26). These results have highlighted some 
potential targets that may contribute to developing protocols for RGC 
maturation of adult Müller stem cells, both in vitro and in vivo. The miRNAs 
enhanced using the RGC differentiation protocol included five miRNAs that 
were significantly upregulated in both conditions (Figure 2.27). These 
miRNAs included hsa-miR-204, hsa-miR-221, has-miR-222, hsa-221* and 
hsa-30d.  
Notably these were highly expressed under both conditions, their differences 
between the treatment with DAPT in the presence or absence of bFGF was 
not significant and demonstrated only a marginal decline with the addition of 
bFGF, with exception to hsa-miR-204 which doubled in its expression (Figure 
2.28). 
  
111 
 
 
 
  
Figure 2.26: The miRNA expression levels in Müller stem cells undergoing 
Notch inhibition, following microarray analysis. Graphical depiction of the 
miRNAs that elevated significantly as compared with untreated Müller stem 
cells, following Notch inhibition with DAPT in the presence of bFGF. In 
ascending order, left to right. n=4 ***p<0.001 **p<0.01; *p<0.05 
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+DAPT/ECM +DAPT+FGF/ECM 
Figure 2.27: miRNA screen in Müller stem cells following Notch 
inhibition in the presence or absence of bFGF. Venn diagram showing 
the number of differentially expressed miRNAs between Müller stem cells 
cultured with DAPT in the presence or absence of bFGF. Five miRNAs 
overlap in significance between the two treatment regimens and include, 
hsa-miR-204, hsa-miR-221, hsa-miR-222, hsa-221-3p and hsa-30d. n=4 
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Figure 2.28: Comparison between miRNA prevalence in Müller stem cells 
undergoing Notch inhibition in the presence and absence of bFGF. hsa-miR-
204, hsa-miR-221, hsa-miR-222, hsa-221-3p and hsa-30d overlap in their 
expression between the different treatment groups however, only hsa-miR-204 is 
markedly altered following  Notch inhibition in the presence of bFGF. DAPT=red, 
DAPT and bFGF=black. n=4 
 
114 
 
2.4. Discussion 
The principal objective of this chapter was to investigate molecular 
mechanisms involved in RGC differentiation of Müller stem cells, following 
Notch inhibition with the γ-secretase inhibitor DAPT (Hayes et al., 2007) and 
the addition of bFGF to cultured cells. 
The initial results demonstrated the regulatory activity of Notch1 on Müller 
stem cells, where its baseline expression was relatively high. Notch was 
detected at the protein level and was found in and around the nucleus 
indicative of the stem cell character of the Müller glia cell lines examined. 
The results also suggested that, similar to that seen in ESCs and other 
progenitor populations, Müller stem cells are under the control of Notch 
signalling. This was inferred by observations that downregulation by DAPT 
led to decreased expression of Hes1 at both the mRNA transcript and protein 
levels. Brn3b, an early marker of RGC development, was also markedly 
upregulated following Notch inhibition, suggesting phenotypic alterations 
leading to expression of RGC markers. This effect was also seen with the 
addition of bFGF. Iselt-1 mRNA was also increased with DAPT treatment, 
providing further evidence of RGC differentiation. Neurite outgrowth was also 
seen upon Notch inhibition indicative of the morphological impact that DAPT 
treatment had on cellular cultures by promoting neurogenesis. 
Following initial experiments, the array data highlighted numerous miRNAs 
whose expression profiles had altered following Notch inhibition. The 
significant upregulation of miRNAs in DAPT treated Müller stem cells suggest 
the emergence of novel targets under the direction of the Notch pathway. A 
number of miRNAs were identified, and are discussed below in relation to the 
Notch pathway and their potential roles in Müller stem cell progenicity. 
hsa-miR-204, a tumor suppressor miRNA, has been reported to play a 
pivotal role in the differentiation of human cardiomyoyte progenitors, as it has 
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been shown to coordinate the beating action of mature cardiomyocytes. 
These cells, like human Müller stem cells, are unable to regenerate their 
native tissue in vivo following injury infarction of the myocardium. Forced 
inhibition of miR-204 in cardiac progenitors in culture promoted proliferation 
instead of differentiation. This suggests that miR-204 is a driving regulator of 
differentiation and proliferation in progenitor cells. The study also showed 
that activating the transcription factor 2 (ATF-2), a member of the CREB 
family and a basic leucine zipper, promotes proliferation of cardiomyocyte 
progenitors. One role of miR-204 was to target ATF-2, subsequently 
preventing cell cycling of cariomyocyte progenitors (Xiao et al., 2012). 
In the medaka fish miR-204 has been shown to regulate various aspects of 
ocular development. Inhibition of miR-204 during development resulted in 
microphthalmia, as well as irregular dorso-ventral retinal patterning. Studies 
also demonstrated that miR-204 targets Meis2 and indirectly Pax6, which are 
upregulated when miR-204 is ablated. This miRNA has also demonstrated its 
expression in mature RPE, cilliary body, lens and neural retina (Conte et al., 
2010).These studies suggest that miR-204 is an important differentiating 
factor in ocular development, with a similar role in cardio progenitors, and 
may provide a clue for its possible role within differentiating Müller stem cells. 
The relationship between Notch and miR-204 may stem from the possible 
involvement of ATF-2. Kalinichenko et al reported that haplo-insufficiency 
((+/-) morphants) of the fork head box f1 transcription factor (Foxf1) in 
embryonic mice led to depleted expression of Notch-2 and its downstream 
target Hes1 in pulmonary tissue. Moreover, other transcription factors were 
also diminished in these morphants including SP-3, B lymphoma Mo-MLV 
insertion region 1 homolog (BMI-1) and ATF-2.These all act on cell cycling 
factors which promote the inhibition of self-renewal, and have been shown to 
prevent ageing in neurons, as well as other tissue types, specifically acting 
on p53 and p21Cip1 (Chatoo et al., 2009). The action of Foxf1 appears to 
trigger and enrich the transcription of Notch2. It directly binds to the murine 
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Notch-2 promoter, which in turn maintains ATF-2 levels to promote an 
undifferentiated and proliferative state. However, this study poses the 
question of whether miR-204 mediates the convergence of the Notch 
pathway and ATF-2 transcription and hence its activity on cell cycling in 
Müller stem cells.  
Array analysis of lens epithelial cells found in opacified human posterior lens 
capsules identified mothers against decapentaplegic-4 (SMAD4) expression 
as a target for repression by hsa-204-5p. This miRNA also prevents 
transduction of the transformation growth factor-beta (TGF-β)/SMAD 
signalling pathway (Wang et al., 2013). This suppressive action prevented 
the progression of TGF-β induced epithelial-mesenchymal transition (EMT) 
and restoration of E-cadherin expression favouring an adherent and 
differentiated phenotype. This repressive molecule may impact on both 
signalling pathways to differentiate its role in different tissues. 
Five members of the miR-30 family were enriched in Müller stem cell cultures 
following Notch inhibition, specifically hsa-miR-30a, hsa-miR-30c, hsa-miR-
30e and hsa-miR-30d. The miR-30 family has been implicated in 
tumourogenesis and the progression of EMT in a number of cancers, and 
during development. The majority of research has found that this miRNA 
family is down regulated, permitting the expression of characteristic EMT 
factors including, Snail1, N-cadherin, vimentin and Beta-catenin. EMT within 
human pancreatic epithelial cells (Joglekar et al., 2009) and murine 
hepatocytes (Zhang et al., 2012) is mediated by different components of the 
miR-30 family. Hepatocyte TGF-β-1 induced EMT is prevented by the 
targeting of Snail1 by miR-30b. This suppression supports the expression of 
E-cadherin, promoting adherent and differentiated phenotypes. Alongside 
restoration of E-cadherin expression, mesenchymal bHLH transcription 
factors are repressed, and include Twist and Zinc finger E-box-binding 
homeobox (ZEB) 1 and ZEB2 factors. ZEB1 has been implicated in the 
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Notch pathway by mediating the transcription of mastermind-like proteins 
(MamL) and subsequent transduction of Notch ICD in pancreatic 
adenocarcinoma (Brabletz et al., 2011). The miR30 family also appears to 
modulate Notch via the Delta-like 4 (DLL4) ligand in lymphatic endothelial 
cells, inhibiting neovascularisation in sarcomas (Bridge et al., 2012). In this 
study, miR-30d was significantly elevated following DAPT treatment in the 
absence and presence of bFGF, suggesting that Müller stem cell 
differentiation into RGC may be controlled by 30d. This is further supported 
by a report that determined that miR-30d is upregulated through the 
repression of the PI3K/Akt pathway in renal cell carcinoma cells, and 
suggests that Notch inhibition is followed by suppression of this proliferative 
pathway (Wu et al., 2013). 
The miR-30 family is also closely associated with the miR-29 family which 
appears to regulate cellular senescence through their targeting of B-Myb, 
blocking its translation to Myb-related protein B2 (MYBL2). B-Myb is an 
oncogene, positively promoting proliferation and upregulating the expression 
of c-Myc. Senescence progresses at the G0/G1 boundary by repressing E2F 
binding to the promoter of B-Myb (Bennett et al., 1996). Its mRNA transcript 
is also disrupted by miR-29 and miR-30, hindering its translation (Martinez et 
al., 2011). These groups of miRNAs may therefore play a role in cell cycling 
in Müller stem cells and may be under the regulation of Notch. A possible 
association between these families and Notch may involve the 
Retinoblastoma-like protein 1 (p107).This factor is involved in the prevention 
of B-Myb transcription, through its association with E2F-4. p107 determines 
the number of proliferative neuron progenitors in the mouse brain. In vitro 
assessment of p107-null murine brain populations demonstrated elevated 
amounts of Notch-1 and exhibited an enhanced capacity to form 
neurospheres (Vanderluit et al., 2004). Inhibiting Notch signalling effectors in 
Müller stem cells may enhance mi-R-30 and miR-29 by mediating the 
production of p107.  
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The upregulation of both hsa-miR-99a and hsa-miR-125b in Müller stem cells 
undergoing Notch inhibition presents a novel chromosome cluster that may 
be under the regulation of the Notch cascade. The miR-125b cluster on 
chromosome 21 includes miR-125b, miR-99a and miR-letc. miR-125b was 
upregulated in differentiating B lymphocytes that were actively dividing within 
germinal centres. Furthermore, ectopic miR-125b expression prevented the 
terminal differentiation of B lymphocytes (Gururajan et al., 2010). This 
suggests that this miRNA is involved in diversification rather than 
differentiation, and may play a similar role in the maturation of Müller stem 
cells towards a ganglion fate. 
Like miR-204 and the miR-30 family, miR-99a is another miRNA upregulated 
in Müller stem cells following DAPT treatment, and appears to be related to 
EMT and TGF-β in cancer development. miR-99a acts in murine mammary 
cells promoting EMT and TGF- β expression. This miRNA has been also 
shown to  prevent cell cycling in human glioblastomas in vitro and in vivo. Its 
action inhibits the PI3k/Akt pathway arresting cell growth. This increased 
expression leads to apoptosis, suggesting that it has an anti-tumourgenic 
role in these cells (Chakrabarti et al., 2013). 
miR-99a has shown to inhibit proliferation in endometrioid cell carcinoma by 
negatively regulating the expression of mammalian target of rapamycin 
(mTOR) kinase. This factor acts to induce cell division but can lead to cancer 
if deregulated. miR-99a alongside miR-100 and miR-199b were 
downregulated in these cancer tissues, with miR-100 being identified as a 
biomarker for this type of malignancy (Torres et al., 2012). Moreover, miR-
99a/100 caused apoptosis in oesophageal squamous cell carcinoma by also 
targets mTOR (Sun et al., 2013). Upregulation of miR-99a was not enhanced 
by DAPT treatment in the presence of bFGF. However, miR-100 and miR-
199b were upregulated. It is therefore suggested that miR99a is initially 
promoted by Notch deregulation arresting cell cycling, although miR-100 and 
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miR-199b may be required for further mTOR ablation to provide a cell state 
suitable for Müller stem cell differentiation. 
miR-100 is another tumour suppressive factor which reduces cell proliferation 
in a number of human cancers including ovarian (Peng et al., 2012), bladder 
(Oliveira et al., 2011) and acute myoleid leukemia (Zheng et al., 2012).  The 
targets of this miRNA are predominantly factors involved in mitosis and one 
such agent is polo-like kinase 1 (PLK1) which is a serine/threonine kinase 
that controls the checkpoints in the cycling process. Though a regulatory role 
of Notch has yet to be demonstrated by miR-100, it can be suggested that 
the role of this miRNAs in Müller stem cells is one of  Notch pathway 
inhibition serving to reduce cell proliferation.  
Unlike some of the previous miRNAs, miR-199b-5p has been shown to 
negatively regulate Hes1 and the Notch signalling pathway by attenuating its 
activity in MB cells. It acts by suppressing their mitotic ability as well as their 
capacity to anchor together to promote paracrinal growth (Garzia et al., 
2009). Therefore the presence of high levels of this miRNA in Müller stem 
cells undergoing Notch inhibition supports the assumption that differentiation 
occurred and that Müller stem cells do in fact maintain their potency via the 
Notch pathway.  
miR-222 was enriched in Müller stem cells following Notch inhibition in the 
presence and absence of bFGF. This miRNA contributes to neural 
regeneration of dorsol root ganglia (DRG) neurons following injury and 
permits neurite branching and outgrowth by targeting the phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN). It has been postulated, 
by the same study, that miR-222 may regulate the phosphorylation of the 
cAMP response element binding protein (CREB) through PTEN and c-Jun 
activation, which may enhance miR-222 expression and therefore disruption 
of PTEN lead to DRG regeneration (Zhou et al., 2012). The association 
between the Notch pathway and this miRNA may converge on the activity 
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between Notch-1 and PTEN. It has been reported that in murine thymocytes 
Notch-1 is able to regulate PTEN via the induction of Hes1 (Wong et al., 
2012). PTEN appears to prevent neural regeneration which is reversed by 
miR-222 action. However, Hes1 also prevents PTEN activity in thymocytes 
promoting proliferation rather than differentiation. This may suggest the 
activity of miR-222 within the Müller stem cell population following Notch 
downregulation, and therefore Hes1 may behave independently on PTEN 
from Notch. Downregulation of Notch and Hes1 may allow PTEN to repress 
the PI3K/Akt pathway in Müller stem cells. This could alter the cellular 
progenicity, favouring a non-proliferative state. Further investigations into the 
expression of PTEN and CREB by Müller stem cells following Notch 
repression, may identify novel pathways involved in Müller stem cell cycling 
and differentiation in humans. 
hsa-miR-100, hsa-miR-221, hsa-miR-222 and hsa-let-7i have been shown to 
be enriched in human umbilical vein endothelial cells (HUVECs) undergoing 
senescence, indicative of their potential role in maintaining an anti-
proliferative, differentiated state of these cells (Dellago et al., 2013). These 
miRNAs were consistently upreguated in Müller stem cells following 
treatment with DAPT. Depending on the tissue the miR-221 family appears to 
have an opposite activity on proliferation in different forms of cancer. 
Prostate cancer cells have reduced levels of cell cycling with elevated miR-
221 expression (Schaefer et al., 2010), while miR-221 acts by promoting 
cellular cycling in neck cancers (Nurul-Syakima et al., 2011). The importance 
of miR-221 in angiogenesis in zebrafish has been shown by its targeting of 
cyclin dependent kinase inhibitor 1b (CDKN1b) and phosphoinositide-3-kiase 
regulatory subunit-1 (pik33r1). It was also shown that Notch had a 
suppressive role on miR-221 activity during controlled angiogenic maturation 
in this species (Nicoli et al., 2012). The repressive action of Notch suggests 
that its inactivation would increase miR-221 presence, although its exact role 
in Müller stem cell differentiation is questionable. However it could be 
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suggested that its role may involve regulation of cell cycling and in this 
instance prevent proliferation.   
Another interesting miRNA that increased following Notch inhibition is hsa-
miR-23a. This miRNA has been found to target Hes1 and has demonstrated 
a high complementarity to the mRNA sequence upstream of the Hes1 STOP 
codon. This suppressive action in human NT2 cells leads to neural 
differentiation upon the addition of retinoic acid (Kawasaki and Taira, 2003). 
This activity may be important for the induction of Müller stem cells 
differentiation following Notch inhibition. 
Profiling miRNAs of Müller stem cells that have undergone standardised 
RGC differentiation by Notch downregulation and bFGF showed significant 
elevations for hsa-miR-204, hsa-miR-100, hsa-miR-151-5p, hsa-miR199b-5p 
and let-7i when compared to untreated Müller populations. Although the 
majority of the miRNAs enriched with this treatment are similar to DAPT 
expression levels, their amounts are considerably higher. The overlapping 
miRNAs expression levels between the two treatments are miRNAs involved 
in regulating proliferation. Crucially the induced increase of let-7i expression 
in Müller stem cells is indicative of RGC development, which has been 
reported to be present within mature murine RGC populations in vivo 
(Loscher et al., 2007).  
hsa-miR-151-5p has been investigated as a potential biomarker for 
metastatic form of breast cancer, where low expression signifies a reduction 
in metastatic ability (Krell et al., 2012). Treatment with DAPT in the presence 
of bFGF increased miR-151 expression in Müller stem cells. This suggests 
that its role in RGC maturation is negatively regulated by Notch, which may 
normally act to suppress its anti-proliferative action, similar to its role in 
breast cancer.  
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The addition bFGF did not increase the level of Notch activity as had been 
suggested by Faux et al, where bFGF encouraged Notch activity in 
neuroepithelium (Faux et al., 2001). This did not apply to Müller stem cells 
and in fact, at the mRNA and protein levels of Hes1 depletes while miRNAs 
associated with anti-proliferate roles are substantially upregulated with 
treatments involving bFGF. The role of bF6F on miRNAs and expression is 
not well understood and current research has been addressed to vascular 
development, in which it has been observed that  bFGF elevation is followed 
by  the subsequent promotion of mature miR-16 and miR-424 in endothelial 
cells (Chamorro-Jorganes et al., 2011).  
In conclusion, a number of miRNAs have been shown to be elevated 
following Notch inhibition. A number of these miRNAs are reported to be 
related to inhibition of proliferation in oncogenic cells. They may represent a 
novel cohort of RNA molecules which are regulated by Notch or converge on 
its signalling pathway at different points. This is represented in a schematic 
diagram suggesting the possible role of various miRNAs on the differentiation 
and/or maintenance of progenicity of Müller stem cells (Figure 2.29). 
Further studies are warranted to determine the possible targets of the 
miRNAs and their relationship to Müller stem cell plasticity to confirm their 
function within this population. This will aid their capacity to differentiate 
towards a ganglion cell fate. Investigations would involve ectopically 
expressing selective miRNAs, or downregulating these to study the 
phenotypic alterations induced. Evaluation of miRNAs contained within 
undifferentiated and differentiated Müller stem cells may also provide novel 
safer strategies for allographic transplantation. These molecules have the 
potential to alter the in vivo senescent state of Müller stem cells and to 
promote neural differentiation and retinal regeneration following damage. 
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Figure 2.29: Proposed association of the Notch signaling pathway 
and upregulated miRNAs in Müller stem cells, following Notch 
inhibition in the presence and absence of bFGF. A schematic 
illustration of Notch targeting by miRNAs, identified by microarray analysis 
of differentiated Müller stem cells, based on the current literature. 
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Chapter 3: Biomaterials and their Potential 
Application for Retinal Cell Transplantation 
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3.1. Introduction 
Biomaterials are defined as substances that interact with any biological 
matter. The science of biomaterials has developed rapidly and embodies a 
multidisciplinary field, which at present involves the interplay between 
biology, chemistry and medicine. Biomaterials can be sourced from nature or 
synthesised substances using a number of laboratory-based processes, and 
are frequently adapted for clinical use. Within the remit of medical research, 
biomaterials are often used for tissue engineering which aims to enhance or 
maintain the physiological function of cellular populations or tissue (Kumbar 
et al., 2006). In order to fulfil their regenerative role, biomaterials need to be 
completely biocompatible for their use within a clinical setting. Currently 
biomaterials are used to deliver drugs for internal therapeutic release into the 
body, prolonging their bioactivity (Ariga et al., 2006, Chavanpatil et al., 2006, 
Gunatillake et al., 2006).   
Research into the scope of biomaterial applications has led to identification 
of their potential use as transplantable materials, supporting the delivery of 
grafted cells into a large variety of tissues. Engineered biomaterials can also 
be made to support cells to enhance their growth, and in the case of stem 
cells their maturation in vitro. Both these supportive roles centre on the ability 
of biomaterials to mimic the native extracellular matrix (ECM). Understanding 
the nature of native cell-matrix interactions, equips bioengineers with clues 
as to how to design and process appropriate materials for cellular grafting 
approaches. The main focus of research in this field has been to model the 
innate ECM of different tissues, and to identify substances that permit the 
highest degree of synergy with the local tissue, yet remain immunologically 
inert (Morais et al., 2010). The biomaterials designed for such tasks include, 
decellularised ECMs, biohybrid blends and completely synthetic-based 
materials, all of which need to be tailored to ensure cellular homeostasis 
(Lutolf and Blau, 2009, Place et al., 2009).   
126 
 
Regeneration of ocular tissues would benefit from the use of biomaterials 
that are engineered to improve the function of residual dystrophic cells or to 
replace damaged cells. The loss of functional RGCs during glaucoma 
progression highlights a retinal dysfunction that would gain from the use of 
suitable materials for cell replacement. Based on the anatomy of the retina 
and the surrounding tissues, a scaffold to support grafted cells would 
facilitate their delivery uniformly across the inner retina, which cannot be 
achieved by injections of cellular suspensions. 
3.1.1. Types of Biomaterials 
3.1.1.1. Natural biomaterials 
Natural biomaterials have immense potential for biomedical application as 
they are sourced from natural materials and interact with cells in vitro in a 
similar manner as that occurring in vivo. Reconstituted ECM proteins have 
been used as 2D protein coats on culturing surfaces, and include collagens, 
fibronectin, laminin and Matrigel (Nojehdehian et al., 2010). These proteins 
are able to provide biocompatible artificial environments, supporting 
adherence, cellular growth and survival in vitro. However, in order to provide 
conditions for cellular grafting, these natural biomaterials need to be adapted 
into 3D topologies.  
Natural hydrogels for culture have been developed from ECM derivatives 
including, collagen, fibrin (Eyrich et al., 2007), hyaluronic acid (Masters et al., 
2004), Matrigel, chitosan, silk and alginate (Barralet et al., 2005). Some 
natural-based materials have been used to build scaffolds and include 
xenogenic proteins such as silk fibroin, chitosan, aliginate, cellulose and 
agarose (Prewitz et al., 2012). The commonality between these natural-
based materials is that they are similar to the native ECM, in structure and 
can be induced to form different structures, ranging from hydrogels to fibrous 
scaffolds. 
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Hydrogels of type I collagen appear to retain vital features attributed to the 
native structure of this molecule, and demonstrates the capacity to support 
the delivery of aortic interstitial cells (Saha et al., 2007, Butcher and Nerem, 
2004). Collagen hydrogels are also used regularly in wound healing studies 
and have shown their ability to support fibroblast survival and proliferation. 
Under culture conditions, fibroblasts have shown to remodel and adapt their 
3D collagen matrix, analogous to their in vivo action (Hadjipanayi et al., 
2009, Sethi et al., 2002). In addition, collagen-based hydrogels have been 
used to model different body environments in order to assess various 
treatments on cellular function. To that end fibroblasts embedded in collagen 
hydrogels have been examined for their ability to contract gels under 
different culture stimuli, including the presence of mitogens, drugs or other 
ECM additives (Nguyen and West, 2002).  
Natural biomaterials have also been used in electrospinning processes to 
produce 3D matrices. Materials used for this purpose have included collagen 
(Matthews et al., 2002), gelatine (Salifu et al., 2011), elastin (Buttafoco et al., 
2006), fibrinogen (McManus et al., 2006) and silk (Min et al., 2004). Silk 
fibroin has also been shown to possess some positive biomedical traits when 
electrospun, and has been found to promote cellular adhesion and 
proliferation (Wang, 2004, Venugopal et al., 2008), indicative of its potential 
for clinical use.  
Cellulose acetate (Zhang and Hsieh, 2008) and Hyaluronic acid (Ji et al., 
2006), are polysaccharides that can be electrospun to yield fibres for cellular 
scaffolds.  Hyaluronic acid (HA) has been widely used in biomedical 
therapies including ophthalmology, surgery and drug delivery.  HA has a very 
large volume to surface ratio making it ideal for incorporating therapeutic 
agents into its framework. 
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3.1.2. Collagen scaffolds 
Choosing an appropriate biomaterial to engineer cellular scaffolds for 
regenerative medicine requires the material to be readily available, easy to 
process and suitable for transplantation to human subjects. Collagens have 
been suggested to be suitable proteins to fulfil this strategy. Due to the good 
knowledge of their synthesis and function within the body, collagens 
constitute an excellent material for the manufacture of 3D scaffolds. They 
represent a group of naturally occurring proteins that impart support and 
mechanical strength to all cells and tissues in the body and are essential 
components of the connective tissue, to which cells adhere. The word 
collagen derives from the Greek word meaning glue, which is a suitable 
description for both its form and function (Bhattacharjee and Bansal, 2005).  
Collectively, collagens have a very complex molecular structure. Fibrillar 
collagens exhibit distinct hierarchical levels of amino acid organisation and 
association. These are similar in molecular structure although their 
configuration determines their ultimate structure and function. Type I, II, III, V 
and XI collagens are fibrillar in their arrangement and can assemble into 
fibrils based on their basic, primary structure. Fibrillar collagen structures are 
based on different combinations of 10 polypeptide chains; known as α-
chains. These chains fold, first into transient tight left-handed secondary α-
helices and finally into its triple helical tertiary structure, when secreted into 
the mature ECM (Ottani et al., 2002). The native structure of type I when 
extracted from tissue retains its tensile strength and has the ability to be 
remodelled ex vivo. Type I collagen therefore represents an attractive natural 
biomaterial to consider when investigating scaffold development for 
therapeutic cell delivery. 
Collagens within tendons form long string-like structures that provide tensile 
strength, collagens contained within the skin give elastic and mechanical 
strength, and collagen fibrils found in bone aid the calcification and 
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maintenance of this tissue. To date, 28 types of collagens have been 
characterised, each with distinct molecular similarities and diversities, 
containing 42 different sub-types of polypeptide chains (Gordon and Hahn, 
2010, Hulmes, 1992). 
Type I Collagen is the most ubiquitous form of collagen present in the human 
body and can be found in almost all tissue types. It constitutes the 
predominate ECM protein in tendons, bone, and dermis, illustrating the range 
of tissues and formations type I collagen undertakes within the human body 
(Di Lullo et al., 2002). In experimental in vitro studies, type I collagen is 
commonly used as a protein coating for culture flasks to promote cellular 
adhesion. It is also used in hydrogel form to support the formation of cell-cell 
interactions in vitro (Franke et al., 2007, Salchert et al., 2005).  
Collagen can be purified from various tissues types by means of enzymatic 
or acidic treatments. These agents act by removing the covalent crosslinks 
between collagen fibrils within the mature ECM. Purified forms of collagen 
may be remodelled into diverse forms with different properties, such as 
sponges, nanofibres and hydrogels, or can be blended with other polymers, 
either natural or synthetic (Rajan et al., 2006). Purified collagen can provide 
cellular support which allows collagen matrices to act as structural cellular 
scaffolds.  
The method of extraction and source of type I collagen, and collagens as a 
whole can influence the mode of processing. This can also modify the 
ultimate structure produced which can play a key role in the biocompatibility 
of the structure made. 
Collagen can be solubilised in acid (Kuznetsova and Leikin, 1999), neutral 
salt (Gross et al., 1955) or by proteolytic solutions (Abou Neel et al., 2013). 
These extraction methods alter the molecular structure of collagen in 
different ways. Proteolytic extraction cleaves the terminal peptides of the 
collagen fibrils, which modifies the rate at which fibrils form in vitro, however 
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this method does not remove the capacity for fibrils to form. In contrast, acid 
solubilisation does not cleave the terminal peptides from collagen fibrils, this 
ensures that stable covalent crosslinks are able to form in vitro, with better 
structural and mechanical integrity as compared to proteolytic extraction.  
All extraction methods of collagen break the bonds between the complex 
networks of fibrils within native tissue. Although some alter its structure 
differently, they all destroy the innate structure which prevents the 
remodelling in vitro to be completely comparable to native collagen and is in 
fact collagen in the form of gelatine. The self-assembly of reconstituted 
collagen can influence the morphology of the fibrils produced and in turn the 
hierarchy of fibrillular structure. Reconstituted collagen in solution is unlike 
the collagen found in tissue, which is completely insoluble. Where this 
chapter describes collagen in solution, the protein described is collagen in its 
soluble form (gelatine). 
3.1.3. Electrospinning 
Electrospinning has become a useful tool for manufacture cellular scaffolds 
and has been employed to remodel type I collagen fibres. This process has 
been used to enhance the functionality of various biomaterials through the 
addition of bioactive agents, either within or outside the fibrous network. 
Bioactive agents are aimed to facilitate cellular adhesion, maturation, 
proliferation and neurite outgrowth (Hodgkinson et al., 2007). Electrospinning 
involves the application of a strong external electrical field to a charged 
polymer solution, which is then fed to a grounded collecting target via a 
needle tip (Figure 3.1A) (Matthews et al., 2002). Electrospinning is widely 
used in tissue engineering and can be refined to produce fibres of diameters  
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Figure 3.1: The Electrospinning process A) Diagrammatic representation of 
the rig used for the electrospinning process illustrating the set up of the 
equipment where the polymer solution is drawn by a high voltage device, (HPV) 
to a grounded target. B) A slow-capture image of a Taylor cone jetted from a 
needle tip at the initiation of electrospinning, and an illustration of the 
entanglement phenomenon which enables fibres to be drawn onto a surface.  
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100nm or less (nanospinning), which can enhance its application in cell 
therapies to treat different tissue degenerations. Scaffolds developed by 
electrospinning have demonstrated a great potential in biomedical 
applications such as wound dressing, drug delivery and enzyme 
immobilisation (Sill and von Recum, 2008).  
During the spinning process, a stable electrospinning jet is formed at the tip 
of the needle and is termed Taylor cone (Figure 3.1B). The Taylor cone and 
subsequent fibre formation is driven by the application of a high electrical 
potential between the polymer solution and the grounded collector. This 
process was first described by Sir Geoffrey Taylor in his 1964 paper entitled 
‘Disintegration of Water Droplets’ in an Electric Field. The jet emerges from 
the charged surface of the needle and accelerates through the electrical field 
toward the grounded target. The fibres are bent whilst being drawn from the 
needle tip creating a web-like non-woven structure on the surface of the 
grounded collector. Deposition of fibres also relies on the rapid evaporation 
of solvent to enable the polymer to solidify efficiently (SL Shenoy, 2005). This 
network mimics a number of native visceral ECMs that have the potential to 
promote cell adherence and proliferation. The ECM supporting the nervous 
system ranges in dimensions depending on the tissue, however the retina 
contains fibres of 100-1000nm in width.  
Scaffolds built by electrospinning techniques can have different properties 
that result in a range of fibre thicknesses and morphologies. The structure 
and final thickness of fibres produced by this method is determined by 
several factors. The main parameters include the properties of the polymer 
solution, such as viscosity, elasticity, and the degree of surface tension. 
Additionally external factors can impose constraints on the spinning process 
and include the external electrical field strength, voltage, temperature and 
humidity. Collagen electrospinning creates a meshwork that resembles the 
physical structure of the innate ECM. The final structure of product, however, 
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can be influenced by extrinsic factors such as solvents and fixatives used to 
develop fibrous scaffolds. 
 Often studies focused on the production of collagen scaffolds for medical 
application have involved the development of gels or solid constructs such as 
powders or films, but these have failed to mimic the native in vivo properties 
of the ECM.  
3.1.3.1. Factors influencing the structure of collagen fibres 
produced by electrospinning 
Acetic and formic acid can be used as solvents for electrospinning collagen, 
although acidic environments can permanently destroy the topology of 
collagen fibres. Moreover, the slow evaporation rates of the acids and their 
strong affinity for collagen leads to the formation of wet, fused fibres which 
can eliminate the fibril structure impacting on its bioactivity. It is essential for 
some cell types to interact with matrices containing collagen fibre diameters 
akin to the native protein fibrils (20– 100nm in diameter) (Matthews et al., 
2002), to ensure adhesive cell-matrix properties. 
Collagen is also soluble in the chemical 1, 1, 1, 3, 3, 3 hexafluoro-2- 
isopropanol (HFIP) which can be used for electrospinning under similar 
parameters used with acid solvents. HFIP is extremely volatile and has a low 
affinity for collagen (J. A. Matthews, 2003), hence it is a suitable 
electrospinning solvent. Though very cytotoxic, cells have been shown to 
proliferate on scaffolds spun with HFIP and have been approved by the 
United States Food and Drug Administration (FDA). HFIP acts by partially 
denaturing the triple helix of native collagen but does not destroy its 
structure. HFIP itself, like collagen, has both highly hydrophobic and 
hydrophillic regions. It is thought that HFIP binds directly to collagen via 
hydrophobic and hydrophilic interactions, which act to support and divide the 
triple helices whilst in solution.  HFIP dissolves the crystalline structures 
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contained within the triple collagen helixes, and stabilises the collagen 
fibrillar structure (Doillon et al., 1997). This ultimately facilitates cellular 
affinity to the scaffold matrix.  
Naturally sourced biomaterials, including collagen, require stabilisation 
following spinning. This involves the formation of crosslinks between fibres to 
improve mechanical integrity. Collagen crosslinking occurs between two 
lysine residues, and can be induced by chemical or natural protein 
crosslinkers. 
Chemical crosslinking agents are widely used to cross link type Ι collagen 
are themselves very cytotoxic. This feature can lead to extensive 
inflammation within tissues, preventing the survival of grafted cells.  
Chemical agents used to crosslink collagen include aldehydes, epoxy 
compounds and isocyanates. They covalently couple neighbouring fibrils and 
target reactive moieties of collagen side chains.  The bonds formed may 
incorporate or retain derivatives of the agent used, for which degradation of 
the scaffolds may then lead to the release of agents that can be severely 
cytotoxic (Rothamel et al., 2005). 
Natural crosslinking agents have offered an alternative strategy for 
crosslinking collagen. Plant derived genipin and nordihydroguaiaretic acid 
are natural products that can be used as crosslinkers, and could pose no 
major concerns of inflammation, compared to other chemicals. Catalysts 
have also been explored as protein crosslinkers. An example of such an 
agent is 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), which 
associate with protein carboxylic groups to form o-isoacylurea structures. 
This results in the activated intermediate being attacked by a nucleophilic 
primary amino-group to form an amide crosslink. Isourea derivative of the 
applied carbodiimide is then eliminated and can be washed out (Everaerts et 
al., 2008). If washed sufficiently, carbodiimide-fixed scaffolds are non-
cytotoxic and are entirely permissive to cell attachment and survival. 
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Biomaterials crosslinked with carbodiimide are in general significantly more 
biocompatible than those crosslinked with agents such as glutaraldehyde 
(GTA). 
3.1.4. Plastic Compression 
Understanding and mimicking the spatial organisation of the native ECM is 
the ultimate aim of bioengineers when fabricating materials for potential 
transplantation. Hydrogels composed of type I collagen constitute a possible 
candidate for use in tissue regeneration techniques. However, in its 
gelatinous state they contain a large amount of water, making its use difficult 
in regenerative medicine. Whilst collagen gels do provide a meshwork of 
randomised fibrils, it lacks the essential tight packing of the fibres, making 
them inherently weak (Brown et al., 2005). Furthermore, cells grown within 
gels may react differently when compared to their native counterparts under 
in vivo conditions, and due to the stringent extraction processes, type I 
collagen can lose its native characteristics and form weaker and less 
extensive interactions with cells in vitro. Though modifications of 3D scaffolds 
have been made for culturing systems, they do not totally parallel the 
features of the original ECM (Tibbitt and Anseth, 2009). 
A novel method of hydrogel compression has been developed to overcome 
the above problems, which has been shown to improve the mechanical 
integrity and biomimicry of collagen. This process involves excluding the 
entire aqueous component of collagenous hydrogels. This results in the 
formation of randomised-tightly packed collagen fibrils reminiscent of the in 
vivo ECM. This process has been termed Plastic compression (PC) (Brown 
et al., 2005) (Figure 3.2). It involves applying a known weight to a collagen 
gel for a short period of time to remove aqueous components and avoiding 
the use of chemicals for crosslinking. The extent of crosslinking can be 
altered depending on the collagen concentration of the hydrogel. This 
protocol can be modified by creating a gradient between the mass applied,  
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Figure 3.2: Plastic compression of Collagen hydrogels. Following 
polymerisation of collagen hydrogels, 150g weight is applied to remove the 
aqueous component. This results in an extensive network of crosslinks between 
collagen fibres. The dehydration process involved collecting the gel between 
two nylon sheets supported on filter paper, and applying the mass onto the rat 
tail (RTT) type I collagen hydrogel for 5 minutes.  
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time for compression and the collagen concentration (Kureshi et al., 2010). 
This results in the formation of scaffolds with different properties that can be 
used for different applications. 
Factors affecting the PC process can alter the fibres created. The volume 
and spatial dynamics of the hydrogel at the start of polymerisation can 
change the density of collagen fibres within the final network. In addition, the 
temperature at the time of neutralisation can disrupt the rate of fibril 
polymerisation and lead to incomplete crosslinking. Compression weightsand 
time creates a dynamic gradient between scaffold elasticity and tensile 
strength. Specifically, longer periods and higher weight increase the number 
of crosslinks between collagen fibrils. Chemical factors influence the internal 
features of the hydrogel prior to neutralisation and centre on the 
concentration and the type of solvent used to dissolve the collagen. Acidic 
solutions of collagen can be made with acetic and hydrochloric acids which 
elicit different polymerisation features, and can ultimately alter the efficiency 
of neutralisation. Furthermore, the concentrations of collagen within the 
solutions also impact on the degree of polymerisation during neutralisation 
and crosslinking during compression procedures. Resulting fibres can be 
either extensively crosslinked, or weaker, with less stabilised fibrils, which 
can be appropriately adapted to target specific tissues.  
These modified collagen hydrogels have been widely used in translational 
research as platforms for cell or therapeutic agent delivery, tissue scaffolds 
for repair, and as in vitro models of disease. Compressed collagen gels have 
been used to culture human bladder smooth muscle cells within its structure 
whilst supporting urothelial cells on their surface (Engelhardt et al., 2010). 
The cell populations were able to thrive and form densely packed cell layers, 
suggesting that PC collagen is an adequate substrate for these cells and that 
it has potential for cell replacement therapy of diseased bladders. 
Furthermore, PC collagen structures have been used to culture corneal cell 
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populations. To date, limbal epithelial stem cells, taken from human corneal 
biopsies have been expanded on PC collagen substrates, where feeder 
fibroblasts have been directly seeded within the matrix (Levis et al., 2010). 
The compressed scaffolds are able to retain the population of fibroblasts and 
create a feeder layer of cells which is suitable for transplantation. This study 
revealed that collagen was able to support both types of cells whilst also 
developing the tissue architecture of the native cornea. 
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3.2. Objectives and Experimental outline 
This project aimed to determine the feasibility of constructing cellular 
substrates to deliver Müller stem cell-derived RGC precursors onto the inner 
retina. To create a biomaterial-based substrate for intraocular cell delivery, 
the scaffold would need to be able to withstand surgical manipulation, 
support migration of grafted cells to the site of degeneration, and allow cell 
integration and long-term survival. Lack of these features could heavily 
impact on the efficiency of successful transplantation. Furthermore 
understanding the development of cell-matrix synergy is key to develop 
suitable cellular scaffolds, and requires knowledge of the ultrastructural 
conformation of the matrix. This information can be used to determine the 
methods to prepare scaffolds using different biomaterials, enhancing the 
success of cell transplantation. On this basis, the following objectives were 
formulated: 
1. To develop protocols for constructing electrospun type I rat tail collagen 
scaffolds and to examine their physical properties. 
2. To develop protocols for constructing compressed type I rat tail collagen 
scaffolds and to explore their physical features. 
3. To compare the biological properties of electrospun and compressed 
collagen scaffolds. 
4. To compare the physical properties of electrospun and compressed 
scaffolds to facilitate in vivo transplantation. 
To fulfil the above objectives, the following experiments were performed: 
1. Investigation of the physical and chemical parameters needed for 
adequate formation of electrospun collagen scaffolds. This involved the 
use of different solvents, voltages, air gap distances and the use of 
different protein crosslinking agents. 
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2. Investigation of the physical and chemical parameters needed for 
adequate formation of compressed collagen scaffolds. This involved the 
use of different concentrations of collagen, volumes, and compression 
parameters. 
3. Assessment of the ability of electrospun and compressed collagen 
scaffolds to support cell adhesion, growth and differentiation in vitro. 
These experiments involved the investigation of scaffolds to promote cell 
viability, as determined by hexosaminidase assays, and by inducing RGC 
differentiation upon Notch inhibition and growth factor stimulation. 
4. Examination of the mechanical handling of scaffolds for transplantation 
purposes. These studies involved the physical handling of scaffolds, as 
well as the ability to pass them through a cannula for transplantation. 
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3.3. Results 
3.3.1. Effect of different solvents on the formation of collagen fibres 
prepared by electrospinning methods 
Rat tail type I collagen was dissolved in either acetic acid or HFIP at a 
concentrations of 50mg/ml. The voltage used to draw fibres was 
standardised to ensure a continuous fibre was draw and collected. It was 
found that the voltage needed for this application ranged between 12-12.5kV, 
with an air gap distance to the grounded target of 15cm for the collagen 
solutions. The feed rate used for the electrospinning process of collagen 
ranged between 2 and 5 ml/hr. 
Under the above voltage conditions, fibres drawn from the solution 
containing acetic acid showed bleb formation (Figure 3.3). Fibres were drawn 
continuously and the ribbons formed were smooth, although large blebs were 
observed on the surface of the scaffolds, making them inappropriate for cell 
adherence. In contrast, collagen solutions made in HFIP, when electrospun 
under the same conditions used for spinning acetic acid solutions, produced 
smooth fibres without irregular blebbing on the scaffolds surface (Figure 3.3). 
3.3.2. Effect of Different Crosslinking Agents on the Maintenance 
of the Ultrastructure of Electrospun Collagen Fibres 
Crosslinking procedures were used to induce and maintain structural integrity 
of electrospun matrices. This investigation examined both physical and 
chemical methods of collagen crosslinking. Glutaraldehyde (GTA) vapour 
was used to chemically crosslink electrospun micro fibrils of collagen for 72 
hours in a sealed environment. Samples crosslinked with GTA vapour 
(Figure 3.4A ii) and EDC/NHS (Figure 3.64A iii) did alter in appearance, 
turning to a straw yellow colour from an initial brilliant white colour (Figure 
3.4A i), indicative of the fixative action of the  
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Figure 3.3: Morphology of Electronspun collagen fibres using various 
solvents.  Triplicate phase-contrast images of rat tail type I collagen fibres 
electrospun from solutions containing 50mg/ml of collagen dissolved in either 
HFIP or acetic acid. The electrospinning parameters were 12kV and a 15cm 
air gap distance. Fibres drawn from a 22G needle for 1hr, HFIP solutions 
were continuous and smooth, whereas fibres produced from acetic acid 
solutions were irregular in morphology. Acetic acid also promoted bleb 
formation on the fibrillar surface possibly due to its slow evaporation rate, 
following fibre deposition on the grounded target. Scale bar= 50µm.  
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Figure 3.4: Effect of Crosslinkers on Electrospun collagen fibres: 
Scanning electron microscopy was used to examine the morphological 
structure of constructs produced by electrospinning. The micro-structures 
resulting from these crosslinking methods showed distinct fibre morphologies. 
A) Photographic images of the macroscopic features of electrospun collagen 
i) non-crosslinked ii) 15% GTA crosslinked and iii) EDC-NHS crosslinked 
collagen scaffolds. The fixation process with the different crosslinkers 
generated characteristic colour change in electrospun scaffolds. Scaffolds 
change from white (non-crossliked) to yellow (GTA) or yellow-brown (EDC-
NHS). This alteration in colour is typical of protein crosslinking and structural 
modification. B) Scanning electron micrographs of the microstructure of 
electrospun collagen matrices i) non-crosslinked, or crosslinked with ii) 15% 
GTA, iii) EDC and iv) EDC-NHS. GTA crosslinked collagen produced matrices 
with well-defined fibres, similar to those observed prior to crosslinking. 
However, EDC crosslinking treatments produced fibres that lacked porosity. 
EDC alone created matrices without well-defined fibrils, compared to non-
crosslinked and GTA treated collagen scaffolds. Fibres appeared to be fused 
when treated with EDC in both the presence and absence of NHS. Scale bar= 
10µm.  
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crosslinkers. Electron microscopic examination of the fibres obtained 
following GTA crosslinking indicated that on average, the fibres had a 
diameter of 1.03± 0.026µm and a thickness of approximately 128 microns 
(Figure 3.4B). 
The chemical 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was 
used as a non-toxic substitute for GTA vapour. It acts as a benign catalyst 
and is generally used in combination with N-hydroxysuccinimide (NHS). This 
acts as an “amine-group” giving substrate and provides a reservoir of amine-
groups (-NH3) for protein crosslinking. However, use of EDC either alone or 
in combination with NHS caused solubilisation of collagen fibres when 
hydrated (Figure 3.4B iii and iv). Whilst with EDC alone some fibrous and 
porous structure remained (Figure 3.4B iii), addition of NHS caused total loss 
of the fibrous architecture (Figure 3.4B iv). This observation prevented the 
progression of this work onto scaled up culturing of Müller stem cell-derived 
RGCs for transplantation. 
3.3.3. Standardisation of methods to develop compressed collagen 
scaffolds 
Ultra-thin collagen scaffolds were produced by compression of collagen 
hydrogels. Acidic solutions of collagen were neutralised with sodium 
hydroxide. Neutralisation was performed at room temperature and was 
indicated by colorimetric alteration of the acidic solution, from straw yellow to 
indigo-pink with the addition of sodium hydroxide (Figure 3.5A). After 
neutralisation, hydrogels were poured into titanium moulds and incubated at 
37°C for 30 minutes to polymerise. Collagen hydrogels were then subjected 
to compression for 5 minutes under 150g/collagen hydrogel to remove their 
aqueous components. Scaffolds were then floated into PBS. To design 
suitable scaffolds for retinal transplantation, it was necessary to take into 
account various parameters required for safe and practical injection of 
cellular scaffolds into the eye. Delivery of ocular transplants would require  
C D C 
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Figure 3.5: Physical appearance of collagen hydrogels. The figures illustrate 
the distinctive appearance of collagen hydrogels prior to compression A) 
collagen suspensions following neutralisation with sodium hydroxide; acidic 
suspension (left) and alkaline suspension (right) as visualised with phenol red. 
B) polymerised hydrogels following incubation of neutralised solutions at 37ºC 
for 30 mins. Titanium rings were used to cast collagen hydrogels.  
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transplantation through conventional sclerotomies formed during vitreoretinal 
surgery, no larger than 18G in size (lumen size of 0.64mm). Parameters 
used to produce compressed collagen scaffolds were set in order to achieve 
their passage through an 18G cannula. These included the use of hydrogel 
volumes of 300μl, cast in 1 cm moulds and concentrations ranging from 
0.75mg/ml-2mg/ml. Both excessive and moderate neutralisation prevented 
polymerisation of hydrogels, giving the appearance of stable hydrogels. 
However, these hydrogels were structurally weak and rapidly lost stability 
when physically manipulated. It was therefore determined that a reduced 
amount of stable crosslinks had been formed between the collagen 
molecules. Compression of these gels resulted in thinner mats with larger 
diameters, suggesting low quantities of collagen fibres per unit of area of 
scaffold. 
The surface of the scaffolds observed under low magnification phase-
contrast microscopy showed the meso-structure with an imprint of the 
compression materials (Figure 3.6A). Microscopic examination using high 
magnification showed an ultrastructure composed of a closely packed 
network of collagen fibres (Figure 3.6B). Fibres produced by PC are on the 
nano-scale and exhibit native dimensions with an average diameter of 
0.75±0.042µm. Thicknesses of collagen fibres produced by compression of 
Hydrogels prepared at different collagen concentrations resulted in 
consistent widths of approximately 20μm (Figure 3.6B).  
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  Figure 3.6: The Macrostructure and Ultrastructure of Plastic Compressed 
(PC) Rat tail type I Collagen hydrogels. The structure of the collagen hydrogels 
following compression recorded under A) phase-contrast illumination in PBS, for 
three concentrations of collagen, with an aerial perspective (top three images) 
and  cross sections of scaffolds embedded in OCT (20 micron transverse 
sections) (bottom 3 images). Scale bar= 100µm. B) Scanning electron 
micrographs of decreasing, left to right, collagen concentrations depicting the 
ultrastructure within PC collagen constructs and the crosslinks formed between 
fibrils (white arrows). Scale bar 200nm. C) Transmission electrograph of native 
type I collagen, scale bar= 100run (taken from Bruns R et al, 2010). 
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3.3.4. Comparison between the Light Absorbent Properties and 
Porosity of Electrospun and Compressed Collagen Scaffolds 
Collagen fibres produced by either compression or electrospinning were 
studied for porosity or area fraction of the pores, and optical density. These 
features may help to establish the physiological functionally of the scaffolds. 
Scaffolds were examined for their suitability for cell adhesion, whilst 
determination of their optical density was used to assess light absorbance 
and their ability to facilitate light passage onto the retina. The porosities 
measured using threshold set (binary black and white) SEM images in 
imageJ, indicated a significant difference between EDC-based methods and 
GTA vapour (Figure 3.7 A-C) with none or very few pores being identifiable 
in EDC scaffolds, whilst GTA crosslinked scaffolds had an average pore size 
of 4.75µm (Figure 3.7 E). Whilst EDC produces matrices that are able to 
undergo culturing systems, it may be assumed the degree of cellular affinity 
would be lower in these systems. The degree of porosity observed in 
compressed scaffolds was on average 50% of the surface area, with pore 
size averaging 475nm signifying the degree of mesoporosity and the size of 
pores being markedly smaller and higher in occurrence compared to 
electrospun scaffolds (Figure 3.7 E and F). Scaffolds that are suitable for 
eventual transplantation into the eye ideally should be transparent. To this 
end, the optical density of the scaffolds was determined within a range of 
350nm-750nm using a spectrophotometer. The extent of visual light 
absorbance by the different scaffolds was negligible, indicating no hindrance 
of visual light transmission. No significant difference was observed between 
the different scaffolds (Figure 3.8 A and B). This finding suggests that both 
processes are able to create scaffolds which allow transmission of light and 
would promote light passage onto the retina, following transplantation. 
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Figure 3.7: Physical Properties of Electrospun and Compressed collagen 
fibres. Constructs that are suitable for eventual transplantation into the eye, need to 
allow cell adhesion, influenced by porosity and pore size (red arrow), as well as 
permitting the passage of light. Porosity was measured from electron micrographs 
and imageJ software, where average pore size and area fraction was determined 
over the whole surface area, through the conversion of SEM images to black and 
white binary figures. Porosity levels were measured for A) 15% GTA, B) EDC, C) 
EDC+NHS electrospun scaffolds and D) compressed collagen scaffolds. Pore 
numbers were sparse for scaffolds processed with EDC treatments. Analysis of 
pore E) number and F) volume showed that the size when present was greater in 
EDC matrices than GTA crosslinked scaffolds and compressed scaffolds. This 
suggests that the original distance between the fibres may have been large, prior to 
fusion. GTA and compressed collagen scaffolds generated small pores with high 
frequencies. However, compressed collagen matrices had markedly higher pore 
density, as well as smaller sizes. (Scale bar=10µl) 
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Figure 3.8: Optical Properties of Electrospun and Compressed collagen fibres. 
Constructs that are suitable for eventual transplantation into the eye, need to permit 
the passage of light through, for which we assessed optical density as an indicator of 
this function. The optical density of the various collagen scaffolds was determined 
over a range of 350nm-750nm using a spectrophotometer. The extent of visual light 
absorbance by A) electrospun scaffolds was negligible, indicating no significant 
hindrance of visual light absorbance. However, the degree of absorbance observed by 
B) compressed collagen fibres did demonstrate an increased level of absorbance 
within the shorter wave lengths (between 350-575nm)which indicates some 
absorption in the blue-green range of the visible spectrum.  
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3.3.5. Ability of Collagen Scaffolds to Support Cell Adhesion, 
Growth and Differentiation 
Following examination of their physical characteristics, scaffolds were 
studied for their ability to support cells adhesion, growth and differentiation. 
Initially the extent of cellular adhesion on collagen scaffolds were examined 
by light microscopy for electrospun (Figure 3.9) and compressed (Figure 
3.10) collagen scaffolds, over a 7 day culture period. Phase-contrast 
microscopy showed the biological capabilities of the cellular scaffolds, as 
indicated by their ability to support cell adhesion. Larger numbers of cells 
were shown to adhere onto scaffolds prepared by electrospinning collagen 
for 2hours, as compared with 1 hour. This indicates that cell adherence is 
dependent on the number of fibres within the scaffolds structure (Figure 3.9). 
Distinct focal adhesions were observed under SEM by both electrospun 
(Figure 3.11 A and B) and compressed collagen scaffolds (Figure 3.11 C, D, 
c and d), where they appeared to form long processes along the fibres. The 
close matrix-cell relationship established by the different scaffolds suggests 
that collagen is a suitable material for cellular scaffolds as it promotes cell 
adhesion and growth. Both electrospun and compressed collagen scaffolds 
were then examined for their ability to support Müller stem cells 
differentiation into RGCs. For this purpose cells were cultured in the 
presence the Notch1 inhibitor DAPT and bFGF for one week. These 
conditions had been previously shown to induce RGC differentiation and had 
been refined in initial experiments presented in this thesis in our laboratory 
(Singhal et al., 2012). Cells cultured with DAPT and bFGF adhered to 
collagen scaffolds; with SEM illustrating the capacity of the different fibres 
assisting in the formation and maintenance of neurite projections (Figure 
3.11A, C and c). The adaptation to a neural morphology  
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Figure 3.9: Light microscopy appearance of Müller stem cells grown on 
electrospun collagen fibres. Cells adhered to collagen scaffolds, with fibres 
assisting in the cell adhesion, viability and maintenance of cellular viability, 
over the course of 7 days culture. Phase contrast images under light 
microscopy of cells cultured in the absence of collagen matrices. Phase 
contrast image under light microscopy of cells cultured in the presence of 
collagen fibres, electrospun for 1 hour. Phase contrast image of cells cultured 
in the presence of collagen fibres, electrospun for 2 hours. Scale bar= 100µm  
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Figure 3.10: Culturing of Müller stem cells on Compressed Collagen 
scaffolds over 7 days. Kholer illumination showed that cells were able to 
adhere to PC collagen constructs over a 7 day period coupled with a decreasing 
collagen concentration, under control treatments. Cells cultured on 0.75mg/ml 
collagen, on 1mg/ml and cultured on 2mg/ml collagen scaffolds. Cells firmly 
adhered to the collagen constructs, with a flattened morphology and maintained 
growth over the 7 day culture period. Scale bar =100µm  
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Figure 3.11: Matrix-cellular interaction between Müller stem cells and 
type I collagen scaffolds. Scanning electron-microscopy showed that cells 
developed long processes resembling axonal processes and neurites, which 
firmly attached to the collagen scaffolds cultured for 5 days. Cells cultured in 
the presence of DAPT and bFGF formed long cellular projections resembling 
axons and neurites, indicated by white arrows. In the absence of DAPT and 
bFGF, cells firmly adhered to the collagen constructs, but their morphology 
showed a characteristic flattened morphology (Figs B,D,d). A and B illustrate 
electrospun scaffolds crosslinked with 15% GTA. C,D,c and d illustrate 
compressed scaffolds. Figs c and d are magnifications of Figs C and D 
respectively to show adhesion details. Scale bar =A-B: 100µm: C-D:100µm; c 
and d:10µm  
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by the Müller stem cells is shown by the formation of long axonal processes 
into and along the fibres of compressed and electrospun scaffolds.  
Acquisition of neural morphology by Müller stem cells cultured on type I 
collagen scaffolds was also shown by immunocytochemistry (Figure 3.12-
3.16). GFP labelled Müller stem cells transfected with the lenti-viral GFP 
vector were seeded onto the scaffolds and cultured for 7 days (Figure 3.12). 
Cells were shown to adhere and form long cytoplasmic projections on 
electrospun collagen. Staining enabled labelled cells to be examined for any 
changes in morphology and phenotype. Müller stem cells cultured for 7 days 
on compressed and electrospun collagen scaffolds acquired neural-like 
morphologies, judged by their adoption of discrete and defined axonal 
projections. To determine whether cells cultured on the scaffolds 
differentiated into RGCs, they were stained with antibodies with mature RGC 
markers including HUD, ISLET-1, BRN3B and RT97. 
Whilst GFP labelled cells showed morphological changes characteristic of 
neural development (Figure 3.12). It was not possible to determine whether It 
was not possible to identify the expression of RGC markers by Müller stem 
cells cultured on electrospun collagen scaffolds in the presence of DAPT and 
bFGF due to the intense autofluorescence observed in these scaffolds 
(Figure 3.13). This was ascribed to the non-specific binding of antibodies to 
the electrospun scaffolds, combined with their underlying autofluorescence 
(Figure 3.13B). Moreover, collagen itself is autoflourescent and it is ionically 
charged, which causes binding of antibodies in a non-specific manner. The 
intensity of fluorescence observed in electrospun scaffolds could also be 
attributed to the chemical crosslinking agent GTA. A protocol was used to 
quench this autoflorecence, where scaffolds were crosslinked with the 
minimum concentration of GTA vapour possible (15%), followed by vigorous 
washing with deionised water for 24 hours to remove excess GTA. Glycine 
(0.1M) and sodium borohydride were then added to remove autoflorescence.  
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Figure 3.12: Morphological changes of Müller stem cells 
cultured on 15% GTA crosslinked electrospun collagen 
matrices in the presence of DAPT and bFGF. Acquisition of 
neural morphology by Müller stem cells cultured on type-I collagen 
scaffolds was shown by immunofluorescence analysis of GFP 
labelled Müller cells (green) seeded onto the scaffolds. Cells 
adhered and formed long cytoplasmic projections in the presence 
of bFGF (20ng/ml) and the Notch inhibitor DAPT (50ng/ml). DAPI 
staining (blue) positively identified the nuclei of florescent cells, 
whilst the green fluorescence showed the neuronal morphology of 
differentiated cells (white arrows). Scale bar=75µm  
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Figure 3.13: Immunofluorescence analysis of Müller stem cells cultured 
on electrospun collagen matrices in the presence of DAPT and bFGF. 
A) Müller stem cells cultured on electrospun collagen and stained for the 
RGC marker; Islet-1, wihich was not identified within cellular populations. 
Electrospun collagen crosslinked with 15% GTA exhibited non-specific 
secondary antibody binding. Identification of Müller stem cell differentiation 
into RGCs was not possible on these substrates due to autofluorescence. B) 
Sodium borohydride was used to quench the non-specific fluorescence 
observed by electrospun scaffolds. Glycine was used before quenching to 
bind any charged collagen molecules to prevent non-specific antibody 
binding. Quenching protocols had no significant effect. Scale bar= 100µm  
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However, this process only partially quenched the fluorescence but did not 
allow visualisation of specfic staining. Hence, to specifically show cellular 
expression of any protein marker in these scaffolds, the background of 
autofluorescence needs to be significantly reduced.  
In contrast to electrospun collagen scaffolds, Müller stem cells cultured on 
compressed collagen in the presence of DAPT and bFGF, showed significant 
morphological changes. GFP labelled Müller stem cells were cultured in the 
absence of PC collagen scaffolds, as well as in the absence of differentiation 
factors (DAPT and bFGF) (Figure 3.14). These controls enable the 
comparsion between the expression of cells cultured in the presence of 
collagen and differentiation conditions. They also made possible the 
identification of phenotypic changes. Differentiated cells showed positive 
staining for markers of RGC precursors, when compared to untreated 
controls in the presence of compressed collgen (Figure 3.15A). Confocal 
microscopy demonstrated the expression of RGC markers expressed by 
Müller stem cells cultured on 0.75mg/ml PC collagen in the presence of 
DAPT and bFGF. Müller stem cells transfected with a lenti virus GFP 
adhered to collagen substrates in the presence or absence of DAPT and 
bFGF.  Differentiation of cells into RGCs was confirmed by their co-
expression of GFP and mature RGC markers HUD and ISLET-1 and the 
RGC precursor marker BRN3B. Staining for BRN3B, HUD and ISLET-1 was 
localised to the nuclei of the cells (Figure 3.15B). Cells were also counted for 
RGC marker expression compared to controls without DAPT+bFGF and 
compressed collagen scaffolds (Figure 3.16).All the RGC markers were 
significantly increased compare to controls. β-3-TUBULLIN and RT97 
staining was localised within the cytosol along the length of the neurite 
outgrowth. Cellular projections were coupled with the enriched expression of 
both neural filament makers, signifying the development of axons. This 
suggests that compressed collagen substrates are able to support and 
maintain axonal growth and Müller stem cell differentiation (Figure 3.17).  
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Figure 3.14: Müller stem cell expression of RGC markers in the absence of PC 
collagen constructs. Confocal microscopy demonstrated the expression of RGC 
markers expressed by Müller stem cells cultured under control conditions for 7 days. 
Human Müller stem cells (hMSC) transfected with a lentivirus GFP (green) grew in the 
absence of DAPT/ bFGF and PC collagen. Control conditions were compared to 
differentiation of cells into RGC, in order to determine the extent of RGC maturation 
using the markers ISLET-1, HuD and the RGC precursor marker BRN3B. Scale 
bar=50μm.  
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Figure 3.15: Müller stem cell differentiation and expression of RGC markers on 
PC collagen constructs. Confocal microscopy  demonstrated the expression of RGC 
markers  expressed by Müller stem cells cultured on 0.75mg/ml PC collagen in the 
presence of DAPT+bFGF for 7 days. Human Müller stem cells (hMSC) transfected 
with a lentivirus GFP (green) readily adhered to collagen substrates in the presence or 
absence of DAPT and bFGF.  Differentiation of cells into RGC was confirmed by their 
co-expression of GFP, mature RGC markers HUD and ISLET-1 and the RGC 
precursor marker BRN3B when compared to controls.  A)  Müller stem cells cultured 
with bFGF and DAPT on compressed collagen constructs. B) Müller stem cells 
cultured in medium alone, without differentiation factors. Scale bar=50μm.  
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Figure 3.16: Graphic representation of Müller stem cell differentiation and 
expression of RGC markers on PC collagen constructs. The confocal microscopy  
demonstrated the expression of RGC markers  expressed by Müller stem cells 
cultured on 0.75mg/ml PC collagen in the presence of DAPT+bFGF for 7 days.  
Differentiation of cells into RGCs was confirmed by their co-expression of GFP, 
mature RGC markers HUD and ISLET-1 and the RGC precursor marker BRN3B when 
compared to controls. Cells which positively expressed the RGC markers were 
counted, in the presence of PC collagen with or without differentiating factors. 
Comparison to no treatment and absence of PC collagen RGC marker expression 
was markedly increased in the presence of PC collagen either in the presence or 
absence of DAPT+bFGF.  
162 
 
  
Figure 3.17: Müller stem cell differentiation and expression of neural markers 
upon culture on PC collagen scaffolds in the presence of DAPT and bFGF. 
Confocal microscopy demonstrated the upregulation in Müller stem cells of neural 
filament markers (ß-III Tubulin  and RT-97), associated with axonal development. A) 
GFP labelled Müller stem cells (green) cultured for 7 days, in the presence of 
compressed collagen scaffolds (0.75mg/ml) and DAPT+bFGF developed neurite 
outgrowths (white arrows), stemming from pronounced cell bodies. Cellular 
projections were coupled with the enriched expression of both neural filament 
makers, signifying the development of axons. This suggests that compressed 
collagen substrates are able to support and maintain axonal growth and Müller stem 
cell differentiation. These were compared to B) controls, which lacked pronounced 
cytoplasmic outgrowths and did not express ß-III Tubulin or stain for RT97. Scale 
bar=50μm.  
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These observations indicate that collagen scaffolds can support and help 
guide cellular differentiation and behaviour of Müller stem cells.  
Cellular toxicity of collagen scaffolds was examined over a seven day period. 
Cells were cultured on collagen scaffolds prepared under different protocols. 
These included electrospun scaffolds crosslinked by three different methods. 
Different concentrations of GTA vapours were used to crosslink the collagen 
microfibres for 72 hours, followed by thorough rinses with deionised water 
prior to seeding cells. A measure of cellular viability was obtained for each 
concentration of GTA using the Hexosaminidase assay to assess cell 
viability following collagen digestion.  
There were no significant differences in cell viability between cells cultured 
on scaffolds crosslinked with low GTA concentrations (5-10%) and cells 
cultured on ECM or non-ECM coated plates (no matrix controls) (Figure 
3.18A). This suggests that electrospun collagen scaffolds supports growth 
and viability of Müller stem cells. In contrast, cells grown on 25% GTA 
crosslinked scaffolds showed a marked decrease in cell viability as 
determined by Hexosaminidase assays readings. This suggests that GTA 
induces cell toxicity in Müller stem cells at concentrations above 10%. GTA 
has been repeatedly reported to be a toxic agent and deemed unsuitable for 
biomedical applications, including crosslinking proteins. On this basis, the 
study investigated other methods of collagen crosslinking. EDC in 
combination with NHS was assessed for their affect on cellular viability. The 
Hexosaminidase assay was again used to examine the amount of viable 
cells in the presence of EDC crosslinked collagen matrices (Figure 3.18B), 
where no differences were recorded. This data indicates that use of EDC 
does not modify cell growth and viability, suggesting that these agents are 
non-toxic to Müller stem cells in culture. Examination of cellular viability on 
collagen compressed scaffolds demonstrated a lack of toxicity indicating  
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Figure 3.18: Müller stem cell viability following culture on collagen-based 
scaffolds. Müller stem cells were cultured on A) GTA cross-linked scaffolds, B) 
EDC+NHS crosslinked scaffolds and C) compressed collagen scaffolds for one week. 
Viability was assessed using the Hexosaminidase assay, based on the uptake of the 
enzymatic substrate by the lysosomes of living cells. Absorbance readings were 
normalised to no matrix controls and ECM (extracellular matrix). Different 
concentrations of GTA vapours were used to cross-link the collagen fibres. A 
significant  decrease in cellular viability was observed with cells cultured on 25% GTA 
crosslinked collagen when compared to cells grown on no matrix controls following 
collagen degradation with collagenase D. Significant changes in cell viability were not 
detected in Müller stem cells cultured on 0.75mg/ml compressed collagen or 
electrospun EDC crosslinked collagen scaffolds.  
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these scaffolds support Müller stem cells for transplantation (Figure 3.18C). 
This study indicated that there was no alteration to cellular proliferation. 
3.3.6. Comparison between the Mechanical Handling of 
Electrospun and Compressed Collagen Scaffolds 
To ensure delivery of scaffolds, aimed at cell transplantation into the eye, scaffolds 
must be able to exhibit plasticity, to endure physical manipulation through cannulas 
used for retinal surgery. The relatively easy handling of GTA crosslinked scaffolds were 
shown to be comparable to human retinal explants. However, depending on the 
thickness of the collagen scaffolds resulting from different periods of electrospinning 
(up to 2 hours), scaffolds demonstrated different strengths when handled. Thin 
electrospun scaffolds did not withstand handling and were unable to pass through the 
lumen of an 18G cannula. These were fragile and became damaged by gentle 
mechanical manipulation. Moreover, the rigidity possessed by GTA crosslinked scaffolds 
made passage through an 18G cannula inconsistent and resulted in damage of the 
scaffold’s structure (Figure 3.19). 
EDC crosslinked electropspun scaffolds altered their macroscopic features 
when hydrated. They acquired a gelatinous consistency that changed their 
structural integrity. This gelatinous structure made cell culturing as wells as 
manipulation impossible and therefore they could not be considered as a tool 
for retinal transplantation. 
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Figure 3.19: Mechanical properties of collagen-based scaffolds. Vitrectomy 
surgeries were performed via 20G ports where PC collagen scaffolds require 
entry into the eye via 18G cannulas. Both compressed and GTA crosslinked 
electrospun scaffolds were examined for their ability to enter the lumen of an 18G 
cannula. GTA crosslinked scaffolds failed to enter the lumen, whilst 0.75mg/ml 
compressed collagen scaffolds were able to withstand entry and expulsion from 
the lumen. Compressed collagen matrices of 0.75mg/ml, were shown to endure 
physical manipulation through an 18G cannula.  
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3.3.7. Ability of compressed collagen scaffolds to retain adherent 
cells for transplantation following passage through an 18G 
cannula 
Compressed collagen scaffolds retained their shape and structural integrity 
through handling (Figure 3.20). Compressed collagen scaffolds 
demonstrated a suitable strength that can be modified in size, and were 
sufficiently elastic to return to its original shape following mechanical 
manipulation. This finding suggested that compressed collagen was a 
suitable candidate for in vivo cell transplantation on the inner retinal layer. 
3.4. Discussion  
The primary objective of this study was to examine the suitability of collagen-
based scaffolds for transplantation of Müller stem cell-derived RGC 
precursors onto the inner retina. The study involved the examination of the 
physical and biological attributes of the collagen scaffolds produced. 
Engineering tissues to support cells either within or on biocompatible 
matrices is currently being applied to design regenerative treatments for 
pathologies affecting a wide range of tissues. The use of natural proteins to 
mimic such tissues emphasises the importance not only of restoring tissue 
architecture but also function, and therefore the arrangement of cellular 
frameworks may help to guide cell behaviour. Topological variations between 
different mature ECM networks centre on the cellular population that it 
contains. It is therefore important to consider the native organisation of 
tissues in need of repair. It has been reported that fibre alignment, topology 
and hierarchical arrangement of fabricated biomaterials is distinctly related to 
cell attachment and growth (Kureshi et al., 2010). Since the level of function 
by a protein is defined at the molecular level, the understanding of collagen 
scaffold structure and plasticity were important for this study. Evaluation of 
the physical attributes of the collagen scaffolds designed demonstrated 
different properties imparted by electrospininning and crosslinking agents, as 
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Figure 3.20: Cell numbers following in vitro manipulation with an 18G 
cannula. Vitrectomy surgeries were performed via 20G ports where PC collagen 
scaffolds require entry into the eye via 18G cannulas. A) 20,000 GFP labelled 
Muller stem cells, were seeded onto 0.75mg/ml compressed collagen matrices 
(0.5cm diameter) for 2 hours. Compressed collagen scaffolds were examined for 
topology and cell presence under confocal microscopy i) transverse sections ii) 
and iii) whole mount preparations. Phase contrast was also used to assess cell 
numbers and scaffold topology prior to and following manipulation. B) The 
Hexosaminidase Assay was used to examine the extent of cell loss following 
mechanical manipulation. There was no significant difference in cell viability 
between the scaffolds that underwent manipulation and those that did not.  
B 
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well as plastic compression. GTA crosslinking procedures, as well as 
compression rendered the collagen fibrils insoluble in water, facilitating 
culturing regimes and manipulation in vitro.  
The electrospinning process used in this study showed to be an easy method 
for preparation of collagen scaffolds for retinal cell transplantation. Relatively 
high voltages were required to overcome the surface tension created by the 
high viscosity of the biomaterial solutions. To overcome blebbing and 
irregular surfaces on the electrospun fibres, HFIP was identified as the most 
appropriate solvent for electrospinning collagen. It is possible that acetic acid 
used to suspend collagen lead to destabilisation of the triple helix structure. 
Damage to this structure may have therefore changed the spinning 
properties needed for producing suitable fibres. HFIP did not appear to 
denature collagen from its native form, but instead stabilise its conformation 
in solution, hence preserving the natural fibrillar structure of the collagen 
molecules whilst being stretched, favouring a uniform, fluid stream of fibres 
(Figure 3.3). The parameters used to electrospin rat tail type I collagen in 
HFIP were consistently reproducible. This enables fibres to be continuously 
fabricated to exhibit similar physical dimensions, unlike collagen solutions 
made with acetic acid. This provided the important initial step in the 
standardisation of electrospun collagen fibre production. 
Following electrospinning, fibres required crosslinking to ensure their integrity 
upon hydration. Crosslinking acts to strengthen electrospun collagen fibres 
and facilitates the design of artificial 3D collagen matrices, suitable for 
maintaining cells in vitro and in vivo. For this study GTA was used as a 
crosslinking agent. This is a well-known fixative that produces insoluble 
crosslinked protein aggregates (Khadka and Haynie, 2010). It acts by 
creating cross bridges between protein molecules rather than producing 
weaker intramolecular (hydrogen) bonds, between the carboxyl groups of 
reactive side lysine residues. EDC was also examined for its crosslinking 
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efficiency either alone or in combination with NHS. However, subsequent 
generation of scaffolds using this agent proved inconsistent, as sufficient 
crosslinking was not always observed. Although EDC and NHS catalysed the 
formation of crosslinks within collagen scaffolds, the mechanism involved in 
this form of catalytic crosslinking is not fully understood. The links created 
originate from the catalytic activity of EDC, and its ability to crosslink free 
amine groups on proteins, specifically lysines, arginines and hydroxylysines. 
The lack of robustness observed with this crosslinker may be due to its 
limited interactions with the internal collagen fibrils of the scaffold. The initial 
incubation of spun fibres with EDC may have led to the crosslinking and 
fusion of fibrils on the surfaces of electrospun scaffolds. This may have 
created sealed matrices and prevented sufficient penetration of these 
agents, rendering scaffolds structurally weak. These crosslinked scaffolds 
may appear to have been sufficiently stable under dry conditions, however 
hydration lead to loss of fibre structure. Further work may be performed to 
crosslink fibrils with EDC as they are being drawn (Beachley, 2009). This 
could involve direct fibre submersion into an EDC solution, alongside the 
electrospinning process. Thinner scaffolds may also limit the generation of 
sealed scaffolds, which could compromise structural integrity and difficulty in 
handling the constructs for ocular implantation.  
Compression of collagen hydrogels allows formation of high collagen density 
fibrils without compromising the macroscopic structure. Hydrogels are readily 
modified by cells (Eastwood et al., 1996) demonstrating their inherent 
weakness. Expulsion of water from collagen hydrogels led to randomised 
crosslinks between collagen fibrils, and constitutes an alternative method for 
rapid preparation of collagen scaffolds. Compressed collagen scaffolds 
supported in vitro culture of Müller stem cells (Figure 3.9 and 3.10) as well as 
facilitated mechanical manipulation for transplantation (Figure 3.19). The 
physical crosslinks between polymerised fibrils following compression 
generated tightly packed fibres (Figure 3.6). The process created collagen 
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networks resembling the native ECMs, and revealed hierarchy of fibrillar 
organisation.  
The porosity of the collagen scaffolds varied between methods used for their 
production. The physical porosity of electrospun scaffolds was dependent on 
the crosslinker used (Figure 3.7). EDC protocols reduced the amount and 
size of the pores on the electrospun scaffolds. The apparent low number and 
size of pores may be ascribed to the fusion of fibres on the surfaces of the 
scaffolds, which could impact on the adherence and survival of Müller stem 
cells during and after implantation. GTA crosslinked scaffolds conserved the 
porosity of the constructs suggesting that this is a suitable agent for retaining 
ECM-like structures that support cellular adhesion and proliferation. Pores 
have been shown to play a vital role in bioengineering, where specific cell 
populations tend to have increased affinities for porous scaffolds (Wray et al., 
2011, Guldberg et al., 2008, Lai et al., 2012). This feature also impacts on 
the diffusion of nutrients into and out of the scaffold matrices. Moreover, 
porous structures would favour drug or bioactive reagent release, as well as 
cellular support within the internal matrix of a scaffold. Low concentrations of 
GTA (<10%) did not prevent cell growth, as determined by the 
hexosaminidase assay to assess cell viability (Figure 3.18). This suggests 
that the porosity of scaffolds is not a determining factor for Müller cell 
adhesion and survival. Although, matrices supported normative growth of the 
Müller populations, without significant differences, increasing GTA 
concentration caused a decrease in cell growth. This suggests that GTA 
scaffolds may encourage immunogenic and inflammatory responses 
following implantation. It is possible that hydrolytic degradation of collagen 
constructs crosslinked with GTA may lead to the eventual release of residual 
cytotoxic chemical derivatives. This would induce cell toxicity within the 
microenvironment whether in situ or in vivo.  
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Optical density of the constructs indicated that they allow the passage of 
visible light through their matrices (Figure 3.8A and B), suggesting that spun 
fibres would not prevent light reaching the retina following scaffold 
implantation. Therefore photoreceptors would be able to transduce their 
sensory information to the brain without disruption. This attribute of collagen 
scaffolds is important when considering implantation onto the light sensitive 
retina, and demonstrates that these scaffolds exhibit appropriate features for 
transplanting retinal cells. 
Subsequently, the relationship between matrix and cellular populations was 
also analysed under SEM, which confirmed close matrix-cell interactions with 
GTA crosslinked and compressed collagen scaffolds. The ability of the 
collagen scaffolds to support cell growth and differentiation was determined 
by light (Figure 3.9 and 3.10), electron (Figure 3.11), confocal microscopy 
(Figure 3.12-3.17) and hexosaminidase assays (Figure 3.18). Both, GTA 
crosslinked and compressed collagen proved to promote adherence and 
growth, whereas RGC differentiation of Müller stem cells was well identified 
on compressed scaffolds. Compressed and GTA crosslinked collagen 
scaffolds facilitated the development of neurite outgrowths by Müller stem 
cells cultured under differentiating conditions. Long axonal processes were 
identified under SEM and confocal microscopy, with primary and secondary 
dendrites on these cells observed on the scaffolds (Figure 3.11).  
To examine the differentiation of Müller stem cells on collagen matrices, 
staining was performed. Confocal microscopy illustrated morphological 
changes as compared with untreated populations, as well as the expression 
of RGC markers. Proteins typical of RGCs were enriched in cultures 
undergoing Notch inhibition in the presence of bFGF on compressed 
substrates. In contrast the determination of RGC maturation of Müller cells 
grown on GTA matrices was not possible due to the autofluorescence 
exhibited by these scaffolds. Singhal et al designed a Brn3b reporter to 
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indicate the differentiation of Müller stem cell derived RGCs both in vitro and 
post transplantation in rodent ocular tissue (Singhal et al., 2012). This 
method could be used in the future to identify differentiation of Müller stem 
cells on GTA crosslinked scaffolds by highlighting cells that expressed Brn3b 
and had undergone neural differentiation. 
Collagenase D was used to fully degrade the collagen scaffolds to allow cell 
release for examination of viability. This study suggested that compressed 
collagen scaffolds supported cell adhesion for transplantation of Müller stem 
cells or neurons derived from these cells. The number of cells obtained after 
collagen digestion, were comparable to cultures on tissue plates. However, 
there is a need to examine the degradation rate of these types of collagen 
constructs in vivo in the absence of ECM degrading agents. The scaffolds 
prepared are therefore useful for differentiation of Müller stem cells and may 
potentially be used as temporary in vivo supports until grafted cells have 
migrated into the RGC layer. 
Thin GTA crosslinked scaffolds, prepared with low spinning times were 
fragile and did not achieve physical properties to allow mechanical handling, 
unlike their thicker equivalent samples. Furthermore, to assess their capacity 
for surgical handling, scaffolds were drawn into 18G cannulas. GTA 
crosslinked scaffolds failed to pass through the lumen of the cannula, 
possibly due to their rigidity and thickness. This would ultimately prevent the 
use of GTA crosslinked collagen scaffolds for surgical implantation.  
Further studies into the potential use of electrospun scaffolds may need 
polymeric enhancement of collagen prior to electrospinning. This may be 
potentially achieved by blending of collagen with other biomaterials to avoid 
the use of harsh crosslinking and prevent the formation of rigid scaffolds.  
Polyesters have been used to improve structural integrity of collagen 
scaffolds for tissue engineering. They come in many forms, some of which 
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are biodegradable such as poly (glycolic acid) PGA, poly(lactic acid) PLA 
and the co-polymer poly (lactic-co-glycolcolic) PLGA. The most common 
method of producing hybrid scaffolds is either to electrospin or freeze-dry a 
synthetic polymer and immerse it in a highly concentrated acidic solution of 
collagen to allow the deposition of the protein. An alternative method is to 
electrospin the collagen and polyester in a common solvent, usually with a 
low synthetic polymer concentration, to produce a matrix based on the 
molecular structure previously outlined. 
Natural polymers have also been used extensively to improve collagen 
scaffolds. Collagen has been spun with denatured collagen (gelatine) (Salifu 
et al., 2011), elastin (Buttafoco et al., 2006) and glycosaminoglycan (GAG) 
(Spilker et al., 2001), (O'Brien et al., 2004), which improve the in vitro cell-
matrix interactions, vital for in vivo therapies. However they require 
stabilisation through crosslinking which is a potential limitation as evidenced 
by the effects of GTA and EDC in this study. 
Our research entails cellular delivery supported on collagen-based scaffolds. 
However, the majority of research within this field is committed to producing 
tissue substitutes where the formulated tissue is incorporated into the body 
of an organ (Prewitz et al., 2012). Whilst we need to simply provide a 
substrate that can support cells for retinal delivery, ultimately the physical 
and biological features of the scaffolds used need to facilitate delivery, and 
support grafted cells temporarily. Scaffolds also need to be biocompatible, to 
remove any potential for long term immune reactivity (Ekdahl et al., 2011), 
which can cause damage to the retina. Degradation of matrices under in vitro 
conditions would not necessarily mimic in vivo degradation, which may alter 
the choice of substrate. In this instance short term stability would be favoured 
over long term durability. 
Collagen is an attractive candidate for the design of scaffolds for retinal 
transplantation, as it is a natural polymer with potentially low immunogenicity 
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as compared to other polymers. Collagen scaffolds can be potentially 
designed to comply with different mechanical requirements needed for cell 
replacement therapies. Macromolecules and other possible therapeutic 
agents such as chondroitinase ABC (ChABC) used to facilitate cell migration 
into the retina, and the precursors themselves can be included within the 
scaffold construct. 
In summary, compressed collagen scaffolds yielded a mechanically strong 
construct without the need for toxic crosslinking chemicals and facilitated cell 
proliferation. They are comparatively inexpensive and rapid to produce. 
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Chapter 4: Transplantation of RGC Precursors ex 
vivo and in vivo using Compressed 
Collagen Scaffolds 
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4.1. Introduction 
When considering the development of cell-based therapies for glaucoma, the 
aim of such research would be to restore and maintain vision by promoting 
the survival of partially damaged RGCs or replacing irreversibly damaged 
RGCs. However, it should be noted that prolonged raised IOP can not only 
damage RGCs leading to the clinical observation of optic disc cupping, but 
may also cause degeneration of other cell populations within the neural 
retina, primarily amacrine cells. (Kerrigan-Baumrind et al., 2000, Hernandez 
et al., 2009). Patients with advanced glaucoma that have not responded to 
conventional treatments may be suitable candidates for such cell-based 
therapies. The aim of this chapter was to study the ability to deliver Müller 
stem cell-derived RGCs onto the retina using compressed collagen scaffolds. 
This would enable assessment of the feasibility of translating such a 
therapeutic approach to a larger mammalian eye similar in size to that of 
humans. 
The majority of research undertaken for the development of stem cells into 
novel treatments for retinal disease has been focused upon identifying 
appropriate cell niches for transplantation and developing protocols to aid the 
differentiation of such cells. The majority of research in this field has 
concentrated on replacing photoreceptors and retinal pigment epithelial 
(RPE) cells, but very little work has been performed to treat RGC loss. 
Experimental studies have led to variable outcomes and further research is 
required before such therapies may be developed further for human 
application. 
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4.1.1. Stem Cell populations used for sourcing RGCs for retinal 
transplantation 
Protocols have been refined for several stem cell populations to induce RGC 
differentiation, with different degrees of differentiation achieved. The stage of 
differentiation has widely been assessed using the phenotypic expression 
profiles of RGCs as well as their functional outcomes evaluating their 
response to various stimuli. 
Murine ESCs have been cultured under a regime involving extrinsic factors 
which lead to elevated expression of RGC markers, including Ath5, Brn3b 
Thy-1 and Isl-1 (Jagatha et al., 2009). Human ESCs have an innate ability to 
spontaneously form neurons, which has facilitated the refinement of 
differentiating protocols. Neuronal precursors derived from such populations 
have been used in various animal models of retinal neuropathies (Aoki et al., 
2009). Intravitreal and sub-retinal injections of these cells in mice have 
shown that neural cells are able to integrate into the host retina and express 
photoreceptor markers over a prolonged period of time (Banin et al., 2006). 
Transplantation of human ESCs with neuronal morphology have been 
transplanted into murine models of NMDA depleted RGCs. Cells were 
observed to migrate and maintain ganglion cell expression profiles whilst 
residing within the host tissue (Aoki et al., 2008). Co-culture systems 
comprising explanted foetal rodent retina with the addition of adult rodent 
hippocampal progenitors have been used to promote the differentiation of 
these progenitors towards a retinal cell fate. These cells, when transplanted 
into the RGC depleted rat retina, successfully integrated into the host retina, 
where cells aligned along the RGC layer and sent out projections into the 
inner plexiform layer (Mellough et al., 2007).  
Cells have been isolated from mammalian adult tissues and re-programmed 
to create populations of iPS cells, forcing these to constitutively express stem 
cell markers. Cells isolated and re-programmed from mice somatic cells have 
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been induced to develop into retinal neurons in vitro, mainly of the RGCs and 
photoreceptors cell lineages (Parameswaran et al., 2010). This suggests that 
they may be used to develop stem cell approaches for treatments of retinal 
degenerative conditions. 
4.1.2. Experimental Models of Glaucoma used to Assess the 
Effect of RGC Transplantation 
Intravitreal transplantation of human mesenchymal stem cells into rodent 
models of optic nerve damage showed little evidence of cellular integration 
into the host tissue and demonstrated lack of RGC maturation of the 
transplanted cells (Hill et al., 2009). Bull et al studied the intravitreal 
transplantation of undifferentiated human Müller stem cells into the laser 
model of rodent glaucoma, which showed a lack of integration within host 
tissue as well as marked activation of microglia (Bull et al., 2008). However 
our laboratory has recently developed a robust protocol for differentiating 
adult human Müller stem cells, into RGC precursors, which have been used 
for transplantation. Differentiated cells exhibit an RGC phenotype, and adopt 
a characteristic neuronal morphology (Singhal et al., 2012). Following 
transplantation into a rodent model of NMDA induced RGC depletion, RGCs 
derived from human Müller stem cells integrated into host tissue and 
demonstrated functionality, as judged by improvement of the negative 
component of scotopic threshold response (nSTR) of the electroretinogram 
(ERG).  The nSTR is an indicator of RGC function and measures 
responsiveness to low light intensity below visual thresholds. These 
observations are to date the only evidence where transplantation of stem 
cells for glaucoma has been successful in achieving integration into host 
tissue whilst aligning within the target cell layer, as well as improving RGC 
function of the host animal. Research undertaken by MacLaren et al revealed 
that in order to achieve optimal integration in vivo; stem cells to be used for 
photoreceptor replacement require differentiation to a specific ontogenetic 
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stage prior to transplantation (MacLaren et al., 2006). The restoration of 
ganglion cell function following RGC-derived Müller stem cell transplantation 
further highlights the importance of differentiating stem cells prior to 
implantation. 
The anatomy of the retina also poses difficulties when transplanting cells 
onto the inner retinal surface. In order to facilitate integration into the RGC 
layer, it will be necessary to ensure widespread distribution of cells across 
the whole retina. In addition, the environment needs to be permissive for cell 
integration and be able to support development of neural connections with 
the transplanted cells (Bull and Martin, 2007). Like other neural replacement 
therapies, functional RGC replacement would entail the formation of 
numerous synapses between host and grafted cells, converging to direct 
new neurite outgrowths to the optic nerve. Therefore it is important to define 
efficient cellular differentiation protocols (MacLaren et al., 2006) prior to 
transplantation, and protocols to maintain cell survival and integration 
following transplantation.  
4.1.3. Barriers for Retinal Stem Cell Migration and Integration 
following Transplantation 
Trauma and progressive degeneration of nerve tissue initiates a cascade of 
events within the site of injury, and can be rapid (spinal cord injury (SCI)), or 
slow (glaucoma). All of these events involve elements of necrosis, apoptosis 
and scarring, leading to functional loss. Gliosis causes the formation of a glial 
scar embodying reactive glia and astrocytes, which upregulate their 
production of chondroitin sulphate proteoglycans (CSPGs) (Fawcett and 
Asher, 1999). This is of important relevance to cell transplantation, as 
CSPGs have been shown to inhibit migration of transplanted cells and 
formation of new synapses (Silver and Miller, 2004). Transplantation of stem 
cell based therapies for inner retinal degeneration in humans will face many 
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natural barriers, including the larger sized vitreous cavity and the presence of 
abnormal extracellular matrix within damaged retina. 
Chondroitin sulphate proteoglycans (CSPGs) belong to the aggrecan family 
of proteins (Yamaguchi, 2000). They regulate the development of the neural 
tube and associated neural crest cells by directing their out-growth patterns. 
The concentration of CSPGs around neurons is thought to underpin the loss 
of progenicity over time within the progenitor population, due to steric 
hindrance (Sharma et al., 2012). These molecules contribute to the lack of 
permissiveness of the neural ECM to respond to the regenerative plasticity of 
resident adult neurons and transplanted cells.  
Gliosis and neurodegeneration cause rapid CSPG up-regulation in reactive 
glia and astrocytes, and deposition within the site of neural damage (McKeon 
et al., 1995). Microglia are the resident inflammatory cells of the retina and 
also produce ECM molecules, specifically the regenerative inhibitors CSPG 
during retinal degeneration (Uhlin-Hansen and Kolset, 1988, Jones et al., 
2002, Ng and Streilein, 2001). CSPGs play a key role in suppressing axonal 
extension and regeneration of apoptotic cells within the site of injury (Silver 
and Miller, 2004, Smith-Thomas et al., 1995), suggesting that inhibition of 
these molecules may aid neural recovery and facilitate integration of grafted 
cells. 
Targeting CSPGs has mainly involved the cleavage of their reactive GAG, 
moieties, preventing their binding and anchorage to other components of 
cells and matrices. Digesting the GAG side chains into simple disaccharides 
promotes their catabolism and ECM permissiveness to regeneration. 
Chrondroitinase ABC (ChABC) is the main enzyme used to cleave GAG. Its 
application to repair spinal cord injury (SCI) (Bradbury et al., 2002) and 
similar CNS injuries have been examined using in vitro and in vivo models of 
neural damage. Such experiments demonstrated re-growth of damaged 
neurites within corticospinal, reticulospinal and nigrostriatal populations 
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following ChABC digestion (Garcia-Alias and Fawcett, 2012). Moreover 
studies assessing the migration of transplanted cells demonstrated that 
axonal integration was enhanced when the peripheral regions of the spinal 
ECM were treated with ChABC (Fouad et al., 2005, Karimi-Abdolrezaee et 
al., 2010, Tom et al., 2009, Garcia-Alias and Fawcett, 2012). Determining 
whether this regeneration was solely due to the breakdown of the ECM or to 
the activation of growth within healthy and damaged axons, was achieved by 
monitoring the regeneration of complete and semi-transected spinal cords 
(Fouad et al., 2005, Tom et al., 2009). Partially severed cords owed their 
regeneration to both transplanted and host cell populations, whilst complete 
transected spinal cords underwent rejuvenation by the regeneration of 
damaged axons. These tests were indicative of the importance of enhancing 
CNS regeneration by creating an environment free of inhibitory molecules. 
Studies of adult rat retina have also been carried out by Tropea et al, which 
involved partial denervation of the superior colliculus. Subsequent treatment 
with ChABC to the superior colliculus restored some damage caused to the 
RGC population (Tropea et al., 2003). Addition of brain-derived neurotrophic 
factor (BDNF) further enhanced sprouting of damaged RGCs. This evidence 
illustrates the synergistic interaction between these two agents, where the 
trophic factor has an improved effect in combination with the degradation of 
CSPGs.  
Inhibiting abnormal production of CSPGs within the degenerate retina may 
enable this tissue to become permissive to integration of transplanted Müller 
stem cells. Treatment with ChABC may also facilitate neural interactions 
between both undamaged and partially damaged ganglion cells in situ. 
183 
 
4.1.4. Vitrectomy as a tool for surgical delivery of cellular 
scaffolds onto the retina 
Methods used for intravitreal injection of therapeutic agents, including cells, 
into small rodent eyes may not be appropriate for the human eye due to 
differences in anatomical features amongst species. The lens contained 
within rodent eyes occupies over 70% of the spatial capacity of the optic 
cavity (Powers and Green, 1978). This feature means that when cells are 
injected into the vitreous, the lens may serve as a scaffold to facilitate cell 
migration into the host retina. Higher order mammals such as rabbits, 
primates and cats have dimensions closer to that of the human eye, where 
the nature of tissue arrangement is significantly different to that of rodents. 
Higher mammals have evolved to have smaller lenses occupying only 10-
20% of the spatial capacity (Coleman, 1979) (Figure 4.1). The lack of a large 
lens means that transplantation of cells into the vitreous of a higher mammal 
would lead to their dispersion and/or pooling within the inferior part of the 
vitreous. There is therefore a need to develop methods to deliver cells to the 
inner retina in higher mammals with this anatomical configuration.  
The design of a scaffold for cell transplantation is determined by the 
anatomical structure and accessibility of the tissues undergoing 
transplantation. In order to provide sufficient cellular integration into the inner 
retina, the implant must align along the inner retinal surface. However to 
facilitate this process, the vitreous would require removal. Vitrectomy, a 
procedure routinely undertaken for treatment of retinal detachment in human 
patients, therefore constitutes a feasible option for implantation of cellular 
scaffolds onto the retina. 
The human eye contains 3.5-4ml of vitreous humour (Coleman, 1979), the 
translucent gelatinous mass that fills the eye cavity. Vitreous is primarily 
composed of water, with a loosely compact network of type II collagen 
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associated with proteins such as hyaluronic acid and glycosaminoglycans 
(Swann, 1980, Itakura et al., 2009).  
The vitreous is loosely attached to the neural retina except at the peripheral 
vitreous base and optic nerve head. The vitreous body functions to maintain 
the structure of the eye whilst also contributing to maintaining a stable 
intraocular pressure.  
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Figure 4.1: Anatomical drawings of A) rat and B) 
human illustrating the major differences in the geometric 
dimensions of these two mammalian ocular structures. 
Images taken from http://www.ratbehavior.org/Eyes.htm  
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Pars plana vitrectomy involves the partial or total removal of the vitreous and 
has been developed over the last 35 years (Aguni et al., 2009, Wallenten et 
al., 2008). A 20 or 23 gauge MVR blade is then used to create three pars 
plana sclerotomies (Aguni et al., 2009, Wimpissinger and Binder, 2007), 
avoiding injuring the neural retina, as well as avoiding touching the lens in 
phakic patients (Figure 4.2). One port is for a suture infusion line to maintain 
globe pressure during the operation and the other two ports allow 
instrumentation to facilitate the removal of the vitreous and manipulation of 
the retina under fluid, followed by fluid-air exchange at the end of the 
procedure. 
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Figure 4.2: Illustration of Vitrectomy surgery. A)  Image of vitreous removal 
following port creation via MVR blade. B) Cross sectional representation of 
instrument placement during vitrectomy, adapted from 
http://www.valleyretina.com/info-surg/info-surg-pars.html  
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4.2. Objectives and Experimental Outline 
Having previously developed protocols to obtain RGCs derived from human 
Müller stem cells, as well as to produce suitable compressed collagen 
scaffolds to support cell delivery, it was a natural progression for research to 
transplant cellular scaffolds onto the retina in vivo. The aim of this chapter 
was therefore to investigate the ability of cellular scaffolds prepared with 
compressed collagen type I to support migration of transplanted cells onto 
the retina ex vivo and in vivo. 
The general objectives of this chapter were: 
1. To examine the ability of cellular scaffolds to support migration 
and integration of RGC precursors onto the RGC layer of 
explanted human retina ex vivo. 
2. To determine the ability of cellular scaffolds to support migration 
and integration of RGC precursors into the RGC layer of rabbit 
retina in vivo.  
The experiments performed to achieve these objectives were as follows:   
1. Cadaveric human retina obtained from Moorfields eye bank, was 
explanted in vitro and transplanted with RGC-derived Müller stem 
cells attached to compressed collagen scaffolds. This was 
facilitated by incubation with ChABC. Following fixation, retinal 
tissue was analysed for transplanted cell integration into the inner 
retina. 
2. For the in vivo studies, transplantation was performed in 
vitrectomised eyes of female pigmented Chinchilla bastard rabbits. 
Efficiency of cell delivery from collagen scaffolds was examined 
using immunohistological techniques 2-3 weeks post 
transplantation. 
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To assess the efficiency of cell delivery using scaffolds, Müller stem cells 
were induced to differentiate into RGCs by culturing with DAPT and bFGF for 
one week, akin to previous studies performed in rat by our laboratory. 
Enriched RGC populations derived from Müller stem cells were prepared for 
transplantation onto explanted human retina, as well as for surgical 
implantation into 2.5-3kg female Chinchilla rabbits, in the presence of 
ChABC (see below). Explanted retinas from the adult human eye were 
cultured for a maximum of 7 days, following in vitro transplantation of cellular 
scaffolds. Rabbit eyes were analysed after 2-3 weeks post transplantation. 
Specimens were analysed for survival and migration of grafted cells into the 
retina using confocal microscopy.  
Vitreoretinal surgery was undertaken by two surgeons from Moorfields Eye 
Hospital, collaborating in this study, Mr DG Charteris and Mr H Jayaram. 
During this investigation I was responsible for the preparation of cellular 
scaffolds and therapeutic agents (ChABC), animal husbandry, sterilisation 
and preparation of surgical instruments, as well as providing technical 
assistance with vitrectomy equipment during surgery. The rabbit eye has an 
axial length of 18-21mm comparable to the adult human eye of 22-23mm, 
indicating that the dimensions of the globe in both species are similar 
(Hughes, 1972). However, the equatorial length of the human lens is 16mm 
with a depth value between 4-5mm (Taylor et al., 1996), 18% of the spatial 
cavity. In contrast, the rabbit contains a relative large lens of 5-7mm depth in 
adults which accounts for 28% of the ocular cavity (Hughes, 1972). The 
rabbit eye has a lower volume of vitreous (2ml) compared to the human (4ml) 
due to the larger lens and smaller outer radius and axial length (Friedrich et 
al., 1997a, Friedrich et al., 1997b). Rabbits have been used extensively to 
study the mode of systemic drug delivery and release within the eye for 
human models of ocular degenerations (Heller, 2005). The rabbit eye has 
more similar anatomical features to the human eye compared to rodents, 
which makes the rabbit an attractive model to examine the feasibility of 
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cellular scaffold transplantation. In this study, this mode of transplantation 
aimed to achieve direct contact between the scaffold and the RGC layer, 
following vitrectomy. 
4.2.1. Transplantation protocol 
Compressed type I rat tail collagen scaffolds were prepared as follows: 300µl 
of 0.75mg/ml collagen were cast in 1cm diameter rings, followed by 
compression under 150g weight for 5 minutes. Human Müller stem cells 
stably transfected with the human immunodeficiency virus type 1 (HIV-1 
based lentiviral vector) expressing human recombinant GFP were used for 
this study to determine the localisation of transplanted cells within the host 
tissue. GFP transfected Müller stem cells were differentiate in RGCs by 
culture on ECM in the presence of bFGF and DAPT. Cells were then 
dissociated from culture surfaces and assessed for their viability. Harvested 
cells were then added to prepared collagen scaffolds at a concentration of 
4x10
5 
per scaffold side. Cellular scaffolds were incubated at 37°C for a 
maximum of 2 hours per side, in DMEM containing 10% FCS, to aid 
adhesion. Scaffolds loaded with cells were then rinsed and washed 3 times 
for 10 minutes in sterile PBS, to remove serum. Scaffolds were stored in 
PBS at room temperature for up to 1 hour prior transplantation. Prior to in 
vitro transplantation, 0.4U/10µl of ChABC were placed onto the retina and 
incubated at 37°C for 10 minutes. When applied onto the retina in vivo, the 
enzyme was left for 5 minutes, prior to implantation of cellular scaffolds.  
Following removal of the lens by phacoemulsification (Figure 4.2) the 
vitreous body was removed using a high frequency pneumatic cutter which 
was inserted into the posterior segment through the pars plana sclerotomy. 
Delivery of both ChABC and cellular scaffolds was achieved using a 18G 
cannula directed towards the medullary raphe. Following scaffold 
implantation local injections of gentamicin and triamcinolone (washed and 
reconstituted in sterile water to 80µg/ml) were given subconjunctivally to 
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prevent post-operative infection and to reduce post-operative inflammation. 
Furthermore, in order to reduce the risk of the xenogeneic transplanted cells 
being rejected by the host, animals were orally immunosuppressed daily with 
cyclosporine (0.15mg/kg/day), three days prior to and following 
transplantation throughout the duration of the experiment, to prevent 
xenographic rejection of the transplanted cells. To control inflammation, 
operated eyes also were given topical drops of dexamethasone 0.1% and 
chloramphenicol daily following surgery until sacrifice. 
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4.3. Results 
4.3.1. Transplantation of RGCs onto explanted human retina 
using compressed collagen scaffolds 
Müller stem cell-derived RGCs were obtained by standardised protocols, and 
were seeded onto one side of compressed collagen scaffolds and incubated 
for 1-2 hours to allow cell attachment. Cellular scaffolds were placed onto 
explanted cadaveric human retina and cultured up to 7 days at 37ºC. The 
cellular scaffolds did not align onto the explanted retina, possibly due to the 
lack of pressure on the construct, permitting it to float. However, in the 
absence of Chondroitinase ABC, cells were observed to detach from the 
scaffolds but did not migrate onto the retina (Figure: 4.3). Following 
incubation in the presence of Chondroitinase ABC, although scaffolds did not 
attach to the retina, cells detached from the scaffolds migrated into the 
retina, possibly aided by this enzyme. This indicates that scaffolds can be 
used as a tool for cellular delivery onto the retina (Figure 4.3B).  
4.3.2. Delivery of RGCs using compressed collagen scaffolds 
onto the inner rabbit retina 
4.3.2.1. Histological assessment of rabbit transplantation without 
lens removal 
Haematoxylin and eosin (H&E) staining, as well as confocal microscopy was 
used to determine the histological features of transplanted rabbit eyes. This 
assessment confirmed that cellular scaffolds were located adjacent to the 
posterior retina. However, microscopic imaging of transplanted retina in 
rabbits where the crystalline lens was left in place, demonstrated severe 
disruption of the retinal architecture when compared to normal non-
transplanted eyes (Figure 4.5). It was thought that the damage caused to the 
retina was induced during surgery for scaffold implantation, due to breaks 
caused at port placement. 
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Figure 4.3: In vitro transplantation onto human retinal explants. GFP-labelled 
Muller stem cell-derived RGCs were differentiated for 7 days prior to in vitro 
transplantation. Cellular scaffolds were incubated for 2 hours at 37ºC, to aid cell 
adhesion. Confocal images and H&E image of cryosections of retina transplanted 
in vitro with collagen constructs supporting GFP-labelled Müller-derived RGCs, 
incubated with and without ChABC prior to transplantation. The upper image 
represents the migration of GFP-labeled cells onto retinal explant in the absence 
of Chondroitinase ABC (-ChABC). The lower image represents incubation of 
retinal explants with ChABC (+ChABC) prior to transplantation. Imaging with the 
addition of ChABC shows migration of cells from the cellular scaffold (cs) (open 
arrow) into or onto the retina (arrowhead). H & E. Yellow arrows correspond to the 
cs (open arrow) and retina (arrowhead). Scale bar=50µm.  
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Ports were introduced at the posterior pars plana to minimise the risk of lens 
touch and retinal breaks. However sclerotomies created in this region were 
associated with retinal detachment and widespread bleeding (Figure 
4.5).This made implantation of the cellular scaffolds onto the medullary raphe 
difficult (Figure 4.6). Due to this complication, a new approach was 
undertaken to perform a lensectomy (surgical lens removal) to allow the port 
entry sites to be placed more anteriorly within the pars plana. 
4.3.2.2. Macroscopic features of the in vivo transplanted rabbit 
with lens removal 
Macroscopic imaging using an inverted florescent microscope, of 
transplanted rabbit eyes, revealed that transplantation of scaffolds onto 
lensectomised and vitrectomised eye resulted in cell delivery onto the retinal 
macula. This was determined by the presence of GFP-positive cells in this 
region (Figure 4.7). Following 14 days after transplantation, scaffolds 
appeared to remain posteriorly in direct contact with the neural retina, within 
regions adjacent to the original delivery site. 
4.3.2.3. Histological examination of the rabbit retina following in 
vivo transplantation 
Initial investigations for transplantation of cellular scaffolds were undertaken 
without lens removal, following the surgical complications lenses were 
removed and examined by Haematoxylin and eosin (H&E) staining and 
confocal microscopy. Cellular scaffolds were found within anterior regions of 
the eye, adjacent to the ciliary body and port site (Figure 4.8). This suggests 
that there are other components involved in the delivery of cellular scaffolds, 
distinct from lens removal and port site location. This also indicated that 
delivery of scaffolds to the anterior part of the eye did not allow scaffold 
alignment along the neural retina preventing cells from attaching and 
migrating into the inner retina.  
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Figure 4.5: Histological examination of vitrectomised rabbit eyes, following in 
vivo transplantation of compressed collagen scaffolds without lens removal. 
Cryosections of a vitrectomy transplanted eye 14 days post surgery, showed retinal 
detachment within the posterior region of the eye and the onset of choroidial and 
vascular bleeding. A) H&E staining of the posterior region of the rabbit eye, proximal 
to the compressed collagen scaffold (yellow arrow). B) Confocal imaging identified a 
minimal amount of GFP-labelled cells within the sites of retinal detachment Confocal 
showed expression of the microglia marker lectin (red), within the regions of 
detached retina. Scale bar=100µm. 
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Figure 4.6: Histological examination of vitrectomised rabbit eyes, following in 
vivo transplantation of compressed collagen scaffolds without lens removal. 
Cryosections of a vitrectomy transplanted eye 14 days post-surgery demonstrated 
retinal detachment within the posterior region of the eye and the onset of choroidal 
and vascular bleeding. B) H&E staining of the posterior and anterior regions of a 
rabbit eye, as well as B) confocal microscopy of the posterior retina. H&E staining 
identified the presence of the cellular scaffold within the anterior segment of the eye, 
adjacent to the iris (yellow arrow). Confocal analysis of a posterior section, showed 
elevated expression of the microglia marker lectin (red), within the retina. Scale 
bar=100µm. 
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  Figure 4.7: Macroscopic imaging of In vivo transplantation of PC 
cellular scaffolds into lensectomised and vitrectomised rabbit eyes. A) 
Images depicting the vitrectomy stages for cellular scaffold transplantation:  
a) lensectomy b) vitrectomy c) insertion of cellular scaffold by cannula 
injection (white arrow). B) fundus imaging of (a) control eyes and eyes (b) 
transplanted with cellular scaffolds to which GFP-labelled Müller stem cell-
derived RGCs had been adhered. Images were taken under FITC 
illumination with cornea and lens removed (control eyes only) to identify 
GFP presence within the transplanted eyes. Imaging confirmed the 
presence of GFP in the posterior portion of the eye. 
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Figure 4.8: Histological examination of vitrectomised rabbit eyes, following in 
vivo transplantation of compressed collagen scaffolds following lensectomy. 
Globes of transplanted rabbit eyes were removed and sectioned 14 days post 
surgery. Cryosectioning and staining demonstrated aggregation of cellular scaffolds 
adjacent and proximal to the vitrectomy port sites. H&E showed the macroscsopic 
location of the cellular mass. Whilst confocal microscopy identified the mass as 
GFP-labelled Müller stem cells, which was also coupled with microglial mobilisation 
to the site of aggregation. Microglia was identified by lectin staining (red). Scale 
bar=100µm. 
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Conversely, there was evidence that cellular scaffolds place on the medullary 
raphe allowed migration of cells onto the retina (Figure 4.9). Although, 
cellular scaffolds were observed adjacent to the neural retina, GFP-positive 
cells were not found to have integrated into host retina within this region. 
However, cells were seen to have migrated into host retina in regions located 
close to the scaffold, where the scaffolds had not attached. 
There was no evidence, in any of the experiments, of conventional RGC 
morphology adopted by transplanted cells. There was a lack of synaptic 
connections made with host cells, as well as a lack of neurite outgrowth 
observed by transplanted cells. 
4.3.3. Examination of the rabbit inflammatory response following 
cellular scaffold transplantation  
Determination of the inflammatory response in rabbit ocular tissues following 
scaffold transplantation was achieved by examining the presence of 
microglia. Immunohistochemistry was carried out by staining histological 
sections of rabbit retinae with the protein lectin. Microscopy of retinal tissue 
revealed that transplanted eyes had accumulation of cells staining for lectin 
at the site of the transplant (Figures 4.5, 4.6, 4.8 and 4.9). Similar 
accumulation of microglia was observed in all retinae, where cellular 
scaffolds had been delivered either posteriorly or anteriorly. Activation of 
microglia within host tissue was also evident when retinal detachment and 
haemorrhaging occurred, even in the absence of grafted cells (4.5 and 4.6).   
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Figure 4.9: Histological examination of vitrectomised rabbit eyes, following in 
vivo transplantation of compressed collagen scaffolds following lensectomy. 
A) H&E stained cryosections of a rabbit eye transplanted with a cellular scaffold. 
This showed the scaffold in the posterior retina (yellow arrow). The cellular scaffold 
appears to attach to the retina at some points without disrupting the retinal 
morphology. B) Confocal imaging of cryosections of the vitrectomised and 
transplanted eye showed migration of cells from the scaffold (open arrow) onto the 
retinal tissue (medullary raphe; arrowhead). Adjacent sections were also stained for 
lectin to identify microglia activity within the transplanted globe, and confirmed 
activation of microglia in the ganglion layer proximal to the GFP-labelled cells, 
highlighted by enhanced view (yellow box). Scale bar=100µm. 
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4.4. Discussion 
Observations from these experiments illustrate the need for vitrectomy 
surgery for adequate cellular scaffold delivery into a large eye. The study 
aimed to transplant appropriately differentiated Müller stem cells supported 
on compressed collagen scaffolds onto the inner retina.  This process was 
clearly facilitated by having direct access to the inner retinal surface. 
Previous work by our laboratory has demonstrated the migratory capabilities 
of Müller stem cells. Their ability to migrate into dystrophic RCS rat retina 
has been shown, as well as their ability to integrate into the RGC layer. This 
was facilitated by breakdown of the inner limiting membrane (ILM) with 
Chondroitinase ABC and anti-inflammatory treatment with Triamcinolone 
(Singhal et al., 2008, Singhal et al., 2012). Moreover, further work carried out 
within our lab demonstrated the migratory ability of Müller stem cell-derived 
photoreceptors when transplanted into the sub-retinal space of dystrophic 
rats. However, transplantation of differentiated Müller stem cell-derived 
photoreceptors displayed the capacity to orientate themselves within the 
photoreceptor lamina whilst maintaining their expression profiles of 
photoreceptors (Jayaram et al, submitted). Importantly, transplantation of 
RGCs and photoreceptors-derived from Müller stem cells also resulted in 
functional improvement in vivo, using experimental models of retinal 
degeneration. 
These findings highlighted the fact that integration within the correct retinal 
laminations cause functional improvement. Integration into respective retinal 
layers centred on appropriate differentiation protocols, in addition to creating 
permissive retinal environments for cells to migrate. Secretion of CSPGs 
following neural degeneration is an inhibitory factor for regeneration of 
nervous tissue. These molecules prevent the re-growth of damaged axons 
and the integration of grafted cells (Bradbury et al., 2002, Diaz-Martinez and 
Velasco, 2009). Activation and proliferation of microglia has been found in 
202 
 
degenerated RCS rat retina and this is an important cause of damage to 
grafted cells (de Kozak et al., 1997, Roque et al., 1996, Thanos and Richter, 
1993).  
The current study aimed to develop protocols for Müller stem cell derived 
RGCs transplantation into the larger eye, analogous to that of humans, to 
examine if similar Müller stem cell migratory capacities were evident. 
Scaffold development aimed to encourage uniform distribution of grafted 
cells onto the retina, preventing their aggregation on the inferior retina. 
Uniformity of grafted cell migration into rodent retinae was aided by the small 
vitreous cavity, allowing direct placement and cell support by the large lens in 
this species. Differentiated RGCs were seen to attach well to compressed 
scaffolds and endured invasive surgical manipulation via an 18 gauge 
cannula (Chapter 3).  
Delivery of cellular scaffolds appeared to be dependent on the surgical 
procedures used. Procedures that did not include removal of the lens 
demonstrated widespread retinal trauma, including detachments alongside 
extensive choroidal and retinal bleeding (Figure 4.5 and 4.6). Cellular 
scaffolds were found within the anterior (Figure 4.5) or posterior (Figure 4.6) 
regions of the retina. Removal of lens prior to transplantation permitted 
revision of port entry sites which prevented the trauma observed in 
procedures without lensectomy. Although the dimensions of the human and 
rabbit eyes are similar, the difference is lens morphology necessitated the 
use of surgical lensectomy which would most likely be unnecessary in 
human subjects. The rabbit lens created a physical barrier for appropriate 
port placement and since the pars plana is smaller in the rabbit, ports were 
subsequently positioned more anteriorly, following lensectomy. As with 
previous surgeries, the delivery sites of the cellular scaffolds varied in 
location following lensectomy. Cellular scaffolds were found within anterior 
(Figure 4.8) and posterior (Figure 4.9) regions of the eye. This suggests that 
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apart from port sites and lens geometry other physical factors are involved in 
surgical delivery. Angulation of cannulas within the ports may have 
contributed to the aggregation of cellular scaffolds within the anterior regions 
adjacent to the entry at the neural retinal-ciliary body junction. Steeper 
angles of the cannulas may promote directed placement of scaffolds onto the 
retina. The rate and/or force used to eject scaffolds from cannulas may have 
also determined the final site of delivery. Visualisation of original scaffold 
delivery positions were not always determined during surgery, but it is likely 
that they remain in the same position throughout the experiment. 
Cellular scaffold transplantation into rabbit eyes, when delivered onto the 
inner retinal surface were subsequently held in place against the retina, 
enabling proximal attachment (Figure 4.9). Attachments between host tissue 
and scaffolds failed to induce migration of RGC precursors into host tissue, 
possibly due to the lack of breakdown of the ECM by insufficient levels of 
ChABC. Limited integration faced in these studies could be improved by 
efficient sustained ChABC release to prolong its activity. In vitro human 
retinal explants demonstrated cell integration by scaffold transplantation of 
RGCs following incubation with ChABC (Figure 4.3). Lack of ChABC 
presence failed to support cellular migration and appeared to induce cellular 
dispersion into the local media, suggesting that ChABC is vital for cellular 
integration (Figure 4.3). The in vivo state of degenerated retina would be 
vastly different to normal ex vivo tissues and in vivo eyes. Dystrophic and 
glaucomatous eyes would contain abnormal amounts of CSPG molecules, 
as well as cellular debris due to retinal degeneration (Zhang et al., 2003). 
Hence the modulation of the normal retinal ECM is a key factor to consider 
for cellular transplantation into degenerated retina. CSPG rich matrices 
treated with active ChABC have been shown to improve integration of 
transplanted photoreceptors (Inatani and Tanihara, 2002). Experiments 
carried out during this study have positively identified cellular migration onto 
host retina, although in many cases these regions were not proximal to the 
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scaffolds. This may indicate that temporary support by cellular scaffolds is 
sufficient for migration onto the retina.  
Where migration was observed, classical axonal organisation was not 
adopted by transplanted cells. The extension of neurite and dendritic 
outgrowths within the RGC population embodies a feature where the 
orientation and direction of axons converge collectively towards the optic 
nerve. In some cases axons do not synapse until they extend into the visual 
cortex. This feature, to date has not been observed following transplantation 
of other stem cells. However, our lab has shown that synapses can form 
between transplanted Müller stem cell-derived RGCs and their local rat host 
neurons (Singhal et al., 2012). This transplantation caused functional 
recovery of a RGC depleted population, suggesting that limited integration 
may be sufficient to improve retinal function rather than having to completely 
replace and mimic the native retinal ganglion cell layer. 
In summary, this chapter demonstrates that Müller stem cell derived RGC 
can be delivered into larger eyes via compressed scaffolds. However, the 
mechanical process of surgery needs to be standardised for further 
investigations. The physical manipulations during operative procedures need 
to comply with stringent parameters for the rabbit. Barriers to surgical 
transplantation include the presence of the lens, cannula angulation and port 
placement. Biological barriers were also highlighted by this investigation. 
Promotion of cellular integration into host tissue requires adequate 
modulation of the adjacent retinal environment using ChABC (Singhal et al., 
2012). Stabilisation and prolonged activity of ChABC would provide a 
permissive retinal microenvironment amenable to cellular integration. At 
present, frequent and numerous injection of the enzyme is the most common 
mode of delivery (Coumans et al., 2001), which can be a lengthy and 
invasive process. Thermal instability and leeching limits the activity of 
ChABC. There is a need to improve the delivery of ChABC by generating a 
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slow-release mechanism that is able to maintain therapeutic dosage of 
ChABC in the retina. Fabricated matrices have been designed to incorporate 
ChABC as well as other agents which aid neural regeneration. Hydrogels 
consisting of fibrin (Taylor and Sakiyama-Elbert, 2006, Hyatt et al., 2010) and 
agarose (Lee et al., 2010) have been used to assess in vivo use and delivery 
of ChABC, and they merit investigation into their suitability for retinal delivery. 
Electrospun collagen has also been nominated as a suitable substrate by 
impregnation with NT-3 and ChABC via microbial transglutaminase (Liu et 
al., 2012). Further investigations would determine the feasibility of sustaining 
ChABC delivery by collagen-based scaffolds for ocular use. Stabilising 
ChABC could improve the integration and survival of transplanted cells over 
an extended period.  
Further determination of compressed cellular scaffolds suitability would 
involve studies in larger mammalian glaucomatous eyes such as hereditary 
animal models, including Siamese cats with primary congenital glaucoma 
(Sigle et al., 2011). 
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Chapter 5: General Discussion 
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5.1. Introduction 
Müller stem cells within the retina of zebrafish and Xenopus have the innate 
capacity to regenerate retina throughout life. Early post natal chicks have 
also shown limited retinal regeneration ascribed to the unique abilities 
possessed by Müller stem cells (Fischer and Reh, 2001). The human retina 
also contains a population of Müller glia with stem cell characteristics. These 
cells express markers of multipotency (Lawrence et al., 2007) specifically 
restricted to retinal neurons. However, unlike zebrafish and amphibians 
these cells are unable to repopulate neural cells endogenously following 
damage. Müller glia like other glial cells can re-enter the cell cycle in order 
to proliferate, forming glial scars and propagating within the spaces of 
apoptotic cells and disconnected synapses (Lewis et al., 2010). This feature 
to de-differentiate and proliferate is harboured by all Müller glia of different 
species, which therefore represent a cellular source to generate new 
neurons. Isolating this population from human retina has led to the 
emergence of stem cell research for human retinal diseases and the 
development of cell-based therapies.  
Degeneration within the retinal ganglion cell population is one of the 
pathological features of glaucoma which accounts for 15% of all registered 
blind in England (Bunce et al., 2010). Current therapies to treat glaucoma 
involve either pharmacological such as Lumican or surgical interventions, 
such as filtration surgery, to reduce ocular pressure by improving the 
drainage of excess aqueous. These aim to delay the onset of neuronal and 
eventual visual loss. Glaucoma, as well as other retinal dystrophies, may 
benefit from Müller stem cell transplantation. These cells can be easily 
isolated from cadaveric tissue and can be grown extensively for allogeneic 
transplantation. Moreover, understanding the pathways involved in the 
differentiation processes of Müller stem cells would enhance the technology 
of cell-based therapies. Patients would also benefit by developing regimes 
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that involve activating the regenerative capabilities of endogenous Müller 
stem cells, possibly via small molecule or gene therapies. 
The main objectives of this thesis were to further study the potential use of 
Müller stem cell-based therapies to treat glaucoma. The present study 
therefore investigated the molecular aspects of Notch signalling in the 
differentiation of Müller stem cells into RGCs. This involved assessing RGC 
markers and miRNA expression of cells undergoing differentiation. This 
study also aimed to examine practical transplantation of Müller stem cell-
derived RGCs onto the retina by determining the suitability of type I collagen 
to engineer a transplantable cellular scaffold. 
5.2. miRNA regulation of RGC development in Müller stem cells 
Studies into the molecular regulation of the Notch pathway in human Müller 
stem cells involved the examination of the presence of mature microRNAs. 
The Notch pathway appears to control the development of RGCs derived 
from human Müller stem cells (Singhal et al., 2012). Inhibition of the Notch 
pathway with a gamma secretase inhibitor (DAPT) prevents the 
translocation of the Notch intracellular domain (ICD) to the nucleus. This 
prevents the transcription of bHLH genes which operate to prevent 
differentiation and promote progenicity of neural stem cells (Kageyama et 
al., 2005).   
Microarray data highlighted the presence of several upregulated miRNAs in 
Müller stem cells following Notch inhibition in the presence and absence of 
bFGF. These findings suggest the emergence of novel targets of the Notch 
pathway, which may promote neural development within Müller stem cell 
populations.  
Treatment with DAPT alone in Müller stem cells generated significant 
upregulation of miRNAs involved in cell cycling, with some being linked to 
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Notch signalling. Others have also been shown to enhance differentiation or 
establish a cellular state which is needed to promote diversification prior to 
terminal differentiation.   
Interestingly, the miR-30 family of miRNAs was enriched in DAPT treated 
Müller stem cells. This family has been implicated in the repression of the 
bHLH transcription factors involved in epithelial-mesenchymal transition 
(EMT), and indirectly on the Notch pathway. One of these targets has been 
linked to Notch, preventing the binding of its intracellular domain to nuclear 
targets. ZEB1 has been reported as a target of miR30, which prevents ZEB1 
promoting the transcription of MamL and the transduction of the Notch-ICD 
(Brabletz et al., 2011). miR-30 members also appear to mediate the 
triggering of Notch by repressing DLL4 in sarcomas, preventing cell cycling 
(Bridge et al., 2012).  A closely related family to miR-30 also demonstrated 
elevated expression in treated Müller stem cells, and is involved in cell 
cycling. The miR-29 family was also upregulated and presents a new target 
of the Notch pathway and may converge on its action on p107 in the 
proliferation of neurons (Vanderluit et al., 2004).  
The mTOR kinase proliferative action was highlighted in this study by the 
markedly enriched expression of miR-99a in Müller stem cells undergoing 
Notch inhibition. This factor is deregulated in oncogenic cells causing 
abnormal rapid proliferation, and may be repressed during Notch inhibition 
in Müller stem cells by miR-99a. Another proliferative cascade implicated by 
this study was the PI3K/Akt pathway. This can be inferred by the 
observation that miR-221 and miR-222 were elevated in cultures undergoing 
Notch inhibition, miR-222 has been associated with preventing cell cycling 
by repressing the expression of factors involved in PTEN, which in turn acts 
to prevent PI3K/Akt signalling (Wong et al., 2012, Zhou et al., 2012), and 
miR221 is known to act by preventing the phosphorylation of a PI3K subunit 
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(Nicoli et al., 2012). Therefore they may play a role in the activation of the 
PI3K/Akt pathway. 
A cluster on chromosome 21 was enriched in DAPT treated Müller cell 
populations, namely the miR-125b cluster, which contains miRNAs that are 
involved in diversification rather than terminal differentiation (Gururajan et 
al., 2010). This suggests that Notch prevents this cluster from promoting this 
initial diversification step in Müller stem cell differentiation.  
miRNAs profiles of Müller stem cells cultured with DAPT and bFGF showed 
enriched expression of hsa-miR-204, hsa-miR-100, hsa-miR-151-5p, hsa-
miR199b-5p and let-7i. These RNA molecules are involved in proliferation, 
whilst miR-199b is linked to Hes1 regulation (Andolfo et al., 2012, Garzia et 
al., 2009) and let-7i indicates the development of RGC within Müller stem 
cell populations (Loscher et al., 2007).  
Five miRNAs were found to be significantly upregulated in Müller 
populations, undergoing Notch inhibition in both the presence and absence 
of bFGF. Although miR-204-5p was significantly enriched following the 
addition of bFGF, this miRNA doubled in expression following DAPT 
treatment and constituted the highest elevation for the array. Subsequent 
addition of bFGF to cultures further enhanced the expression of miR-204-
5p, which was the only miRNA that was common to both treatment groups. 
miR-204 in the eye appears to target Pax6 indirectly, impacting on the final 
size and organisation of the ocular tissue in the medaka fish (Conte et al., 
2010).  This miRNA is also expressed in the mature neural retina. The 
interplay between RGC development and Notch inhibition may converge 
mainly on miR-204 in Müller stem cells.  This relationship presents a novel 
target of the Notch pathway, and possible involvement of miR-204 in the 
maturation of human RGCs derived for Müller stem cells.  
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In conclusion, miRNAs that appear to be under the regulation of the Notch 
pathway were upregulated following DAPT treatment of Müller stem cells. 
This not only demonstrates the impact of Notch inhibition in the 
development of RGCs, but also identifies targets that may be used to induce 
regeneration of the ganglion cell population by quiescent Müller stem cells in 
vivo.       
5.3. Investigations into the potential use of Electrospun Collagen 
scaffolds as a tool for Müller stem cell transplantation 
Investigations into scaffolds produced by electrospinning type I collagen 
suggested that the 3D matrices obtained were able to support cellular 
attachment and growth. However, the need for crosslinking with cytotoxic 
chemicals makes them unsuitable for translation to human therapies. 
Culturing of Müller stem cells was possible on electrospun collagen, with the 
degree of cell recovery being dependent on the crosslinking process. 
Crosslinking involved using agents that propagated the formation of 
crosslinks between lysine groups of adjacent collagen fibres. Those agents 
were then washed from the scaffolds, resulting in a construct able to 
maintain its 3D structure under culture conditions. EDC coupled with the 
amine group donator NHS provided a catalyst for crosslinking, ensuring 
complete leaching of the chemicals following incubation. Cells were 
observed to adhere and proliferate at a normal rate when supported on 
these matrices although the degree of crosslinking was not consistently 
reproducible with the same experimental parameters. The use of 
glutaraldehyde vapour to crosslink proved to induce cell death at high 
concentrations, possibly due to remnants of the chemical remaining within 
the matrix network. GTA forms protein crosslinks through incorporation of its 
reactive moiety into the link. This creates a potential chemical reservoir that 
releases its contents when the matrix is either disrupted or remodelled. It 
was therefore expected that lower concentrations would provide culture 
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systems more conducive to maintain cell viability. However, very low 
concentrations of GTA led to a lack of crosslinks within the fibrillar 
framework resulting in instability and rapid structural deterioration when 
placed into culture media. GTA also prevented the identification of inherent 
and mature markers of both retinal stem cells and RGCs due to the high 
charge on the collagen surface; causing non-specific binding of secondary 
antibodies. Additional experiments using electrospun collagen could assess 
the use of alternative crosslinkers such as genipin or vitamin B. However, 
the extent of crosslinking by these agents has been reported as being 
insufficient for in vivo application. Further investigations could examine the 
use of different polymers; natural or synthetic, and their competencies for 
physical implantation into the body as well as their biocompatibility. 
Synthetic polymers are currently being investigated by tissue engineers for 
dermal grafts as well as internal visceral enhancers or supports. Many of the 
proposed materials are easily produced within finite parameters and can be 
modelled under different conditions generating fibrous, gelatinous structures 
or sheets. An additional factor which limited the use of electrospun collagen 
scaffolds for transplantation was the lack of biodegradability under culture 
conditions. The removal of such cellular supports following transplantation 
would not be desirable in those patients with damaged retinal tissue. Further 
surgery may lead to increased risk of inflammation and damage to residual 
functional retina, hence it would be preferable to design a substrate which is 
able to degrade under physiological conditions.  
Although the scaffolds produced by electrospinning were stable when 
crosslinked with GTA, the therapy proposed for cell transplantation using an 
engineered support is primarily dependent on the biocompatibility of the 
substrate. Collagen, being a natural polymer, would be suited to the 
physiological conditions of the human body, and would potentially be more 
appropriate than those scaffolds composed of synthetic materials. However, 
 
 
213 
 
 
chemical processing of the fabricated collagen is a limiting factor when 
designing an electrospun scaffold and would also be the limiting factor to 
produce cellular scaffolds for human application. 
5.4. Plastic compressed collagen scaffolds as a potential tool for 
Müller stem cell transplantation 
The present results indicated that Müller stem cells readily adhered to 
collagen substrates that had undergone crosslinking via plastic 
compression. Collagen is innately strong and is the main protein found in 
the body which provides a variety of cells with mechanical support. Collagen 
is sourced from dermal mammalian tissues and is extracted for in vitro 
culturing; being a naturally occurring polymer, the degree of biocompatibility 
of the protein is thought to be much greater than that of synthetic sources. 
The various extraction methods used denature the collagen, weakening the 
original framework of the proteins ultrastructure. Unlike other chemical 
measures taken to crosslink extracted collagen samples, plastic 
compression involves physical crosslinking by removing the water 
component of hydrogels (Brown et al., 2005).   
Müller stem cells are able to firmly attach to compressed collagen 
substrates and are able to grow at normal rates when compared to no 
matrix controls. Müller stem cells subjected to differentiation protocols 
involving culture with DAPT and bFGF were also observed to adhere firmly 
to constructs. Examination of the presence of RGC markers in Müller cell-
derived RGCs demonstrated that these cells positively stained for proteins 
of mature retinal ganglion cells and early neural precursors in vitro. 
Constructs were also stable when subjected to physical manipulation for 
surgical processing, although at low concentrations of the protein, 
constructs were easily damaged through handling.  
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Further studies on the preparation of these constructs would entail exploring 
the extent of their degradation under both in vitro and in vivo conditions. Like 
electrospun collagen, compressed substrates were not seen to degrade 
over extended periods of time (up to 3 months) at any concentration.  The 
degree of protein breakdown could be determined by ELISA analysis in 
order to quantify the amount of collagen present within the supernatants. 
Furthermore, in order for the structure of the constructs to be suitable for 
transplantation the structure must be temporary. Although the scaffolds 
designed during this investigation were not found to biodegrade, future 
studies could be aimed at designing protocols to create a transplantable 
construct which can deliver cells and therapeutic agents to the ganglion 
layer and later degrade without releasing products that activate local 
microglia. Tailoring the structure of collagen constructs may aid their 
degradation by creating weak junctions within the collagens fibres. Blends of 
polymers; natural, synthetic or a mixture of both could also be employed to 
yield a construct suitable for in vivo use. The rationale behind blends is to 
merge favourable traits of the different materials that could potentially yield a 
biodegradeable and biocompatible scaffold for Müller stem cell 
transplantation. This may also help overcome the contraction processes 
imposed on the collagen substrates by cells. Further understanding of the 
extent of crosslinks created via physical compression could also lead to 
possible modifications of the constructs. 
The evidence presented in this study suggests that compressed collagen 
creates matrices support Müller stem cells in culture as well as their 
differentiation towards a retinal ganglion cell fate. Following modifications of 
these constructs, they may constitute a potential tool for cell transplantation 
onto the inner retina.  
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5.5. Transplantation of RGC precursors ex vivo and in vivo using 
compressed collagen scaffolds 
Vitrectomy followed by intraocular transplantation of human Müller stem cell 
derived RGCs led to delivery of cells onto the inner retinal surface. Although 
alignment of scaffolds was observed within some subjects, aggregation was 
also observed within anterior segments of the ocular cavity, adjacent to port 
entry sites.      
Supporting Müller stem cells on compressed collagen for transplantation 
aimed to prevent cell aggregation following a single bolus injection. While 
Müller stem cells were supported on PC scaffolds, the extent of uniform 
migration onto the retina was dependent on surgical parameters, as well as 
modulation of the local retinal ECM. Transplantation of stem cells for cell-
based therapies encounter many barriers, where the mode of 
transplantation, locality of the region undergoing transplantation and the 
source of cells used are all relevant to the choice and design of cellular 
scaffolds. However, one major limitation of functional integration of stem 
cells into host tissue is the microenvironment condition, created by abnormal 
deposition of ECM and the presence of inflammatory microglia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
(Gehrmann et al., 1995, Singhal et al., 2008).   
Cellular scaffolds delivered directly onto the inner retinal surface, were seen 
to facilitate alignment of cells uniformly along the inner retina. However, 
integration into host tissue was not observed. The lack of migration 
observed in regions of close contact between the scaffold and retina may be 
ascribed to insufficient delivery of ChABC. This enzyme acts by targeting 
the neural ECM which acts to direct neural tissue during development, and 
is present within adult tissue. Following neurodegeneration in the CNS, 
including the retina, these proteins are known to accumulate (Steinmetz et 
al., 2005, Zhang et al., 2003). ChABC digests the reactive 
glycosaminoglycan (GAG) side chains into simple disaccharides, from their 
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CSPG core. The application of ChABC to treat spinal cord injury (Bradbury 
et al., 2002) and similar CNS injuries have been extensively examined both  
in vitro and in vivo, and have been shown to have a positive impact upon the 
extent of axonal regeneration. Such experiments demonstrated re-growth of 
damaged neurites within corticospinal, reticulospinal and nigrostriatal 
populations following ChABC treatment (Garcia-Alias and Fawcett, 2012). 
Moreover, studies assessing the migration of transplanted cells illustrated 
that generation of axons was enhanced when the peripheral regions of the 
spinal ECM, interfacing the graft, had undergone treatment with ChABC 
(Fouad et al., 2005, Karimi-Abdolrezaee et al., 2010, Tom et al., 2009, 
Garcia-Alias and Fawcett, 2012). 
Therefore, and as previously described (Singhal et al., 2012, Singhal et al., 
2008), injection of ChABC onto retinal tissue prior to transplantation is 
important for providing optimal conditions for integration of transplanted 
Müller stem cell derived RGCs into the retinal ganglion cell layer.  
Entry sites made for surgical instruments and the infusion line were directed 
into the pars plana which is the junction between the neural retina and ciliary 
body. This region measures between 2-3mm in humans, but the rabbit 
equivalent is smaller and more vascular in nature. In addition, the rabbit eye 
also houses a larger lens within the anterior chamber. These anatomical 
differences required modification of the surgical technique. Therefore, 
rabbits underwent lensectomy (lens removal) in order to correct the 
limitation of spatial placement of portals. However, cellular scaffolds were 
observed to remain proximal to the site of entry. This localisation of 
scaffolds may have been due to their insufficient expulsion from the cannula 
or due to the angulation and depth of the cannula which may have 
contributed to cellular aggregation, cell death, changing the properties of the 
original scaffolds. To that end, extensive repopulation of the ganglion layer 
was not observed. Cells tended to integrate within the region close to the 
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scaffolds if aligned along the retina. Extensive microglial mobilisation was 
also seen within regions of cellular aggregation, indicating a local immune 
response to grafted cells. This could be prevented in future studies by 
ensuring administration of sufficient anti-inflammatory drugs prior and 
throughout the experiment.  
The application of Müller stem cell derived RGCs for human glaucoma 
therapies would require implantation into degenerated retina where the 
structure and microenvironment would be abnormal, posing difficulties for 
cells to integrate into the retina. Future studies would need to identify 
whether transplanted Müller stem cells are able to integrate into diseased 
tissue where the architecture is deteriorated. This would entail creating a 
model of retinal ganglion depletion or glaucoma in a large mammal. 
Furthermore, functional assessment by ERGs, alongside histological 
analysis would determine the extent of retinal repair by these cells. The 
degree of migration and cell replacement is likely to be coupled with the 
efficiency of ILM and local ECM modulation achieved by ChABC, hence 
effective delivery would entail stabilising this proteolytic enzyme.     
5.6. Conclusions 
This work demonstrated that miRNA profiles alter following Notch inhibition 
in Müller stem cells, suggesting that the maturation of RGCs in vitro can be 
modulated by small molecules. This work also demonstrated that although it 
is possible to generate collagen-based scaffolds that support cell growth 
and adhesion, there are still many factors that need to be assessed for 
appropriate fabrication and delivery. Preparation of cellular scaffolds for 
retinal transplantation require emphasis upon their structural integrity and 
the biocompatibility of the biomaterials used. Müller stem cells could be 
cultured in vitro with type I collagen, however plastic compressed collagen 
scaffolds generated the most suitable constructs for transplantation. 
Implantation of these scaffolds demonstrated that Müller stem cells could be 
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supported during the grafting process, and could be positioned in close 
proximity to the retina during surgery. Therefore, it can be proposed that PC 
collagen scaffolds may constitute a viable source of material to support 
inner retinal cell grafting, but further studies are needed to evaluate and 
refine the optimal conditions and modifications required to produce 
biodegradable and non-contractile scaffolds. A final limitation to cellular 
integration in vivo following scaffold delivery is the efficiency of modulation 
to the local retinal ECM. In order to restore function to the ganglion layer, 
grafted cells need to migrate and synapse with host neurons to promote 
residual cell survival or cell replacement, and appropriate degradation of the 
ECM in vivo by ChABC needs to be established. 
Müller stem cells from human retina constitute a potential source of cells 
that may be used to produce RGCs in vitro, for delivery onto the inner retina 
in vivo. However, the alterations of miRNAs following Notch inhibition 
suggest that these cells house intrinsic regulatory molecules for RGC 
maturation and have the potential to be modified in vivo. This would remove 
the financial and regulatory implications of stem cell transplantation, and 
merit further studies to induce their endogenous regeneration without the 
need for transplantation.   
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Chapter 6: Materials and Methods 
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6.1. Construction of type I collagen scaffolds using  Electrospinning 
methods 
Electrospinning was performed within an interlocked extraction cabinet. Rat 
tail type I collagen (First link UK) was dissolved in either acetic acid or 
hexafluoroisopropanol; HFIP, (Appollo scientific Ltd), at a concentration of 
50mg/ml. Solutions were brought up to room temperature before transferring 
to a syringe attached to a 22 gage cannula. Under appropriate voltages 
ranging between 12kV-15kV, using a HPV power supply, collagen fibres 
were drawn onto a grounded target enclosed within aluminium foil. The 
grounded targets were set at a range of distances between 10cm-20cm. 
Fibres were drawn for a maximum of two hours. The infuse rates ranging 
between 2-5ml/hr were applied via a Harvard 4400 syringe pump. 
6.1.1. Crosslinking of electrospun collagen scaffolds 
6.1.1.1. Glutaraldehyde vapour crosslinking 
Air dried non-crosslinked collagen scaffolds supported on foil were 
crosslinked within a sealed desiccator. Collagen scaffolds were placed onto 
a perforated ceramic tray within the desiccator and, exposed to 
glutaraldehyde (GTA) vapours (Sigma-Alrich). The presence of aqueous 
solutions of 5-25% glutaraldehyde within the desiccator, contained in a glass 
Petri dish under the perforated tray, ensured the release of glutaraldehyde 
fumes and the progression of chemical crosslinking. Collagen scaffolds were 
allowed to crosslink for 72 hours at room temperature, followed by washes 
over 24 hours with deionised water. Matrices were then air dried in a fume 
cupboard at room temperature. 
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6.1.1.2. EDC crosslinking 
Collagen scaffolds were crosslinked within a sealed glass dish containing 
aqueous solutions of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
(Appollo Scientific), alone or supplemented with N-hydroxylsucinimide (NHS) 
(Sigma-Aldrich). A solution of 30wt% EDC alone or EDC in combination with 
NHS at a ratio of 1:1 (w/w), in a 9:1 (v/v) mixture of acetone and water was 
used to induce the crosslinking process. Scaffolds were fully immersed in the 
solutions for 2 hours at room temperature on a slow shaker. Collagen 
scaffolds were then air dried overnight in a fume cupboard and repeatedly 
rinsed and washed with deionised water several times, in order to remove 
any residual reagents. 
6.2. Construction of type I collagen scaffolds by plastic compression 
Rat tail type I collagen (FirstLink UK) solutions were made in 0.06% acetic 
acid  at a stock concentration of 2mg/ml. Solutions were subsequently diluted 
to 1-0.75 mg/ml in 0.06% acetic acid. One part of Minimum essential medium 
10x (Invitrogen Ltd, UK) was added to 8 parts of collagen solution to aid 
neutralisation. Under sterile culture conditions, solutions underwent 
neutralisation by the addition of 5M sodium hydroxide (Sigma-Aldrich, 
Dorset, UK) drop-wise, to ensure collagen polymerisation. This was 
monitored by colorimetric change from straw yellow to pale pink (neutral pH). 
The solutions were left on ice for 20 minutes to disperse bubbles formed 
during neutralisation. Volumes of these solutions, 300µl-1ml were then 
added to titanium circular moulds ranging from 0.5cm-2cm diameters and 
subsequently incubated at 37°C in 5% CO₂ for up to 30 minutes to induce 
fibrillogenesis. Hydrogels were removed from incubation and placed between 
two nylon meshes. Hydrogels were then compressed under 150g loads for 5 
minutes. Compressed collagen scaffolds were floated off the nylon into 
Phosphate Buffered Saline (PBS) before cell culture procedures. 
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6.3. Cell culture 
6.3.1. Müller Stem Cell Culture  
Established Müller stem cell lines at the Institute of Ophthalmology were 
used in this study. To passage these cells, monolayers of cultured cells were 
dissociated using TryplE
TM 
x1 (Life technologies), followed by 5 minute 
incubation at 37°C, 5% CO₂. Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with FCS (5mls per T-175) was added to the flasks to collect 
the dissociated the cells. Cell suspensions were centrifuged at 1400 rpm at 
15°C for 5 minutes. Supernatants were aspirated, whilst cell pellets were 
resuspended in fresh media and added to new culture flasks. Fully confluent 
monolayers formed after 7 days and were maintained through passaging in a 
1/5 dilution. 
Cell stocks were maintained by cryopreservation of cultured cells and was 
performed by resuspending cell pellets from T-25 culture flasks in 1ml of 
freezing mix composed of; 40% FCS and 10% Dimethyl Sulfoxide (DMSO) 
(Sigma-Aldrich, UK) in DMEM. Cell suspensions were transferred to 
cryovials that were placed within an isopropanol freezing cassette at -80°C 
for 24 hours, this ensured controlled cryopreservation. Frozen suspensions 
were then transferred to -150°C for long term storage. 
All cells were grown and passaged in DMEM containing L-Glutamax without 
pyruvate (PAA, UK), 10% FCS (Biosera), 5ml mixture of penicillin 
(2,000U/ml) and streptomycin (2,000µl/ml) (Life technologies) in 500mls of 
DMEM. Incubated at 37°C in 5% CO₂ air atmosphere. 
6.3.2. Use of extracellular matrix substrates and growth factors to 
culture Müller stem cells 
For differentiation Müller stem cells were cultured on polystyrene tissue 
culture plates or flasks (Nunc, Thermo Scientific) coated with ECM Gel from 
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Engelbreth-Holm-Swarm murine sarcoma (ECM) (cat no: E1270, Sigma-
Aldrich, UK), reconstituted to stock concentrations as per company 
instructions and subsequently aliquoted and stored at -20°C. Aliquots were 
diluted in sodium bicarbonate buffer; 15mM Na2CO3, 35mM NaHCO3, pH 9.6 
to a working concentration of 50ng/ml. They were also stored at -20°C until 
use. To coat the surfaces of culture plastics, it was ensured that the matrix 
solution covered the entire area (a minimum of 1ml/ T-25 flask). Flasks or 
plates were incubated at 4°C overnight or at 37°C for 2 hours. Prior to cell 
culture, ECM solutions were fully aspirated and flasks were washed with 
sterile PBS. 
Recombinant Human Fibroblast Growth Factor-2 (bFGF; cat no: F0291, 
Sigma-Aldrich, UK) and N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-
phenylglycine t-butyl ester (DAPT; cat no: D5942, Sigma Aldrich, UK) were 
reconstituted according to the manufacturer’s instructions and stored in 
aliquots at -20°C prior to use. bFGF was diluted in culture medium to yield a 
final concentration of 20ng/ml, whilst DAPT was diluted to a concentration of 
50ng/ml. These factors and their concentrations were determined by 
previous studies performed in the laboratory (Singhal et al., 2012). There 
was no subsequent replenishment of factors during the progression of the 
experiments. For differentiation studies the FCS content of culture media 
was reduced to 5% in order to reduce Müller stem cell proliferation. 
6.3.3. Use of collagen-based scaffolds for Müller Stem Cell Culture 
Electrospun collagen scaffolds were sterilised by immersion in 70% ethanol 
for two hours at room temperature. Under cell culture conditions the ethanol 
solutions were removed and scaffolds were rinsed with sterile PBS. Scaffolds 
were then repeatedly washed three times for 10 minutes with sterile PBS. 
DMEM containing 10% FCS and Penicillin Streptomycin was added to 
scaffolds and incubated for 8hrs, or overnight, at 37°C in 5% CO₂. Media 
was then removed and cells seeded onto “wet” scaffolds. Compressed 
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collagen scaffolds were transferred from PBS into 2.5cm tissue culture 
dishes prior to DMEM and Müller stem cells addition. 
100% GFP lenti-viral labelled MIO-M1 were grown to a confluent layer in a T-
25 tissue culture flasks, using DMEM containing 10% FCS (as above). Once 
a confluent layer was formed, cells were detached by trypsinisation, following 
subsequent pelleting and resuspension cells were counted using a 
haematocytometer. Cell viability and number were determined by dilution 
with trypan blue (1:1 ratio, 10µl) and added to the haemotocytometer. 
Unstained viable cells were counted within the squares of the central grid; 
the inner and four corner squares. Following counting cells were suspended 
at a concentration of 12,500 cells/ml. 2ml of this suspension was added to 
scaffolds, which were incubated at 37ºC until a subconfluent layer was 
obtained after 7 days. 
6.3.4. In vitro transplantation of cellular scaffolds onto explanted 
retina 
Donor human eyes from Moorfields eye bank were obtained under ethical 
approval for ex vivo explant culture. Anterior portions of the globes were 
removed 4mm from the Limbus. The vitreal body was then gently removed 
and the globe dissected into quadrants down to the optic nerve head. The 
retina was carefully separated from the RPE layer by folding the retinal 
quadrants towards the centre; the optic nerve was then cut to detach the 
retina. Retinas were then placed on 0.4 µM pore PTFE hydrophilic cell 
culture insert 30 mm diameter filter (Millipore, USA) contained in a 6-well 
plate. Müller stem cell derived RGCs were placed onto 1cm, 300µl-
0.75mg/ml compressed collagen scaffolds at a concentration of 11.25x10
4
 
cells/ml for 2 hours prior to placing onto retinal explants. Explants were 
cultured for a maximum of 7 days. The culture medium comprised 48.5 ml 
Neurobasal A-Medium (cat no: 12349, Life Technologies, UK) and 1.5 ml 
mixture of media supplements (Wang et al., 2002). Supplements were made 
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of 500 µl of 2% B-27 (cat no: 17504-044, Life Technologies), 200 µl of 
0.8mM L-Glutamine (cat no: 25-005-CI, Cellgro), 250 µl of 1% N-2 (cat no: 
17502048, Life Technologies) and 500 µl of 100U/ml Penicillin/Streptomycin 
(cat no: 15140122, Life technologies). Ex vivo tissues were then prepared for 
cryosectioning and confocal microscopy. 
6.4. Cell Viability Assay 
Cell viability was assessed using the hexosaminidase assay which evaluates 
the number of living cells by colorimetric determination of hexosaminidase 
levels within lysomes. 96 well plates were seeded with 5,000 cells/well (in 
accordance with growth rate analysis) and cultured for 7 days at 37°C in 5% 
CO₂. Examination of hexosaminidase levels involved initial centrifugation of 
the plates at 1400rpm for 3 minutes. Culture media was subsequently 
removed from the plates and rinsed with PBS to remove residual serum. 
Plates were then centrifuged again prior to substrate addition. 60µl per of 
hexosaminidase substrate was transferred to each well and incubated at 
37°C for 4 hours. The reaction was blocked by the addition of 90 µl of 0.1M 
glycine-sodium hydroxide buffer, pH 10.4. The absorbance was read at 
405nm with a blank reading taken at 620nm. Control readings were also 
collected for substrate and buffer alone at the time of recording. 
The hexosaminidase substrate was made by adding 200mg of p-nitrophenyl-
N-acetyl-β-D-glucosaminide to 78ml of 0.1M Tris sodium citrate, adjusted to 
pH 5.0 and 78ml of 0.5% Triton X-100 in water.  
6.5. Collagen digestion of scaffolds 
Stock solutions of 0.5% collagenase D (Roche) in PBS containing calcium 
and magnesium were diluted 1:10(v/v) with PBS. Media was removed from 
the collagen scaffolds and 90µl of diluted collagenase D was added to each 
scaffold. The collagen scaffolds were then incubated for 30 minutes at 37°C. 
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The digestion system was disrupted at 10 minute intervals by severe 
pipetting. The plates were centrifuged at 9,000rpm for 5minutes to separate 
the cells and collagen from the enzyme solution. The collagenase D was 
then removed and the cell viability assessed by trypan blue exclusion and 
hexosaminidase assay. 
6.6. Measurement of optical density of collagen scaffolds 
Ocular densities of collagen scaffolds were analysed using absorption 
spectra and the Safire software. For the assay, collagen scaffolds were place 
onto the culture surfaces of 96 or 24 well plates (Nunc) in PBS and 
measured, without lids, for light absorption over the visual range (350nm-
750nm) with 10 averaged readings taken per well.  
6.7. Electron microscopy analysis of collagen scaffolds 
The adhesion and cellular-matrix behaviour were assessed by scanning and 
transmission electron-microsopy (SEM and TEM) respectively. The collagen 
scaffolds were fixed in Karnovsky’s fixative for 2 hours and then rinsed and 
washed with 0.1M sodium cacodylate at pH 7.4, 3 times for 10 minutes.  
Secondary fixation was achieved by submerging scaffolds in 1% (w/v) 
aqueous osmium tetroxide for 2 hours in the dark. The scaffolds were rinsed 
repeatedly with deionised water to remove excess secondary fix. The 
specimens were then dehydrated by ascending alcohol concentrations; 50%, 
70%, 90% and 100% ethanol solutions, with 4 changes for each ethanol 
concentration. Specimens for SEM analysis were air dried for 8 hours and 
subsequently mounted onto carbon stubs. The specimens underwent 
vacuum gold coating before examination under scanning electron 
microscopy (JEOL JSM 5500 LV). ImageJ was used to measure the area 
fraction of SEM mcrographs to determine both the pore size and the number 
of pores per surface area. 
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6.8. Western Blotting 
6.8.1. Protein Isolation from cultured cells 
Following culture under varying conditions, whole cell lysates from 
dissociated monolayers of Müller stem cells were processed to study their 
protein expression profiles. Radio immunoprecipitation Assay Buffer (RIPA, 
Sigma-Aldrich) was used to isolate nuclear and cytoplasmic proteins. To 1ml 
of cold RIPA buffer; 10µl of protease inhibitor cocktail (P8340, Sigma-Aldrich, 
UK), 0.05mM Dithiothreitol (DTT), 1mM Phenylmethylsulphonyl Fluoride 
(PMSF) and 3mM Sodium Orthovanadate were added. Cells were detached 
by scraping, and washed with cold PBS to remove residual FCS. 
Subsequent to centrifugation, supernatants were removed and pellets were 
disrupted with cold RIPA containing protease inhibitors (100µl/ T75 pellet). 
Pellets were homeogenised, vortexed briefly and left on ice for 5 minutes for 
cells to complete lysis. Suspensions were then centrifuged at 9000rpm to 
remove cellular debris. The supernatants containing the cellular proteins 
were collected and placed at -20°C for short-term storage or -80°C for long-
term storage. 
Protein levels were measured using the Bio-Rad Protein Assay Dye Reagent 
(cat no: 500-0006, Bio-Rad Labs, UK) and the colorimetric Bradford Assay. 
The assay dye, consisting of coomassie brilliant blue G-20 was diluted 1 in 4 
with 50µl of this reagent added to 2.5µl of protein sample. The mixture was 
vigorously pipetted and incubated at room temperature for 5 minutes. The 
dye binds to proteins altering the conformation of the dye’s structure 
changing its colour from brown to blue. The absorbance was measured at 
450nm to 595nm, against a blank reading consisting of the diluted reagent 
with 2.5µl of molecular grade water (Roche). Protein levels were determined 
by extrapolation of absorbance onto standard curves prepared with bovine 
serum albumin of known concentrations. 
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6.8.2. Protein Gel Electrophoresis 
The NuPAGE system was used to perform gel electrophoresis (Life 
Technologies, UK). To detect proteins with molecular weights between 14-
55kDa, 4-12% Bis-Tris gels were run with MES SDS running buffer (cat no: 
B0002, Life technologies, UK). For proteins larger than 55KDa, 12% Bis-Tris 
gels with MOPS SDS running buffer (cat no: NP0001, Life Technologies, UK) 
were used. The gels used contained 15 wells of 1.5mm size. Preparation of 
protein for gel loading involved denaturing the complex structures into linear 
conformations that could be resolved as separate bands and thus their 
molecular weights. The total volume run for each sample was 30µl. This was 
prepared by mixing 3µl of 10x reducing agent (cat no: NP0009, Life 
technologies, UK), 7.5µl of NuPAGE loading buffer (cat no: NP0007, Life 
Technologies, UK) and a maximum volume of 19.5µl of protein lysate. The 
volume 19.5µl for the protein was adjusted based on the lowest protein 
concentration yielded for each set of control and test samples and brought 
up to this volume with water. Samples were then heated for 10 minutes at 
80°C to denature the proteins. 
Gels were placed into the internal chambers of XCell Surelock Mini-Cell Gel 
Electrophoresis cassettes (cat no: EI0001, Life Technologies, UK) and 200ml 
of running buffer were added to this chamber (200ml containing 500µl of 
antioxidant) (cat no: NP0005, Life Technologies, UK). The external chamber 
was filled with water to keep the system cool during running. Gels combs 
were removed gently and loaded with protein sample solutions (15µl) and 
protein ladder (5µl, cat no: P7709L, Biolabs, UK) and run at 180V for 1 hour. 
6.8.3. Protein transfer onto PVDF membranes 
Polyvinylidene fluoride (PDVF) membranes (Immobilon-FL PVDF, 0.45 µm; 
cat no: IPFL00010, Millipore) were prepared for wet transfer and involved 
cutting membranes to size and submersion into methanol for 2 minutes, 
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washed in distilled water and placed into NuPAGE transfer buffer containing 
(cat no: NP0006-1, Life Technologies, UK) 15% methanol v/v for a minimum 
of 10 minutes. Wet transfer was conducted using the XCell Surelock Mini-
Cell Gel Electrophoresis cassette at 35V for 90 minutes.  
6.8.4. Protein immunodetection  
Subsequent to protein transfer onto PDVF membranes, these were blocked 
at 37°C for 1 hour with 5% FCS in 1x TBS and containing 0.1% Tween20. 
Following blocking, relevant antibodies were diluted in the blocking solution, 
and added to the membranes, which were placed in plastic casing and 
sealed to avoid dehydration. Membranes were incubated overnight at 4°C on 
a slow shaker, then washed 3 times with 1x TBS and 0.1% Tween20 for an 
hour. The membranes were incubated at room temperature on a slow shaker 
with appropriate horseradish peroxidise secondary antibody (HRP) for 2 
hours and washed again as previously described. These were X-rayed 
following rapid incubation (maximum of 5 minutes) with Pierce ECL Western 
Blotting Substrate (cat no: 32209, Thermo Scientific Intl) where substrate A 
and B were diluted at a ratio of 40:1 (v/v).   
6.9. Reverse- transcription polymerase chain reaction 
6.9.1. RNA Isolation 
Müller stem cells cultured under various conditions were analysed for mRNA 
and miRNA expression levels. Cells were detached and centrifuged to obtain 
a cell pellet which was then washed with 1 ml of cold PBS and spun at 
4000rpm for 5 minutes. Pellets were resuspended in QIAzol lysis Reagent to 
extract RNA in accordance with the manufacturer’s instructions. Total RNA 
from T-75 cell monolayers was isolated using the miRNeasy Mini Kit (cat no: 
217004, Qiagen). This enabled purification of total RNA using a column 
isolation system which includes RNA from 18 nucleotides (nt) upwards. Total 
RNA was eluted with 22µl of RNase free water and the concentrations 
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measured using a spectrophotometer (Nanodrop-1000, Thermo Scientific). 
Samples were stored at -80°C and thawed prior to use for both array 
analysis and RT-PCR processing.  
6.9.2. Reverse Transcription (RT) 
SuperScript III Reverse Transcriptase kit for RT-PCR (cat no: 18080-093, 
Life Technologies, UK) was used to generate cDNA from isolated RNA 
samples. Each RT preparation contained 500ng of RNA to ensure 
comparative results were obtained for the various conditions examined. A 
20µl mixture was made as per manufacturer’s instructions where RNA/water 
samples were made up to 11µl containing 500ng of RNA. Samples were 
initially incubated at 65°C for 5 minutes, with 25µM of oligo-d(T)
20
 primer and 
10mM of dNTP
12-18
. Following this initial incubation, the solution was then 
mixed with 4µl of 5x reaction buffer, 2µl of 0.1M Dithiothreitol (DTT), 2µl 
RNase Inhibitor (40U/µl) and 2µl SuperScript III reagent. The solution was 
vortexed and transferred to a gradient thermo cycler (Eppendorf, UK). The 
incubations were carried out at 25°C for 10 minutes, 42°C for 1 hour, 99°C 
for 5 minutes and then held at 4°C. The cDNA produced was stored at -20°C 
until processed for PCR. 
 
6.9.3. Polymerase Chain reaction (PCR) 
Gotaq x2 Master mix (Promega, UK) was used to process cDNA synthesised 
from RNA samples in order to perform PCR. A 25µl solution was prepared 
per PCR reaction over ice, using 1-2µl of cDNA according to the 
manufacturer’s instructions. Solutions contained 13µl of GoTaq x2 Master 
Mix, forward and reverse primers of the genes of interest and molecular 
grade water. Primers were obtained in desalted forms from Life technologies 
Custom primer service and resuspended to a working dilution of 50µM in 
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molecular grade water. Final primer concentrations were adjusted at 
concentrations between 0.2-0.4µM/ml. PCR mixtures were then transferred 
to a thermocycler where they were subjected to an initial denaturation step at 
94°C for 2 minutes, 94°C for 30 seconds, primer annealing temperature for 
30 seconds, 72°C for extension for 1 minute. Steps 2-4 were then repeated 
between 28-35 cycles followed by a final extension at 72°C for 7 minutes and 
finally held at 4°C. PCR products were analysed by electrophoresis on a 2% 
agarose gel containing 1:15000 Gel Red nucleic acid gel stain. Each well 
was loaded with 10µl of PCR product. In each gel had at least one well was 
loaded with 1 kb DNA ladder (TrackIt, cat no: 10488-072, Life Technologies, 
UK) to enable band size identification for specific genes. Gels were cast and 
run at 110V for 45 minutes and subsequently imaged under UV light using 
the Genesnap Image Acquisition program. Densitometry measurements of 
autoexposed images were used to analyse the relative levels of gene 
expression using Image J software. All genes were normalised to the 
respective β-Actin levels. 
6.9.4. microRNA Analysis  
Total RNA was isolated as described previously. Each sample was eluted 
into 22µl of RNAse free water. A 2µl volume was examined for degradation 
using the Agilent 2100 Bioanalyzer RNA 6000 Nano LabChip Kit (Agilent 
Technologies, USA). The quality of each sample was assigned an arbitrary 
unit based on a graphical read-out of nucleotide size against fluorescence.  
The RNA was then assessed for miRNA levels using Aligent miRNA 
Microarray system with miRNA Complete Labelling and Hyb kit (Agilent  
 
 
233 
 
   
Figure 6.1: Microarray work flow. Total RNA samples were isolated from Müller 
stem cultures, after one week and processed for array analysis.  Microarray 
analysis techniques enabled miRNA profiling of Müller stem cell cultures. Protocol 
follows the Agilent methods for miRNA detection.  
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Technologies, USA) (Figure 6.1), in which dephosphorylation of 100ng RNA 
was performed. Samples were then labelled with Cyanine3-pCp and 
incubated for 2 hours at 16°C. Labelled RNA was desalted and dried under 
vacuum for 3 hours at 55°C. RNA samples were then loaded onto a SureHyb 
8-well chamber and hybridised for 20 hours at 55°C under agitation at 
20rpm. Slides were scanned under FITC fluorescence and emission profiles 
recorded. 
6.10. Immunostaining 
6.10.1. Immunostainning of cells and retinae 
Cells were cultured as described previously on 13 mm glass coverslips 
coated with ECM in 24 well plates for a maximum of 7 days, without factor or 
medium replenishment.  
Following culture media was aspirated and cells fixed with 4% 
paraformaldehyde for 10 minutes. Wells were then rinsed and washed twice 
for 5 minutes, with PBS. Cryropreservation was achieved by incubating the 
wells with 30% sucrose for 10 minutes at room temperature, followed by 
removal of sucrose. Aired dried specimens were stored at -20°C for later 
use. 
Blocking solution was prepared by adding 5% Donkey serum (cat no: 017-
00-121, Jackson Labs) and 0.3% triton X-100 to 1xTBS. Cells were 
incubated for 1 hour at room temperature with freshly made blocking 
solution. Primary antibodies were diluted in the same solution and added to 
the wells overnight at 4°C or 2 hours at room temperature. Wells were 
subsequently washed three times with TBS for 5 minutes. Secondary 
antibodies labelled with Alexa Fluoros fluorescent dyes (Life Technologies, 
UK) were diluted 1:500 in block solution. Cells were then incubated in the 
dark for 2 hours at room temperature with the secondary antibodies. Wells 
were rinsed and washed with TBS as before. Nuclei were stained with 4,6-
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diamidino-2-phenylindole, DAPI (Sigma-Aldrich) 5mg/ml, diluted 1 in 5000 in 
PBS for 1 minute at room temperature. Cells were rinsed again and washed 
once for 5 minutes with TBS. Buffer was then aspirated and coverslips were 
mounted on glass slides using Vectashield Mounting Medium (cat no: H-
1000, Vector labs, USA). Edges were sealed with nail vanish, air dried under 
darkness and stored at 4°C prior to microscopical analysis. 
Cryostat tissue sections were obtained between 15-20µm thickness and air 
dried overnight at room temperature before processing as described above, 
although tissues were fixed in 4% PFA, overnight at 4°C and placed in 30% 
sucrose for 48 hours at 4°C. Prior to sectioning tissue was embedded in OCT 
medium (cat no: SURG08609E, VWR, UK) over dry ice. Images were 
captured using a Zeiss LSM 710 confocal microscope and Zen Lite software. 
6.10.2. Quenching auotofluorescence of glutaraldehyde 
crosslinked collagen scaffolds 
To quench the autofluorescence of the chemically crosslinked constructs a 
1% solution of sodium borohydride in PBS was added. The scaffolds were 
incubated in the actively bubbling solution for 40 minutes and then rinsed 
twice with PBS. 
6.10.3. Wholemount Immunostaining of Müller stem cells on 
collagen scaffolds 
Scaffolds were incubated for 10min with 4% paraformaldehyde and washed 
with PBS for 5 minutes prior to staining. Scaffolds were then incubated with 
blocking solutions (0.3% triton X-100, 5% donkey serum and 2% BSA in 
TBS) for 1 hour at room temperature.  200µl of primary antibodies diluted in 
blocking solution were added, and incubated overnight at 4ºC. Primary 
antibodies were then removed and scaffolds were washed with TBS 3 times 
for 5 minutes.  500µl of Alexa-fluor secondary antibodies diluted 1:500 in 
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blocking solution were then added, and scaffolds were incubated for 1 hour 
at room temperature, covered in foil to preserve fluorescence.  Scaffolds 
were washed as before, and stained with 4,6-diamidino-2-phenylindole, DAPI 
(Sigma-Aldrich) 5mg/ml, diluted 1:5000 in PBS for two minutes at room 
temperature. Finally they were washed as before, and rinsed with distilled 
water.  Collagen scaffolds were gently removed, placed onto slides and left 
to dry at room temperature. Subsequently the scaffolds were mounted with 
vector shield (Vectalabs). Coverslips were placed over scaffolds and sealed 
with clear vanish.  Slides were imaged using the Leica DM  IRE2 confocal or 
the Zeiss LSM 710 microscope and images obtained by over-lay snapshots 
taken at different wavelengths. Images were analysed using the LSM Zeiss 
browser or Leica confocal software. 
6.11. In vivo transplantation of cellular scaffolds onto the rabbit 
retina  
6.11.1. Cellular and scaffold preparation 
Müller stem cells were transfected with an immunodeficiency virus type 1 
(HIV-1) based lentiviral vector which expresses low toxicity hrGFP (Yanez-
Munoz et al., 2006). Transfection was undertaken by the molecular therapy 
laboratory at the Institute of Ophthalmology, where transfection efficiency 
was 90%. Cells were expanded and later stored at -150°C for future work. 
Preceding transplantation GFP-lentiviral transfected Müller stem cells were 
placed in culture and differentiated into RGC precursor for a maximum of 7 
days. For the duration of the experiment cells were examined under light 
microscopy to observe morphology and viability. Prior to transplantation, 
compressed collagen scaffolds were made as follows: 0.75mg/ml collagen 
with a volume of 300µl were added to a 1cm diameter casting ring which 
underwent compression under 150g for 5 minutes. Scaffolds were removed 
from nylons and placed onto 1cm coverslips contained within 2.2cm diameter 
MaTek dishes and flattened. Cells were added dropwise onto the scaffolds at 
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a density of 4x10
5
/250µl per side and incubated at 37°C at for a maximum of 
2 hours in DMEM containing 10% FCS to aid adhesion. Scaffolds loaded 
with cells were then rinsed and washed 3 times for 10 minutes with sterile 
PBS (PAA) to remove residual serum. Scaffolds were stored in PBS at room 
temperature prior to transplantation.  
6.11.2. Rabbit Husbandry 
Chinchilla bastard female rabbits between 2.5-3kg were maintained 
according to Home Office regulations for the care and use of laboratory-
based animals in the UK (Scientific Procedures Act). This species was 
chosen to examine the applicability of collagen scaffolds for Müller stem cell 
derived RGC transplantation. Scaffold transplantation was made after 
surgical removal of the vitreous body via 18G Pars Plana vitrectomy 
performed by Mr David G Charteris and Mr Hari Jayaram, surgeons from 
Moorfields Eye Hospital. 
Animals were immunosuppressed with oral Ciclosporin A (Sandimmun, 
Novartis, UK) administered orally once a day in water; 150ml/kg/day together 
with Prednisolone. The steroid Prednisolone was given for the duration of the 
experiment but dosages were lowered weekly as follows: week 1- 
2.1mg/kg/day; week 2- 1.4mg/kg/day; and week 3- 0.7mg/kg/day. Rabbits 
were immunosuppressed 3 days prior to transplantation, and 
immunosuppression was continued for the duration of the study.  
6.11.3. Vitrectomy 
Rabbits were anaesthetised with an intramuscular injection of Ketamine; 
50mg/kg (Ketaset, Fort Dodge Animal Health, UK) and 20mg/ml of Xylazine 
(Rompun, Bayer). The pupils of the eye to be vitrectomised were dilated with 
15 tropicamide and 2.5% Phenylephrine (Chauvin Pharmaceuticals, UK). 
Following dilation, rabbits were placed under the surgical microscope. The 
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animals were then draped, leaving the operated eye exposed. The eye was 
then disinfected with povidone iodine eye drops (Moorfields 
Pharmaceuticals, UK). An adolescent speculum was placed within the ocular 
cavity to fix the globe in a firm position. The conjunctiva was then dissected 
equatorially down to the sclera for vitrectomy port entry. To maintain ocular 
pressure during surgery a Lewicky infusion line was placed anteriorly at the 
cornea-iris junction and screwed into the cornea. Two entry ports were made 
2mm posteriorly from the limbus via 20G MVR blade. Port sites were located 
generally at 4 and 8 o’clock on the limbal circumference; inferotemporally. 
Bleeding at port entry sites was controlled using bipolar diathermy. 
Lensectomy was undertaken via one port with a phacoemulsification probe. 
Its action involved disrupting the lens structure using ultrasound, whilst 
simultaneously aspirating the debris. The second entry site was used to 
insert a subsidiary infusion line with saline, to maintain pressure within the 
eye. Upon completion of lensectomy, the probe was removed and a 
vitrectomy cutter inserted with the alternative port used for insertion of a 
fiberoptic instrument set to 100% illumination. This was to visualise the retina 
for the duration of the vitrectomy. This apparatus simultaneously cuts and 
aspirates the vitreous and was set at 750cpm (cuts per minute) with a 
maximum aspiration of 250mmHg. Total removal of the vitreous was 
conducted to ensure direct access to the retinal inner surface. Once 
achieved, the intraocular infusion was exchanged to air in order to remove 
the fluid contained within the posterior chamber of the eye, to maintain the 
ocular pressure. ChABC (0.4U/10µl) was injected prior to delivery of the 
scaffolds, via a 18G cannula and incubated at body temperature for 5 
minutes. Prepared cellular scaffolds were then drawn up into an 18G cannula 
attached to 1ml syringe and inserted via an existing entry port. The cannula 
was angled down towards the medullary raphe and subsequently injected, 
delivering the cellular scaffolds supported onto the inner retinal surface. 
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Ports were sequentially sutured, with the conjunctiva being sewn back into 
place at the limbus. A subconjunctival injection of gentamicin and 
triamcinolone was given at the end of the procedure (washed and 
reconstituted in sterile water at a concentration of 80µg/ml); (Kenalog, 
Squibb Pharmaceuticals). Operated eyes were given topical drops of 
Dexamethasone 0.1% (Alcon Laboratories, UK) to control post-operative 
inflammation. Procedures lasted no more than 90 minutes.    
6.11.4. Tissue Acquisition 
Upon completion of in vivo studies, rabbits were sacrificed via ear 
cannulation and sodium pentobarbitone injection (1ml/kg), to achieve rapid 
terminal anaesthesia. Both eyes were then removed via excision of the distal 
ocular tissues and optic nerve. Globes were fixed overnight in 4% PFA at 
4°C and transferred to 30% sucrose for 48 hours for cryopreservation. Eyes 
were embedded into OCT medium (cat no: SURG08609E, VWR, UK) over 
dry ice and subsequently sectioned and processed as outlined previously for 
immunohistochemistry.
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8.1. Tables 
8.1.1. Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Raised in Supplier Catalogue no. Dilution 
B-actin mouse Sigma A5316 
(clone-AC-74) 
1/5000  
Β-III-Tubulin mouse Millipore MAB1637 1/100 
BRN3B goat Santa Cruz N-15 sc-31987 1/200  
HUD rabbit Santa Cruz sc-2536 1/500 
ISLET-1 mouse DSHB 39.4D5 1/50 
Neurofilament 200 mouse DSHB RT97 1in 10 
Notch 1 AND NICD rabbit Santa Cruz C-20 sc-6014 1/100  
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8.1.2. Primers 
 
 
Gene Accession no. Sequence 
cDNA 
position 
Annealing 
Temp. 
Product 
size Source 
B-ACTIN 
F NM_001101 
CATGTACGTTGCTATCCAGG
C 393 60 
  B-ACTIN 
R 
 
CTCCTTAATGTCACGCACGA
T 642 60 250 
primer bank 
(id:4501885a1) 
BRN3B F NM_004575 CAGGTTCGAGTCCCTCACAC 903 60 
  
BRN3B R 
 
ATGGCAAAGTAGGCTTCGAG
C 1100 60 198 
primer bank 
(id:4758948a2) 
HES1 F NM_005524.2 
AAGATAGCTCGCGGCATTCC
A 200 60 
  HES1 R 
 
CGTTCATGCACTCGCTGAAG 358 60 160 self 
HES5 F 
NM_001010926
.2  AAGCTGGAGAAGGCCGACAT 244 60 
  HES5 R 
 
CGAGTAGCCTTCGCTGTAGT 360 60 116 self 
HEY2F NM_012259 CAACCCCTTGTCGCCTCTC 620 60 
  
HEY2R 
 
CCG TGG ATG GCA TTC GGA 
G 730 60 111 
primer bank 
(id:6912414a3) 
HUD F NM_021952.2 
GAAACTGTCCTTCTCCCATG
C 310 64 
  
HUD R 
 
GATTGAGGCAGAGCTCGGA
C 611 64 301 self 
ISL1 F NM_002202 
CAGGTTGTACGGGATCAAAT
GC 207 60 
  
ISL1 R 
 
CACACAGCGGAAACACTCGA
T 315 60 109 
primer bank 
(id:4504737a2) 
NOTCH1 
F NM_017617 GCTGGACTGGTGAGGACTG 977 60 
  
NOTCH1 
R 
 
AGCCCTCGTTACAGGGGTT 1153 60 180 
primer bank 
(id:27894368a3
) 
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